,PageNo,Text
0,page_0,"Clinical Investigation Plan Title STOP AF First Clinical Investigation Plan Identifier MDT16012AFS001 Study Product Arctic Front Advance™ Card iac CryoAblation Catheter Application Number IDE #G1160219 ClinicalTrials.gov Identifier NCT03118518 Sponsor Medtronic 8200 Coral Sea St NE Mounds View, MN 55112 Document Title STOP AF First Clinical Investigation Plan Document Version (Date) 5.0 (05-DEC-2017)"
1,page_1,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 1 of 130 Version 5.0 STOP AF First Page 1 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Clinical Investigation Plan Clinical Investigation Plan/Study Title STOP AF First Clinical Investigation Plan Identifier MDT16012AFS001 Study Product Name Arctic Front AdvanceTM Cardiac CryoAblation Catheter Sponsor/Local Sponsor United States of America Medtronic, Inc. 8200 Coral Sea St NE Mounds View, MN U .S.A. 55112 Europe Medtronic, Bakken Research Center B.V. Endepolsdomein 5 6229 GW Maastricht The Netherlands Document Version Version 5 .0, 05DEC2017 Lead Principal Investigator Oussama Wazni, MD Cleveland Clinic 9500 Euclid Ave, Cleveland , OH 44195 Coordinating Investigators Gopi Dandmudi , MD Indiana University Krannert Institute of Cardiology 1801 N. Senate Blvd, Suite 4000 Indianapolis, IN 46202 Steve Nissen , MD Cleveland Clinic 9500 Euclid Avenue Cleveland, OH 44195 Confidentiality Statement The information contained in this document is confidential and the proprietary property of Medtronic. Any distribution, copying, or disclosure without the prior written authorization of Medtronic is strictly prohibited. Persons to whom the information is disclosed must know that it is confidential and that it may not be further disclosed by them."
2,page_2,
3,page_3,
4,page_4,
5,page_5,
6,page_6,
7,page_7,
8,page_8,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  6HFRQGDU\2EMHFWLYHV ......................................................................................................... 27 3ULPDU\(QGSRLQW ................................................................................................................. 28  3ULPDU\(IILFDF\(QGSRLQW .............................................................................................. 28  3ULPDU\6DIHW\(QGSRLQW ................................................................................................. 29 6HFRQGDU\(QGSRLQWV ..........................................................................................................30 6. Study Design ............................................................................................................. 32 'XUDWLRQ ....................................................................................................................... 33 5DWLRQDOH ..................................................................................................................... 33 0LQLPL]DWLRQRI%LDV .................................................................................................. 34 7. Product Description .................................................................................................. 35 *HQHUDO ......................................................................................................................... 35 $UFWLF)URQW$GYDQFH&DUGLDF&U\R$EODWLRQ&DWKHWHUV ................................... 37 )UHH]RU ®0$;&DUGLDF&U\R$EODWLRQ&DWKHWHUV ................................................. 37 )OH[&DWK$GYDQFH6WHHUDEOH6KHDWK ..................................................................38 $FKLHYHRU$FKLHYH$GYDQFH0DSSLQJ&DWKHWHU ........................................... 38 &U\R&DWK&U\R$EODWLRQ&RQVROH ............................................................................. 39 &RD[LDO8PELOLFDO&DEOH ............................................................................................ 40 (OHFWULFDO8PELOLFDO&DEOH ........................................................................................ 40 0DQXDO5HWUDFWLRQ.LW ............................................................................................... 40 $GGLWLRQDO6WXG\'HYLFHV ......................................................................................... 41 3URGXFW7UDLQLQJ5HTXLUHPHQWV ............................................................................. 41 3DFNDJLQJ .................................................................................................................... 41 ,QYHVWLJDWLRQDO'HYLFH6WRUDJH+DQGOLQJDQG7UDFHDELOLW\ ............................. 41 8. Investigator/Investigator Center Selection ................................................................ 43 9. Center Activation ....................................................................................................... 44 10. Selection of Subjects .................................................................................................. 45 6WXG\3RSXODWLRQ ....................................................................................................... 45 6XEMHFW(QUROOPHQW .................................................................................................... 45 ,QFOXVLRQ&ULWHULD ....................................................................................................... 45 ([FOXVLRQ&ULWHULD ....................................................................................................... 45 11. Study Procedures ....................................................................................................... 47 6FKHGXOHRI(YHQWV .................................................................................................... 47 0RGHVRI'DWD&ROOHFWLRQ ............................................................................................... 48 0HGLFDWLRQV ................................................................................................................. 48 6XEMHFW&RQVHQW ......................................................................................................... 49 5DQGRPL]DWLRQDQG7UHDWPHQW$VVLJQPHQW ........................................................ 51 'HVFULSWLRQRI$OO6WXG\3URFHGXUHVDQG9LVLWV ................................................... 51"
9,page_9,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  (QUROOPHQW %DVHOLQH ..................................................................................................... 51 &RQWURO$UP$$',QLWLDWLRQ ........................................................................................... 52 7UHDWPHQW$UP&U\RDEODWLRQ3URFHGXUH ..................................................................... 53  (VRSKDJHDO9LVXDOL]DWLRQDQG7HPSHUDWXUH0RQLWRULQJ ......................................... 53  3UHSURFHGXUH$QWLFRDJXODWLRQ .................................................................................. 53  ,QWUDSURFHGXUH$QWLFRDJXODWLRQ ............................................................................... 53  3RVWSURFHGXUH$QWLFRDJXODWLRQ ................................................................................. 54  'LDSKUDJP0RYHPHQW ................................................................................................. 54  %DOORRQ3XOPRQDU\9HLQ 39 &U\RDEODWLRQ .............................................................. 54  2WKHU$EODWLRQV'XULQJ,QGH[3URFHGXUH ................................................................. 55  &DUGLRYHUVLRQ ................................................................................................................ 55   3URFHGXUH'RFXPHQWDWLRQ .......................................................................................... 55 +RVSLWDO'LVFKDUJH .......................................................................................................... 56 0HGLFDWLRQ&RPSOLDQFH ................................................................................................... 56 6XEVHTXHQW$EODWLRQ3URFHGXUHV .................................................................................. 57 &DUGLRYHUVLRQV .................................................................................................................. 57 6FKHGXOHG)ROORZXS9LVLWV ............................................................................................ 57  2QH0RQWK2IILFH9LVLW ................................................................................................ 58  7KUHH0RQWK2IILFH9LVLW ............................................................................................. 59  6L[0RQWK2IILFH9LVLW .................................................................................................. 59  7ZHOYHPRQWK2IILFH9LVLW .......................................................................................... 60 8QVFKHGXOHG2IILFH9LVLWV ............................................................................................... 61 5H$EODWLRQ&URVVRYHU$EODWLRQ ................................................................................. 61 OHDG(OHFWURFDUGLRJUDPV ........................................................................................ 61 $PEXODWRU\0RQLWRULQJ ............................................................................................... 61 6WXG\([LW ...................................................................................................................... 62 $VVHVVPHQWRI(IILFDF\ ............................................................................................. 62 $VVHVVPHQWRI6DIHW\ ................................................................................................ 62 5HFRUGLQJ'DWD ..........................................................................................................62 'HYLDWLRQ+DQGOLQJ .................................................................................................... 63 6XEMHFW:LWKGUDZDORU'LVFRQWLQXDWLRQ ............................................................ 64 12. Risks and Benefits ..................................................................................................... 65 3RWHQWLDO5LVNV ........................................................................................................... 65 5LVN0LQLPL]DWLRQ ...................................................................................................... 68 3RWHQWLDO%HQHILWV ...................................................................................................... 68 5LVN%HQHILW5DWLRQDOH .............................................................................................. 68 13. Adverse Event Assessments ....................................................................................... 69 'HILQLWLRQV&ODVVLILFDWLRQV ...................................................................................... 69 5HSRUWLQJRI$GYHUVH(YHQWV ...................................................................................73 'HYLFH'HILFLHQFLHV .......................................................................................................... 73 $GYHUVH(YHQW5HSRUWLQJ5HTXLUHPHQWV ...................................................................... 74"
10,page_10,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  $GYHUVH(YHQW&ODVVLILFDWLRQ ................................................................................... 77 6XEMHFW'HDWK .................................................................................................................. 78  'HDWK'DWD&ROOHFWLRQ ................................................................................................. 78  'HDWK&ODVVLILFDWLRQDQG5HSRUWLQJ ........................................................................... 79 3URGXFW&RPSODLQWV ......................................................................................................... 80 14. Data Review Committees .......................................................................................... 81 15. Statistical Design and Methods ................................................................................. 82 3ULPDU\(IILFDF\2EMHFWLYH ...................................................................................... 83 +\SRWKHVLV ........................................................................................................................ 83 (QGSRLQW'HILQLWLRQ .......................................................................................................... 83 3HUIRUPDQFH5HTXLUHPHQWV ........................................................................................... 83 5DWLRQDOHIRUSHUIRUPDQFHFULWHULD ................................................................................ 84 $QDO\VLV0HWKRGV ............................................................................................................. 84 6DPSOH6L]H ...................................................................................................................... 85 'HWHUPLQDWLRQRI3DWLH QWV'DWDIRU$QDO\VLV ............................................................... 85 3ULPDU\6DIHW\2EMHFWLYH .........................................................................................86 +\SRWKHVLV ........................................................................................................................ 86 (QGSRLQW'HILQLWLRQ .......................................................................................................... 86 3HUIRUPDQFHUHTXLUHPHQWV ............................................................................................ 86 5DWLRQDOHIRU3HUIRUPDQFH&ULWHULD ............................................................................... 86 $QDO\VLV0HWKRGV ............................................................................................................. 87 6DPSOH6L]H ...................................................................................................................... 87 'HWHUPLQDWLRQRI3DWLH QWV'DWDIRU$QDO\VLV ............................................................... 88 6HFRQGDU\2EMHFWLYHV ............................................................................................... 89 $WULDO)LEULOODWLRQ(IIHFWRQ4XDOLW\RI/LIH $)(47 .................................................... 89  +\SRWKHVLV .................................................................................................................... 89  (QGSRLQW'HILQLWLRQ ...................................................................................................... 90  $QDO\VLV0HWKRGV ......................................................................................................... 90  3HUIRUPDQFH&ULWHULD ................................................................................................... 90  5DWLRQDOHIRU3HUIRUPDQFH&ULWHULD ............................................................................ 90  'HWHUPLQDWLRQRI6XEMHFWV'DWDIRU$QDO\VLV ........................................................... 90  $GGLWLRQDODQDO\VHV ...................................................................................................... 90 (4'4XHVWLRQQDLUH ...................................................................................................... 91  +\SRWKHVLV .................................................................................................................... 91  (QGSRLQW'HILQLWLRQ ...................................................................................................... 91  $QDO\VLV0HWKRGV ......................................................................................................... 91  3HUIRUPDQFHFULWHULD .................................................................................................... 91  5DWLRQDOHIRU3HUIRUPDQFH&ULWHULD ............................................................................ 91  'HWHUPLQDWLRQRI6XEMHFWV'DWDIRU$QDO\VLV ........................................................... 91 &DUGLRYDVFXODUKRVSLWDOL]DWLRQV ('DQGXQVFKHGXOHGRIILFHYLVL WV .......................... 92  +\SRWKHVLV .................................................................................................................... 92"
11,page_11,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  (QGSRLQW'HILQLWLRQ ...................................................................................................... 92  $QDO\VLV0HWKRGV ......................................................................................................... 92  3HUIRUPDQFH5HTXLUHPHQWV ........................................................................................ 92  5DWLRQDOHIRU3HUIRUPDQFH5HTXLUHPHQWV ................................................................ 92  'HWHUPLQDWLRQRI6XEMHFWV'DWDIRU$QDO\VLV ........................................................... 93 &DUGLRYHUVLRQV ..................................................................................................................93  +\SRWKHVLV .................................................................................................................... 93  (QGSRLQW'HILQLWLRQ ...................................................................................................... 93  $QDO\VLV0HWKRGV ......................................................................................................... 93  3HUIRUPDQFH5HTXLUHPHQWV ........................................................................................ 93  5DWLRQDOHIRU3HUIRUPDQFH&ULWHULD ............................................................................ 94  'HWHUPLQDWLRQRI6XEMHFWV'DWDIRU$QDO\VLV ........................................................... 94 16. Ethics ........................................................................................................................ 99 6WDWHPHQW V RI&RPSOLDQFH ................................................................................... 99 17. Study Administration ............................................................................................... 101 5ROHRIWKH6SRQVRU5HSUHVHQWDWLYHV .................................................................. 101 0RQLWRULQJ ................................................................................................................. 101 'DWD 0DQDJHPHQW ...................................................................................................101 'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV ......................................................... 102 &RQILGHQWLDOLW\ .......................................................................................................... 102"
12,page_12,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  &,3$PHQGPHQWV ..................................................................................................... 102 5HFRUG5HWHQWLRQDQG5HSRUWV ............................................................................. 102 ,QYHVWLJDWRU5HFRUGV ..................................................................................................... 103 ,QYHVWLJDWRU5HSRUWV ..................................................................................................... 103 6SRQVRU5HFRUGV ............................................................................................................ 106 6SRQVRU5HSRUWV ............................................................................................................107 3XEOLFDWLRQDQG8V HRI,QIRUPDWLRQ .................................................................... 111 0DQDJHPHQWRI3ULPDU\6HFRQGD U\DQG$QFLOODU\3XEOLFDWLRQV ............................. 112 &ULWHULDIRU'HWHUPLQLQJ$XWKRUVKLS ............................................................................ 112 7UDQVSDUHQF\ ................................................................................................................. 113 6XVSHQVLRQRU(DUO\7HUPLQDWLRQ ......................................................................... 113 3ODQQHG6WXG\&ORVXUH .................................................................................................. 113 (DUO\7HUPLQDWLRQRU6XVSHQVLRQ ................................................................................ 113 6WXG\ZLGHWHUPLQDWLRQRUVXVSHQVLRQ ....................................................................... 113 6LWHWHUPLQDWLRQRUVXVSHQVLRQ .................................................................................... 113 3URFHGXUHVIRU7HUPLQDWLRQRU6XVSHQVLRQ ............................................................... 114   0HGWURQLFLQLWLDWHGDQGUHJX ODWRU\DXWKRULW\LQLWLDWHG ......................................... 114   ,QYHVWLJDWRULQLWLDWHG ................................................................................................. 114   ,5%(&LQLWLDWHG .......................................................................................................... 114 18. References ............................................................................................................... 116 19. Appendices .............................................................................................................. 118 /LVWLQJRI7DEOHV 7DEOH 6WXG\VSRQVRUDQGPRQLWRULQJFRQWDFWLQIRUPDWLRQ   7DEOH &52LQIRUPDWLRQ   7DEOH 6WHHULQJ&RPPLWWHHFRQWDFWLQIRUPDWLRQ   7DEOH 'HYLFH,QIRUPDWLRQ   7DEOH 9LVLW6FKHGXOHDQG'DWD &ROOHFWLRQ5HTXLUHPHQWV6XPPDU \  7DEOH )ROORZXS9LVLW:LQGRZV    7DEOH $GYHUVH(YHQWDQG'HYLF H'HILFLHQF\5HSRUWLQJ5HTXLUHP HQWV  7DEOH $GYHUVH(YHQW&ODVVLI LFDWLRQ5HVSRQVLELOLWLHV   7DEOH ,QYHVWLJDWRUUHSRUWVD SSOLFDEOHIRUDOOJHRJUDSKLHVSH U0HGWURQLF5HTXLUHPHQWV  7DEOH $GGLWLRQDO,QYHVWLJDWRU UHSRUWVDSSOLFDEOHWRWKH8QL WHG6WDWHV 7DEOH ,QYHVWLJDWRUUHSRUWVDSSOLFDEOHWR(XURSH   7DEOH 6SRQVRU5HSRUWVIRUWKH8QLWHG6WDWHV  "
13,page_13,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 13 of 130 Version 5.0 STOP AF First Page 13 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Table 13: Sponsor reports for Europe ............................................................................................... 110 Table 14: Foreseeable Adverse Events ............................................................................................. 125 Table 15: Arctic Front and Arctic Front Advance™ Complications Reported in Literate for Paroxysmal and Persistent AF Patients ...................................................................................................................... 127 Listing of Figures Figure 1: Study Design ..................................................................................................................... 32 Figure 2: Arctic Front AdvanceTM Cardiac Cryoablation Catheter ........................................................... 37 Figure 3: FlexCath AdvanceTM Steerable Sheath with Cryoablation Catheter .......................................... 38 Figure 4: Achieve™ Mapping Catheter ................................................................................................ 39 Figure 5: CryoCath CryoAblation Console ............................................................................................ 39 Figure 6: Coaxial Umbilical Cable ....................................................................................................... 40 Figure 7: Electrical Umbilical Cable ..................................................................................................... 40 Figure 8: Manual Retraction Kit .......................................................................................................... 41 Listing of Appendices Appendix A: CRYOBALLOON SAFETY DATA LITERATURE SEARCH ...................................................... 118 Appendix B: DRAFT DATA COLLECTION ELEMENTS (CASE REPORT FORMS) ...................................... 121 Appendix C: INFORMED CONSENT FORM TEMPLATE ........................................................................ 122 Appendix D: PARTICIPATING INVESTIGATOR AND INSTITUTIONS .................................................... 123 Appendix E: IRB LIST ...................................................................................................................... 124 Appendix F: FORESEEABLE ADVERSE EVENTS .................................................................................. 125 Appendix G: PRE -CLINICAL TESTING ............................................................................................... 130"
14,page_14,
15,page_15,
16,page_16,
17,page_17,
18,page_18,
19,page_19,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 19 of 130 Version 5.0 STOP AF First Page 19 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 3. Synopsis Title STOP AF First Clinical Study Type Pivotal (US)/ Post- market interventional (Europe) Product Name Arctic Front AdvanceTM Cardiac CryoAblation Catheter Sponsor United States of America Medtronic, Inc. 8200 Coral Sea St NE Mounds View, MN U .S.A. 55112 Local Sponsor Europe Medtronic, Bakken Research Center B.V. Endeplosdomein 5 6229 GW Maastricht The Netherlands Indication Under Investigation Current indication in the US : The Arctic Front Advance ™ Cardiac CryoAblation Catheter is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. Indication under investigation for the US : The Arctic Front Advance™ Cardiac CryoAblation Catheter is indicated for the treatment of recurrent symptomatic paroxysmal atrial fibrillation. The indication under investigation is within the approved indication in Europe. Investigation Purpose The purpose of the s tudy is to provide data demonstrating the safety and effectiveness of the Arctic Front Advance ™ Cardiac CryoAblation Catheter for the treatment of recurrent symptomatic paroxysmal AF, without the requirement that the subjects be drug refractory. Product Statu s The Arctic Front Advance ™ Cardiac CryoAblation Catheter is market released and will become investigational when used as indicated in the study in the US. The catheter is market released and will be used within the approved indication s in Europe, therefore is not considered investigational for the intended patient population in Europe. Primary Objective Primary Efficacy Objective : Demonstrate the superiority of cryoballoon ablation as compared to antiarrhythmic drug (AAD) therapy in terms of the rate of freedom from AF/AT/AFL in a non -drug refractory paroxysmal AF population."
20,page_20,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 20 of 130 Version 5.0 STOP AF First Page 20 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Primary Safety Objective : Demonstrate an acceptable safety profile of the cryoballoon ablation procedure as a first line therapy in a non-drug refractory paroxysmal AF population . Secondary Objectives Secondary Objectives are as follows: 1. Assess changes in quality of life (QoL) between baseline and 12 months in the cryoballoon ablation arm. 2. Compare health care utilization (HCU) between the treatment and control arms. Primary Endpoint Primary Efficacy Endpoint: The primary endpoint is treatment success at 12 months after AAD initiation (control arm) or after the pulmonary vein isolation ablation procedure utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter (treatment arm). A treatment success is th e opposite of a treatment failure. Treatment failure is defined as any of the following components: • Acute procedural failure (treatment arm only) • Documented AF/AT/AFL on ambulatory monitoring/12 -lead ECG after the 90 day post -ablation blanking period (treatment arm)/AAD optimization period (control arm) o Minimum of 30 seconds on ambulatory monitoring or 10 seconds on 12 -lead ECG. o Note: Documented occurrence and treatment of typical right-sided cavotricuspid isthmus dependent atrial flutter is not considered a failure if confirmed by entrainment maneuvers during EP testing. • Any subsequent AF surgery or ablation in the left atrium. • Any subsequent cardioversion after the 90 day post -ablation blanking period (treatment arm) /AAD optimization period (control arm). • Class I or III antiarrhythmic drug (or sotalol) use after the 90 day blanking period (treatment arm only). The AAD optimization period is defined as the first 90 days after AAD initiation (control arm). The post -ablation blanking period is defined as the first 90 days after the index ablation procedure (treatment arm) ."
21,page_21,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 21 of 130 Version 5.0 STOP AF First Page 21 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Recurrences of atrial arrhythmias during the AAD optimization/ blanking periods will not be counted in the determination of the first clinical failure for the primary endpoint. Within the AAD optimization period/ post-ablation blanking period, recurrent arrhythmias can be managed with medications or cardioversions. Reablation will be considered a primary endpoint failure at all times, including during the 90 day post -ablation blanking period . Acute procedural failure (treatment arm only) is defined as: a) Inability to isolate all accessible targeted pulmonary veins (assessed for entrance block and, where assessable, exit blo ck) during the index ablation procedure. b) Left atrial non -PVI ablations including but not limited to, ablation of linear lesions c) Use of a non -study device in the left atrium. Primary Safety Endpoint: The following adverse events will be counted towards the primary safety endpoint: • Transient Ischemic Attack (TIA)within 7 days • Cerebrovascular accident within 7 days • Major bleeding that requires transfusion or results in a 20% or greater fall in hematocri t (HCT) within 7 days • Development of a significant pericardial effusion within 30 days. A significant pericardial effusion is one that results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1 -cm or more pericar dial effusion as documented by echocardiography. • Symptomatic PV stenosis within 12 months; accompanied by one of the following: 50%-70% reduction in diameter of the pulmonary vein, with symptoms not explained by other conditions; OR >70% reduction in diam eter of the pulmonary vein • MI within 7 days • PNI unresolved at 12 months • AE fistula within 12 months • Major vascular complication that requires intervention, prolongs the hospital stay, or requires hospital admission (within 7 days). Secondary Endpoints 1. The difference in composite scores from the AFEQT questionnaire taken at baseline and 12 month visits, and the difference in composite scores for the EQ- 5D questionnaire taken at baseline and 12 -month visits. 2. 12-month rates of cardiovascular HCU events, a nd 12-month rates of cardioversion (either electrical or pharmacological) ."
22,page_22,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 22 of 130 Version 5.0 STOP AF First Page 22 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Study Design Prospective, interventional, multi -center, randomized, controlled , unblinded clinical study . The study will be conducted at up to 30 sites in the US and up to 10 in Europe. Study Duration All randomized study subjects will be followed from the time of consent through 12 months post-index cryoballoon ablation procedure (treatment arm), or AAD initiation (control arm). Subjects will be exited from the study at the conclusion of the 12 month follow-up visit. The expected total study duration is approximately 30 months, representing 1 8 months of enrollment and 12 months of subject follow-up. Sample Size 210 enrolled subjects in the US and Europe . Inclusion/Exclusion Criteria The following is a list of inclusion/exclusion criteria: Inclusion criteria • A diagnosis of symptomatic paroxysmal AF with the following documentation: (1) physician’s note indicating recurrent self - terminating AF or paroxysmal AF; and (2) any ECG documented AF within 6 months prior to enrollment . • Age 18-80 Exclusion criteria"
23,page_23,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 23 of 130 Version 5.0 STOP AF First Page 23 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential • History of AF treatment with class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence. However, p atients pretreated with above AAD for less than 7 days with the intention to convert an AF episode are allowed. • Prior persistent AF ( continuous AF that is sustained >7 days) • Left atrial diameter greater than 5.0 cm • Prior left atrial ablation or left atrial surgical procedure • Presence or likely implant of a permanent pacemaker, biventricular pacemaker, loop recorder, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) • Presence of any pulmonary vein stents • Known p resence of any pre -existing pulmonary vein stenosis • Pre-existing hemidiaphragmatic paralysis • Presence of any cardiac valve prosthesis • Moderate or severe mitral valve regurgitation or stenosis • Any cardiac surgery, myocardial infarction, PCI / PTCA or coronary artery stenting which occurred during the 90 day interval preceding the date the subject signed the Informed Consent Form • Unstable angina • NYHA class III or IV congestive heart failure and/or known left ventricular ejection fraction (LVEF) less than 45% • Diagnosis of primary pulmonary hypertension • Rheumatic heart disease • Thrombocytosis, thrombocytopenia • Contraindication to anticoagulation therapy • Active systemic infection • Hypertrophic cardiomyopathy • Cryoglobulinemia • Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism , severe obstructive sleep apnea, and acute alcohol toxicity. • Any cerebral ischemic event (strokes or TIAs) which occurred during the 180 day interval preceding the date the subject signed the Informed Consent Form , or any known unresolved complications from previous stroke/TIA • Existing thrombus • Pregnancy • Patient with life expect ancy that makes it unlikely 12 months of follow-up will be completed. • Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of this study not pre-approved by Medtronic • Patients with contraindications to a Holter monitor • Unwilling or unable to comply fully with study procedures and follow-up"
24,page_24,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 6WXG\3URFHGXUHVDQG $VVHVVPHQWV6XEMHFWVLQWKHWUHDWPHQWDUPZLOOXQGHUJRDSXOPRQDU\YHLQLVR ODWLRQ 39, DEODWLRQSURFHGXUHZLWKWK H$UFWLF)URQW$GYDQFH&DUGLDF  &U\R$EODWLRQ&DWKHWHU 6XEMHFWVLQWKHFRQWURODUPZLOOEHWUHDWHGZLWKDQDQWLDUUK\WK PLFGUXJ DVSUHVFULEHGE\WKHVW XG\LQYHVWLJDWRU 6XEMHFWVZLOOKDYHIROORZXSYLVL WVDWDQGPRQWKVS RVW$$' LQLWLDWLRQRUDEODWLRQ6XEMH FWVZLOOEHH[LWHGDWWKHFRQFOXV LRQRIWKH PRQWKYLVLW 6DIHW\$VVHVVPHQWV $GYHUVHHYHQWGDWDFROOHFWLRQZ LOOEHJLQRQFHVXEMHFWVVLJQWKH ,QIRUPHG &RQVHQW)RUPDQGZLOOFRQWLQXHWKU RXJKVWXG\H[LW)RUWKHSXU SRVHVRI WKHVWXG\WKHIROORZLQJ$GY HUVH(YHQWVZLOOE HFROOHFWHG  x$OOSURFHGXUHUHODWHG$(V x$OOFU\RDEODWLRQV\VWHPUHODWHG$(V x$OO$$'UHODWHG$(V x$OOFDUGLRYDVFXODUUHODWHG$(V x$OO6HULRXV$GYHUVH(YHQWV 6$( V UHJDUGOHVVRIUHODWHGQHVV ,QWURGXFWLRQ  %DFNJURXQG $WULDO)LEULOODWLRQ $) LVDFRPPRQDQGGLVDEOLQJFDUGLDFDUUK \WKPLDZLWKDKHWHUR JHQHRXVFOLQLFDO SUHVHQWDWLRQ7KHIXQGDPHQWDOSDWKRSK\VLRORJ\FRQVLVWVRIDWUL DOZDYHOHWVSURSDJDWLQJLQGLIIHUHQW GLUHFWLRQVFDXVLQJGLVRUJDQL]HGDWULDOGHSRODUL]DWLRQZLWKRXW HIIHFWLYHDWULDOFRQWUDFWLRQZLWKFRQFRPLWDQW UDSLGDQGLUUHJXODUYHQWULFXODU FRQWUDFWLRQV$)FDQEHFOLQLF DOO\VWUDWLILHGEDVHGRQZKHWKHUHSLVRGHVDUH VHOIWHUPLQDWLQJ SDUR[\VPDO RUSHUVLVWHQW3DUR[\VPDO$) 3$ ) LVGHILQHGDVUHFXUUHQW$)WKDW WHUPLQDWHVVSRQWDQHRXVO\RUZLWKL QWHUYHQWLRQZLWKLQGD\VRI RQVHW3HUVLVWHQW$)LVGHILQHGDV FRQWLQXRXV$)WKDWLVVXVWDLQHGEH\RQGGD\V &DONLQVHWDO   $)LVWKHPRVWFRPPRQRIWKHVXVW DLQHGDUUK\WKPLDVDIIHFWLQJPL OOLRQVRISHRSOHZRU OGZLGH,QWKH86 $)DIIHFWVEHWZHHQ PLOOLRQDQGPLOOLRQDGXOWV -DQXDU\ :DQQHWDO DQGWKDWQXPEHULV H[SHFWHGWRGRXEOHRYHUWKHQH[W\HDUV *RHWDO 3 URORQJHG$)PD\OHDGWRHOHFWULFDO PHFKDQLFDODQGVWUXFWXUDOFKDQJHVWRWKHOHIWDWULXPZKLFKPD \WKHQSURJUHVVWRWDFK\FDUGLDLQGXFHG FDUGLRP\RSDWK\KHDUWIDLOXUHDQG SHUVLVWHQW$)7KHSURJQRVLV LVUHODWHGWRWKHXQGHUO\LQJFDXVHRIWKH GLVHDVHZLWKLGLRSDWKLFFDXVH VKDYLQJWKHEHVWSURJQRVLVDQGL VFKHPLFFDUGLRP\RSDWK\KDYLQJDSRRU SURJQRVLV7KHPRUWDOLW\UDWHL QSDWLHQWVZLWK$)LVWZLFHWKD WRISDWLHQWVZLWKRXW $)DQGWKHULVNRI$) UHODWHGVWURNHLVIROGFRPSDUHG WRWKHULVNLQSDWLHQWVZLWKR XW$) :ROI$EERWWDQG.DQQHO   ,QWKH86DSSURYHGWUH DWPHQWRSWLRQVIRUQHZO\GLDJQRVHGV\PSW RPDWLFSDUR[\VPDO$)DUHOLPLWHGWR SKDUPDFHXWLFDOWKHUDS\EHFDXVHW KHODEHOLQJRIFDUGLDFDEODWLRQ FDWKHWHUVLVIRU³GUXJUHIUDFWRU\´ SDWLHQWV3DWLHQWVPXVWEHUHIU DFWRU\RULQWROHUDQWWRDWOHDV WFODVV,RU,,,DQWLDUUK\WKPLFGUXJ $$' "
25,page_25,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 25 of 130 Version 5.0 STOP AF First Page 25 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential before ablation may be attempted. Pharmacological therapy for AF (paroxysmal and persistent) has limited antiarrhythmic efficacy, with recurrence of AF reported at 44% to 67% within one year, based on a systematic review of 45 randomi zed controlled clinical trials (Lafuente -Lafuente, Mouly, et al. 2006) . Treatment with AADs may also result in an increased risk for adverse events. Results of an AFFIRM sub study showed that adverse events resulting in disconti nuation of the treatment were common for AADs, occurring in 11.1% to 28.1% of patients, depending on the AAD used (AFFIRM First Antiarrhythmic Drug Substudy Investi. 2003) . The RAAFT -2 study found that AAD’s had a success rate of 42% at one year in 61 previously treatment -naive paroxysmal AF patients; meanwhile, the 2014 AHA/ACC/HRS guideline for the management of patients with AF stated that “much like other antiarrhythmic drugs, with the exception of amiodarone, the rates of maintaining sinus rhythm at 1 year for sotalol are 30 -50%” (January et. al. 2014) (Morillo, et al. 2014) . Atrial fibrillation is known to cause electrical remodeling of the atria as well as structural changes that promote perpetuation and progressi on of symptoms (Wijesurendra and Casadei 2015) (Shulka and Curtis 2014) (Jalife and Kaur 2015) . Untreated PAF can give rise to persistent or permanent forms of the disease (De Vos, et al. 2010) , which may be more resistant to contemporary AF treatments (Oral, et al. 2002) (Romero, e t al. 2015) . As such, early and effective intervention is key for normalizing sinus rhythm (SR) and preventing further remodeling and disease progression (Nattel, et al. 2014) (Cosio, et al. 2008) . AAD treatments have little to no effect on remodeling (Nattel, et al. 2014) and although may restore SR in the short -term, have high long -term rela pse rates (45 -90%) (Cosio, et al. 2008) making this treatment largely ineffective at preventing progression of AF. By contrast, early evidence seems to indicate that catheter ablation may reverse indicators of structural remodeling associated w ith AF (Walters, et al. 2016) (Wu, et al. 2016) . Furthermore, catheter ablation, particularly using the Arctic Front Advance ™ Cardiac CryoAblation Catheter, hereafter also referred to as the cryoballoon, has a much higher efficacy rate and may be even more effective when provided earlier after AF onset (Arena, et al. 2016) (Tanner, et al. 2011) . Catheter ablation treatment strategies for AF have evolved over time and currently include pulmonary vein isolation (PVI) as a cornerstone of ablation therapy in all types of AF (paroxysmal and persistent) (Raviele 2012) (Jais, et al. 2006) . AF arises primarily from the left side of the heart in (or near) the atrium, particularly where the pulmonary veins (PVs) join the atrium. The fundamental basis for the AF ablation procedure is the creation of myocardial lesions that block the propagation of AF wave fronts from the triggering source. The mus cular sleeves within the PVs have been established as a critical source of AF triggers (Caulkins and et. al. 2007) . The safety profile of cryoballoon ablation is also well established. The STOP AF trial (Packer, et al. 2013) was a prospective, multicenter, randomized, controlled investigation device exempti on (IDE) study designed to compare outcomes of cryoballoon and antiarrhythmic drug therapies in patients with PAF. Six point one percent (6.1%) of cryoballoon subjects experienced a procedure- related event or major adverse event versus 8.5% of AAD subjects. An analysis of 149 cryoballoon studies with 11,242 patients (see Appendix A for literature search methodology) showed similar complication r ates to STOP AF. The STOP AF Post Approval Study was designed to provide long -term safety and effectiveness of the Arctic Front and Arctic Front Advance™ Cardiac Cryoablation Catheter System, including the Freezor® MAX Cardiac cryoablation catheter acc ording to the Product Labeling. Inexperienced users were selected as study Investigators in order to understand complication rates in a real world setting. There were 402 subjects enrolled. The study is currently in the follow -up phase, with all enrolled su bjects having been followed for on e year post- ablation procedure. Major procedure related events occurred in 20/341 patients (5.9% of pa tients and 5.7% of procedures). No device or procedure related deaths were reported (Knight, e t al. 2016) ."
26,page_26,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  3XUSRVH 7KHSXUSRVHRIWKH6723$))LUVWVWXG\LVWRSURYLGHGDWDGHPRQ VWUDWLQJWKHVDIHW\DQGHIIHFWLYHQHVVRI WKH$UFWLF)URQW$GYDQFH70&DUGLDF&U\R$EODWLRQ&DWKHWHUIRUWKHWUHDWPHQWRIUHFXUUHQWV \PSWRPDWLF SDUR[\VPDO$)ZLWKRXWWKHUHTXLUHPHQWWKDWVXEMHFWVEHGUXJUH IUDFWRU\7KHFXUUHQWLQGLFDWLRQLVWKH 86LVDVIROORZV 7KH$UFWLF)URQ W$GYDQFH&DUGLDF&U\R$EODWLR Q&DWKHWHULVLQGLFDWHGIRUWKHWUHDWPHQW RIGUXJUHIUDFWRU\ UHFXUUHQWV\PSWRPDWLFSDUR[\VPDODWULDOILEULOODWLRQ7KHSUR SRVHGLQGLFDWLRQLQWKH86 LVDVIROORZV 7KH$UFWLF)URQW$GYDQFH&DUGLDF&U\R$EODWLRQ& DWKHWHULVLQGLFDWHGIRUWKHWUHDWPHQWRI UHFXUUHQWV\PSWRPDWLFSDUR[\VPD ODWULDOILEULOODWLRQ7KHSURSR VHGLQGLFDWLRQLVZL WKLQWKHDSSURYHG LQGLFDWLRQVIRUXVHLQ(XURSH "
27,page_27,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 2EMHFWLYHVDQG(QGSRLQWV  2EMHFWLYHV 3ULPDU\2EMHFWLYH V   3ULPDU\(IILFDF\2EMHFWLYH 'HPRQVWUDWHWKHVXSHULRULW\RIFU\REDOORRQDEODWLRQDVFRPSDUHG WR$$'WKHUDS\LQWHUPVRIWKHUDWHRI IUHHGRPIURP$)$7$)/LQDQRQG UXJUHIUDFWRU\SDUR[\VPDO$)S RSXODWLRQ  3ULPDU\6DIHW\2EMHFWLYH 'HPRQVWUDWHDQDFFHSWDEOHVDIHW\ SURILOHRIWKHFU\REDOORRQDEO DWLRQSURFHGXUHDVDI LUVWOLQHWKHUDS\LQD QRQGUXJUHIUDFWRU\SDUR[\VPDO$)SRSXODWLRQ 6HFRQGDU\2EMHFWLYHV 6HFRQGDU\2EMHFWLYHVDUHDVIROORZV  $VVHVVFKDQJHVLQTXDOLW\RIOLIH EHWZHHQEDVHOLQHDQGPRQWK VLQWKHFU\REDOORRQDEODWLRQ DUP &RPSDUHKHDOWKFDUHXWLOL]DWLRQ EHWZHHQWKHWUHDWPHQWDQGFRQWU RODUPV           "
28,page_28,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  3ULPDU\(QGSRLQW  3ULPDU\(IILFDF\(QGSRLQW  7KHSULPDU\HQGSRLQWLVWUHDWPHQW VXFFHVVDWPRQWKVDIWHU$$ 'LQLWLDWLRQ FRQWURODUP RUDIWHUWKH SXOPRQDU\YHLQLVRODWLRQDEODWLRQSURFHGXUHXWLOL]LQJWKH$UFWL F)URQW$GYDQFH&DUGLDF&U\R$EODWLRQ &DWKHWHU WUHDWPHQWDUP $WUHDWPHQWVXFFHVVLVWKHRSSRVLWH RIDWUHDWPHQWIDLOXUH 7UHDWPHQWIDLOXUHLVGHILQHGDVDQ\RIWKHIROORZLQJFRPSRQHQWV  D $FXWHSURFHGXUDOIDLOXUH WUHDWPHQWDUPRQO\  E 'RFXPHQWHG$)$7$)/RQDPEXODWR U\PRQLWRULQJOHDG(&*DIWHU WKH GD\SRVWDEODWLRQ EODQNLQJSHULRG WUHDWPHQWDUP $$'RSWLPL]DWLRQSHULRG FRQWUR ODUP  R0LQLPXPRIVHFRQGVRQDPEXODWRU\PRQLWRULQJRUVHFRQGVRQ OHDG(&* R1RWH 'RFXPHQWHGRFFXUUHQFHDQGWUHDWPHQWRIW\SLFDOULJKWVLGH GFDYRWULFXVSLGLVWKPXV GHSHQGHQWDWULDOIOXWWHULVQRWFR QVLGHUHGDIDLOXUHLIFRQILUP HGE\HQWUDLQPHQW PDQHXYHUVGXULQJ(3WHVWLQJ F $Q\VXEVHTXHQW$)VXUJHU\RUD EODWLRQLQWKHOHIWDWULXP G $Q\VXEVHTXHQWFDUGLRYHUVLRQDIW HUWKH GD\SRVWDEODWLRQEOD QNLQJSHULRG WUHDWPHQW DUP $$'RSWLPL]DWLRQSHULRG FRQWURODUP  H &ODVV,RU,,,DQWLDUUK\WKPLFGUXJ RUVRWDORO XVHDIWHUWKH GD\EODQNLQJSHULRG WUHDWPHQWDUP RQO\  7KH$$'RSWLPL]DWLRQSHULRGLVGHILQHGDVWKHILUVW GD\VDIW HU$$'LQLWLDWLRQ FRQWURODUP 7KHSRVW DEODWLRQEODQNLQJSHULRGLVGHILQH GDVWKHILUVW GD\VDIWHU WKHLQGH[DEODWLRQSURFHGXUH WUHDWPHQW DUP 5HFXUUHQFHVRIDWULDODUU K\WKPLDVGXULQJWKH$$'RSWLPL] DWLRQEODQNLQJSHULRGVZLOOQRWEHFRXQWHG LQWKHGHWHUPLQDWLRQRIWKHILUV WFOLQLFDOIDLOXUHIRUWKHSULP DU\HQGSRLQW :LWKLQWKH$$'RSWLPL]DWLRQSHUL RGSRVWDEODWLRQEODQNLQJSHULR GUHFXUUHQWDUUK\WKPLDVFDQEHPDQDJHG ZLWKPHGLFDWLRQVRUFDUGLRYHUVLRQV5HDEODWLRQZLOOEHFRQVLGH UHGDSULPDU\HQGSRLQWIDLOXUHDWDOOWLPHV LQFOXGLQJGXULQJWKH GD\SRVWDEODWLRQEODQNLQJSHULRG $FXWHSURFHGXUDOIDLOXUH WUHD WPHQWDUPRQO\ LVGHILQHGDV  D ,QDELOLW\WRLVRODWHDOODFFHVVLEOH WDUJHWHGSXOPRQDU\YHLQV D VVHVVHGIRUHQWUDQFHEORFNDQG ZKHUHDVVHVVDEOHH[LWEORFN GXU LQJWKHLQGH[DEODWLRQSURFHGX UH E /HIWDWULDOQRQ39,DEODWLRQVLQ FOXGLQJEXWQRWOLPLWHGWRDEO DWLRQRIOLQHDUOHVLRQV F 8VHRIDQRQVWXG\GHYLF HLQWKHOHIWDWULXP "
29,page_29,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 29 of 130 Version 5.0 STOP AF First Page 29 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 5.1.4.2. Primary Safety Endpoint The following adverse events will be counted towards the primary safety endpoint: • TIA within 7 days • Cerebrovascular accident within 7 days • Major bleeding that requires transfusion or results in a 20% or greater fall in hematocrit (HCT) within 7 days • Development of a significant pericardial effusion within 30 days. A significant pericardial effusion is one that results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1 -cm or more pericardial effusion as documented by echocardiography. • Symptomatic PV stenosis within 12 months; accompanied by one of the following : 50%-70% reduction in diameter of the pulmonary vein , with symptoms not explained by other conditions; OR >70% reduction in diameter of the pulmonary v ein • MI within 7 days • PNI unresolved at 12 months • Atrial-esophageal fistula within 12 months • Major vascular complication that requires intervention, prolongs the hospital stay, or requires hospital admission (within 7 days)."
30,page_30,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  6HFRQGDU\(QGSRLQWV 7KHGLIIHUHQFHLQFRPSRVLWHVFRUHVIURPWKH$)(47TXHVWLRQQDLUH WDNHQDWEDVH OLQHDQG PRQWKYLVLWVDQGWKHG LIIHUHQFHLQFRPSRVL WHVFRUHVIRUWKH(4 'TXHVWLRQQDLUHWDNHQDW EDVHOLQHDQGPRQWKYLVLWV x7KH$)(47DQG(4'TXHVWLRQQDLUHVZLOOEHXWLOL]HGIRUWKLVRE MHFWLYH7KH$)(47 TXHVWLRQQDLUHLVDQDWULDOILEU LOODWLRQVSHFLILFKHDOWKUHODWHG TXDOLW\RIOLIHTXHVWLRQQDLUHWR DVVHVVWKHLPSDFWRI$)RQDVX EMHFW¶VOLIH7KHRYHUDOOVFRUH UDQJHVIURP±ZKHUH FRUUHVSRQGVWRFRPSOHWHGLVDELOL W\DQGFRUUHVSRQGWRQRGLV DELOLW\7KH(4' TXHVWLRQQDLUHLVDVWDQGDUGL]HGLQ VWUXPHQWIRUPHDVXULQJJHQHUL FKHDOWKVWDWXV7KH(4' KDVWZRVHFWLRQV7KHILUVWVHF WLRQLVDGHVFULSWLYHVHFWLRQZ KHUHWKHVXEMHFW FKHFNVDER[E\ WKHPRVWDSSURSULDWHVWDWHPHQW 7KHVHFRQGVHFWLRQLVDYLVXDO DQDORJVFDOH PRQWKUDWHVRIFDUGLRYDVFXODUKHDOWKFDUHXWLOL]DWLRQ +&8  HYHQWVDQGPRQWKUDWHVRI FDUGLRYHUVLRQ HLWKHUHOHFWULFDORUSKDUPDFRORJLFDO x7KHQXPEHURIFDUGLRYDVFXODUUHOD WHGKRVSLWDOL]DWLRQVHPHUJHQF \GHSDUWPHQWYLVLWVDQG XQVFKHGXOHGYLVLWVZLOOEHUHSRUWH GDQGFRPSDUHGEHWZHHQWKHWU HDWPHQWDQGFRQWURODUPV x7KHQXPEHURIHOHFWULFDODQGSKD UPDFRORJLFDOFDUGLRYHUVLRQVH[S HULHQFHGE\VXEMHFWVZLOOEH UHSRUWHGDQGFRPSDUHG EHWZHHQWKHWUHDWPHQWDQGFRQWURODUPV                            "
31,page_31,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 31 of 130 Version 5.0 STOP AF First Page 31 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential"
32,page_32,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 6WXG\'HVLJQ 0HGWURQLF,QFLVVSRQVRULQJWKH6 723$))LUVWVWXG\ DSURVSH FWLYHLQWHUYHQWLRQD OPXOWLFHQWHU UDQGRPL]HGFRQWUROOHGXQEOLQGH GFOLQLFDOVWXG\7KHVWXG\ZL OOEHFRQGXFWHGDWXSWRVLWHVLQWKH86 DQGXSWRLQ(XURSH7ZRKXQG UHGDQGWHQ  VXEMHFWVZLO OEHHQUROOHG7KHPD[LPXPQXPEHURI VXEMHFWVWKDWPD\EHUDQGRPL]H GDWDVLQJOHFHQWHUZLOOEHV XEMHFWV RIWKHWRWDOVXEMHFWV UDQGRPL]HG 1RJUHDWHUWKDQ RIWKHVXEMHFWVZLOOEHHQURO OHGRXWVLGHRIWKH867KHUHLVQR PLQLPXPQXPEHURIUHTXLUHGHQUROOPHQWVSHUVLWH KRZHYHUVLWHV ZLOOEHHQFRXUDJHGWRHQUROODQG UDQGRPL]HDWOHDVWVXEMHFWV 6XEMHFWVZLOOEHUDQGRPL]HGWR HLWKHU$$'WKHUDS\ FRQWURODUP RU FU\RDEODWLRQ WUHDWPHQWDUP  6XEMHFWVZLOOEHIROORZHGDWP RQWKPRQWKVPRQWKVDQGPRQWKV IROORZLQJHLWKHUFU\RDEODWLRQRU$$'LQLWLDWLRQ6XEMHFWVZLOO EHH[LWHGIURPWKHVWXG\DWWKHPRQWK IROORZXSYLVLW$WOHDVWRQH$U FWLF)URQW$GYDQFH&U\R$EODWLR Q&DWKHWHUZLOOEHXVHGSHUVXEMHFWLQWKH WUHDWPHQWDUP$GGLWLRQDOFDWKHWHUVPD\EHXVHGLQWKHFDVHRI UHDEODWLRQRUFURVVRYHUDEODWLRQ DWOHDVW RQHSHUVXEMHFW   )LJXUH 6WXG\'HVLJQ "
33,page_33,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  'XUDWLRQ $OOUDQGRPL]HGVWXG\VXEMHFWVZL OOEHIROORZHGIURPWKHWLPHRI FRQVHQWWKURXJKPRQWKVSRVWLQGH[ FU\REDOORRQDEODWLRQSURFHGXUH  WUHDWPHQWDUP RU$$'LQLWLDWL RQ FRQWURODUP  6XEMHFWVZLOOEHH[LWHG IURPWKHVWXG\DWW KHFRQFOXVLRQRIWKH PRQWKIROORZXSY LVLW7KHH[SHFWHG WRWDOVWXG\GXUDWLRQLVDSSUR[LPDWHO\PRQWKVUHSUHVHQWLQJ PRQWKVRIHQUROOPHQWDQGPRQWKVRI VXEMHFWIROORZXS6XEMHFWVZ LOOQRWEHUHSODFHGZLWKQHZO\HQ UROOHGVXEMHFWVXSRQHDUO\VWXG\H[LW7KH REMHFWLYHVZLOOEHDQDO\]HGIRUD3UHPDUNHW$SSURYDO6XSSOHPHQW  30$6 DIWHUDOOUDQGRPL]HGVXEMHFWV FRPSOHWHPRQWKVRIIROORZXSDIWHUWKHLQGH[FU\REDOORRQDEO DWLRQSURFHGXUH WUHDWPHQWDUP RU$$' LQLWLDWLRQ FRQWURODUP  5DWLRQDOH 7KHVWXG\KDVSULPDU\REMHFWLYHVGHVLJQHGWRHYDOXDWHWKHVDIHW \DQGHIIHFWLYHQHVVRIWKH$UFWLF)URQW $GYDQFH&DUGLDF&U\R$EODWLRQ&D WKHWHUIRUWUHDWPHQWRIUHFXUUH QWV\PSWRPDWLFSDUR[\VPDO$),QWKH 86WKHUHDUHQRDEODWLRQFDWKHWHUVDSSURYHGWRWUHDWSDWLHQWV ZLWKSDUR[\VPDO$)XQOHVVWKH\KDYH GHPRQVWUDWHGLQWROHUDQFHRUUHIUDFWRULQHVVWRDQWLDUUK\WKPLFG UXJWKHUDS\7KHVWXG\ZLOOSURYLGH SDWLHQWVZLWKPRUHRSWLRQVIRUW UHDWPHQWDQGWKH SRVVLELOLW\RI LPSURYLQJWKHLUKHDOWKDQGTXDOLW\RIOLIH DQGDGHFUHDVHLQVWURNHULVN,I VXFFHVVIXOWKH6723$))LUV WVWXG\ZLOOGHPRQVW UDWHPHDQLQJIXO WKHUDSHXWLFEHQHILWLQWKLVSRS XODWLRQ7KLVHYDOXDWLRQZLOOV XSSRUWDQLQGLFDWLRQH[SDQVLRQIRUWKH WUHDWPHQWRIUHFXUUHQWV\PSWRPDWLFSDUR[\VPDO$)7KHVWXG\ZL OOEHFRQVLGHUHGVXFFHVVIXOLILWPHHWV WKHSULPDU\REMHFWLYHVFRQWLQJH QWXSRQ)'$UHYLHZDQGDSSURYDO  7KHVWXG\ZLOOFRPSDUHFU\RDEODWL RQWR$$'WKHUDS\WKHFXUUHQW VWDQGDUGRIFDUHIRUVXEMHFWV H[SHULHQFLQJDWULDOILEULOODWL RQIRUWKHILUVWWLPH &U\RDEODWLRQHIILFDF\ZLOOEHGH PRQVWUDWHGE\VKRZLQJWKDWVXEM HFWVLQWKHFU\RDEODWLRQDUPZLOO H[SHULHQFHDKLJKHUUDWHRIHIIL FDF\VXFFHVVWKDQWKH$$'DUP WUHDWPHQWVXFFHVVGHVFULEHGLQ6HFWLRQ  7KH6723$)3LYRWDOWULDOVKRZHGDQHIILFDF\VXFFHVV UDWHRI  6HYHUDOWULDOVZHUH FRPSOHWHGFRPSDULQJUDGLRIUHTXHQ F\DEODWLRQWR$$'VLQWKHVDPH QRQGUXJUHIUDFWRU\SDWLHQWSRSXODWLRQ 1LHOVHQHWDO  0RULOOR HWDO  :D]QLHWDO  7KH5$$)7VWXG\PRQLWRUHGIRU UHFXUUHQWDUUK\WKPLDLQDPDQQHU VLPLODUWRWKHUHTXLUHPHQWVRI WKLVSURWRFRO WKH\UHTXLUHGUHJXODUDQG V\PSWRPDWLFWUDQVWHOHSKRQLFPRQLWRUWUDQVPLVVLRQV 0RULOORHW DO ,Q5$$)7DSSUR[LPDWHO\ RIVXEMHFWVLQWKH$$'DUPH [SHULHQFHGUHFXUUHQWDWULDOILE ULOODWLRQE\RQH\HDU7KHVXSHULRULW\ DQDO\VLVLQWKLVVWXG\LVGHVLJQHGWRVKRZWKDWVXEMHFWVLQWKH FU\RDEODWLRQWUHDWPHQWDUPZLOOH[SHULHQFH OHVV$)UHFXUUHQFHWKDQVXEMHFWVLQWKH$$'DUPDVVXPLQJVLPLO DUUHFXUUHQFHUDWHVWRWKRVHLQWKH6723 $)3LYRWDOWULDODQG5$$)7 &U\RDEODWLRQVDIHW\ZLOOEHGHPRQV WUDWHGE\VKRZLQJWKDWWKHUD WHRIDSUHVSHFL ILHGOLVWRINQRZQ SRWHQWLDOFRPSOLFDWLRQVLVFRQVLVW HQWZLWKSUHYLRXVWULDOVDQG FXUUHQWOLWHUDWXUH 3DFNHUHWDO  "
34,page_34,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  0LQLPL]DWLRQRI%LDV 6HOHFWLRQRIVXE MHFWVWUHDWPHQWRIVXEMHFWVDQGHYDOXDWLRQRI VWXG\GDWDDUHSRWHQWLDOVRXUFHVRIELDV 0HWKRGVLQFRUSRUDWHGLQWKHVWXG\ GHVLJQWRPLQLPL]HSRWHQWLDO ELDVLQFOXGH EXWDUH QRWOLPLWHGWR  x6XEMHFWVZLOOXQGHUJRVFUHHQLQJW RFRQILUPHOLJLELOLW\IRUHQUR OOPHQWZLWKGHILQHG LQFOXVLRQH[FOXVLRQFULWHULDSULRUWRHQUROOPHQW x6XEMHFWGHPRJUDSKLFVZLOOEHFR OOHFWHGDWEDVHOLQHLQRUGHUWR ODWHUDVVHVVSRVVLEOHFKDUDFWHULVWLFV WKDWPD\LQIOXHQFHHQGSRLQWV x$OOFHQWHUVDQGJHRJUDSKLHVZLOOX VHWKHVDPHYHUVLRQRIWKHFO LQLFDOLQYHVWLJDWLRQSODQDQGFDVH UHSRUWIRUPV x$OOLQYHVWLJDWLRQDOFHQWHUSHUVR QQHODQG0HGWURQL FSHUVRQQHOZL OOEHWUDLQHGRQWKHLUUHVSHFWLYH DVSHFWVRIWKHVWXG\XVLQJVWDQ GDUGL]HGWUDLQLQJPDWHULDOV x$OOLQYHVWLJDWLRQDOFHQWHUSHUV RQQHOZLOOEHWUDLQHGRQDQGUHT XLUHGWRIROORZWKH&,3 x$QLQGHSHQGHQW&OLQLFDO(YHQW V&RPPLWWHH &(& ZLOOEHXWLOL]HG UHJXODUO\WRUHYLHZDQG DGMXGLFDWHUHSRUWHGDGYHUVHHYHQWVDQGGHDWKV x$QLQGHSHQGHQWFRUHODEZLOOEH XWLOL]HGWRUHYLHZDQGDGMXGLFD WHDOO(&*UHFRUGLQJVIURPVWXG\ UHTXLUHGOHDG(&*VDQGDPEXODWRU\PRQLWRULQJ x$VWDWLVWLFDODQDO\VLVSODQ 6$3  ZLOOEHGHYHORSHGSULRUWRDQ DO\]LQJGDWD7KHSODQZLOOGRFXPHQW DOOSUHVSHFLILHGDQDO\VH VDQGDQDO\VLVPHWKRGV x0RQLWRULQJZLOOEHFRQGXFWHGWR UHYLHZDGKHUHQFHWRWKH&,3DQG SHUIRUPVRXUFHGDWDYHULILFDWLRQ SHUWKH0RQLWRULQJ3ODQ x$PD[LPXPRIWUHDWHGVXEMHF WVZLOOEHDOORZHGDWDVLQJOHLQ YHVWLJDWLRQDOFHQWHUWRHQVXUHDQ HYHQGLVWULEXWLRQRIWRWDOVXEMHFWVDFURVVFHQWHUV x$OOVWXG\LQYHVWLJDWRUVLQDOOJ HRJUDSKLHVZLOOEHUHTXLUHGWR FRPSO\ZLWK&)53DUW)LQDQFLDO 'LVFORVXUHE\&OLQLFDO,QYHVWLJDWRUV ,QVXPPDU\SRWHQWLDOVRXUFHVRI ELDVWKDWPD\EHHQFRXQWHUHGL QWKLVFOLQLFDOVWXG\KDYHEHHQ FRQVLGHUHGDQGPLQLPL]HGE\WK RURXJKFDUHIXOVWXG\GHVLJQ "
35,page_35,
36,page_36,
37,page_37,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  $UFWLF)URQW$GYDQFH&DUGLD F&U\R$EODWLRQ&DWKHWHUV ,QWKH86WKH$UFWLF)URQW$GYDQFH&DUGLDF&U\R$EODWLRQ&DWKH WHUV PPDQGPP DUH)'$ DSSURYHGDQGLQGLFDWHGIRUWKHWUHDWPHQWRIGUXJUHIUDFWRU\UHF XUUHQWV\PSWRPDWLFSDUR[\VPDODWULDO ILEULOODWLRQ 7KHLQYHVWLJDWLRQDOLQGLFDWLRQLQWKH86LVIRUWKHWUHDWPHQWR IUHFXUUHQWV\PSWRPDWLFSDUR[\VPDODWULDO ILEULOODWLRQZLWKRXWWKHUHTXLUH PHQWWKDWWKH$)EHGUXJUHIUDF WRU\ ,Q(XURSHWKH$UFWLF)URQW$GYDQFH70&DUGLDF&U\R$EODWLRQ&DWKHWHUV PPDQGPP DUH&(PDUNHG DQGLQGLFDWHGIRUWKHWUHDWPHQW RISDWLHQWVZLWKDWULDOILEULOO DWLRQ7KHFDWKHWHULVQRWFRQVLGHUHG LQYHVWLJDWLRQDOIRUWKHLQWHQGHG SDWLHQWSRSXODWLRQLQ(XURSH DVLWLVEHLQJXVHGZLWKLQWKHDSSURYHG LQGLFDWLRQ 7KHFDWKHWHUVDUHVWHULOHVLQJOH XVHPLQLPDOO\LQYDVLYHLQWUD YDVFXODUEDOORRQFDWKHWHUVVSHFLILFDOO\ GHVLJQHGIRUWLVVXHFU\RDEODWLRQ 7KH$UFWLF)URQW$GYDQFH&D UGLDF&U\R$EODWLRQ&DWKHWHULVXVHG WRJHWKHUZLWKWKH&U\R&RQVROHDQGUHODWHGGHYLFHV$UFWLF)URQ W$GYDQFH&DUGLDF&U\R$EODWLRQ &DWKHWHUVDUHSHUFXWDQHRXVO\DGY DQFHGWRWKHKHDUWFKDPEHUIURP WKHIHPRUDODFFHVVYLDDWUDQVVHSWDO VKHDWKLQWKHYDVFXODWXUH2QFHWKHFDWKHWHUUHDFKHVWKHOHIW DWULXPWKHEDOORRQLVLQIODWHGDQGWKH FRROLQJVHJPHQWFUHDWHVFLUFXP IHUHQWLDOOHVLRQVDWWKHDQWUXPR IWKHWDUJHWHGSXOPRQDU\YHLQV )LJXUH $UFWLF)URQW$GYDQFH70&DUGLDF&U\RDEODWLRQ&DWKHWHU )UHH]RU ®00$;&DUGLDF&U\R$EODWLRQ&DWKHWHUV ,QWKH86DQG(XURSHWKH)UHH]RU 0$;&DUGLDF&U\R$EODWLRQ&DWKHWHULVPDUNHWUHOHDVHGDQGDSSURYHG IRUXVHLQWKHVWXG\LQWHQGHGSDW LHQWSRSXODWLRQ WKHUHIRUHLV QRWFRQVLGHUHGLQYHVWLJDWLRQDO $SSURYHGLQGLFDWLRQLQWKH86 7KH)UHH]RU 0$;&DUGLDF&U\R$EODWLRQ&DWKHWHULVXVHGDVDQDGMXQFWLYH GHYLFHLQWKHHQGRFDUGL DOWUHDWPHQWRISDUR[\VPDODWULDOILEULO ODWLRQLQFRQMXQFWLRQZLWKWKH$UFWLF)URQW $GYDQFH&DUGLDF&U\R$EODWLRQ&DWKHWHU"
38,page_38,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  $SSURYHGLQGLFDWLRQLQ(XURSH 7KH)UHH]RU 0$;&DUGLDF&U\R$EODWLRQ&DWKHWHULVLQWHQGHGIRUXVHLQ WKHWUHDWPHQWRIFDUGLDFDUUK\WKPLDV 7KH)UHH]RU 0$;&DUGLDF&U\R$EODWLRQ&DWKHWHU LVDIOH[LEOHVWHHUDEOHFDWKHWH UXVHGWRDEODWHFDUGLDF WLVVXH,WLVXVHGWRJHWKHUZLWKWKH&U\R&RQVROHDQGUHODWHGF RPSRQHQWV7KHWLSRIWKH)UHH]RU 0$; &U\RFDWKHWHUUHDFKHVFU\RDEODWLRQ WHPSHUDWXUHVZKHQUHIULJHUDQW LVLQMHFWHGIURPWKH&U\R&RQVROHWRWKH WLSRIWKHFDWKHWHU7KHFDWKHWHUWLSKDVDQLQWHJUDWHGWKHUPR FRXSOHIRUWHPSHUDWXUHUHDGLQJFDSDELOLW\ 7KHFDWKHWHULVLQWURGXFHGLQWRWKHYDVFXODWXUHE\WUDGLWLRQDO PLQLPDOO\LQYDVLYHWHFKQLTXHV )OH[&DWK$GYDQFH6WHHUDEOH6KHDWK 7KH)OH[&DWK$GYDQFH706WHHUDEOH6KHDWKLVDSHUFXWDQH RXVLQWURGXFHUILWWHGZLWKDKH PRVWDVLVYDOYHWR DOORZIRULQWURGXFWLRQZLWKGUDZDODQGVZDSSLQJRIFDWKHWHUVDQ GZLUHVZKLOHSURYLGLQJDEDUULHU SUHYHQWLQJDLULQJUHVVLQWRWKHYDOYHDQGPLQLPL]LQJEORRGORVV $VLGHSRUWZLWKVWRSFRFNLVLQWHJUDWHG LQWRWKHKHPRVWDVLVYDOYHWRDOORZFRQWLQXRXVGULSLQIXVLRQLQ MHFWLRQWKURXJKWKHFHQWHUOXPHQIOXVKLQJ DVSLUDWLRQEORRGVDPSOLQJDQGSU HVVXUHPRQLWRULQJ7KH)OH[&D WK$GYDQFH706WHHUDEOH6KHDWKLV LQWHQGHGWRDOORZVKHDWKGHIOHFW LRQWRIDFLOLWDWHFDWKHWHUSRVL WLRQLQJ,WLVVXSSOLHG VWHULOHDQGSDFNDJHG WRJHWKHUZLWKDGLODWRU  )LJXUH )OH[&DWK$GYDQFH706WHHUDEOH6KHDWKZLWK&U\RDEODWLRQ&DWKHWHU $FKLHYHRU$FKLHYH$ GYDQFH0DSSLQJ&DWKHWHU 7KH$FKLHYH70DQG$FKLHYH$GYDQFH700DSSLQJ&DWKHWHUVDUHLQWUDFDUGLDFHOHFWURSK\VLRORJ\GLDJQRVW LF FDWKHWHUVLQGLFDWHGIRUPXOWLSOHH OHFWURGHHOHFWUR SK\VLRORJLFDO PDSSLQJRIWKHFDUGLDFVWUXFWXUHVRIWKH KHDUWLHUHFRUGLQJRUVWLPXODWLRQRQO\7KH$FKLHYH70DQG$FKLHYH$GYDQFH0 DSSLQJ&DWKHWHUVDUH GHVLJQHGWRREWDLQHOHFWURJUDP VLQWKHDWULDOUHJLRQVRIWKHKH DUW"
39,page_39,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH  RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO )LJXUH $FKLHYH0DSSLQJ&DWKHWHU &U\R&DWK&U\R$EODWLRQ&RQVROH 7KH&U\R&RQVROHKRXVHVWKHHOHFW URQLFVDQGFRPSDWLEOHVRIWZDUH IRUFRQWUROOLQJDQGUHFRUGLQJWKH DEODWLRQSURFHGXUHVWRUHVDQG FRQWUROVGHOLYHU\RIOLTXLGUHIU LJHUDQWXQGHUKLJKSUHVVXUHWKURXJKWKHFR D[LDOXPELOLFDOWRWKHFDWKHWHUUHFRYHUVWKHH[SDQGHGUHIULJHU DQWYDSRUIURPWKHFDWKHWHUXQGHUYDFXXP DQGGLVSRVHVRIWKHUHIULJHUDQWWKURXJKWKHKRVSLWDOVFDYHQJLQJ V\VWHP 7KHKDUGZDUHFRQWUROVWKHVDIHW\ PRQLWRULQJV\VW HPZKLOHWKHVR IWZDUHSURYLGHVWKHXVHULQWHUIDFH SDWLHQWLQIRUPDWLRQSURFHGXUHW HPSHUDWXUHWLPHVHWSRLQWLQD XWRPDWLFPRGHDQGSURFHGXUHGDWD LQIRUPDWLRQ7KHPRVWFXUUHQWPD UNHWDSSURYHGVRIWZDUHYHUVLRQ DYDLODEOHZLOOEHXVHGDWWKHVLWH )LJXUH &U\R&DWK&U\R$EODWLRQ&RQVROH"
40,page_40,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  &RD[LDO8PELOLFDO&DEOH 7KH6WHULOH&RD[LDO8PELOLFDOGH OLYHUVWKH1LWURXV2[LGH 12  JDVIURPWKHFRQVROHW RWKHFDWKHWHUDQG WUDQVSRUWVUHIULJHUDQWYDSRUVIURPWKHFDWKHWHUWRWKHFRQVROH ZKLFKLVWKHQYHQWHGLQWRWKHKRVSLWDO VFDYHQJLQJV\VWHP )LJXUH &RD[LDO8PELOLFDO&DEOH  (OHFWULFDO8PELOLFDO&DEOH 7KH6WHULOH(OHFWULFDO8PELOLFD OLVDQHOHFWULFDOH[WHQVLRQFDE OHWKDWWUDQVSRUWV  x7HPSHUDWXUHIHHGEDFNIURPWKHFDWKHWHUWRWKHFRQVROH x/HDNGHWHFWLRQVLJQDOVIURPW KHFDWKHWHUWRWKHFRQVROH x%ORRGVHQVRUVLJQDOVIURPWKHFDWKHWHUWRWKHFRQVROH x3UHVVXUHVHQVRUIRUPWKHFDWKHWHUWRWKHFRQVROH  )LJXUH (OHFWULFDO8PELOLFDO&DEOH    0DQXDO5HWUDFWLRQ.LW 7KHPDQXDOUHWUDFWLRQNLWFRQWDLQVRQHODUJHV\ULQJHRQHZD\ VWRSFRFNDQGDFRD[LDOWROXHUDGDSWRU 7KHNLWLVXVHGGXULQJWKHUHZUD SSURFHGXUHRIWKH$UFWLF)URQW $GYDQFH&DUGLDF&U\R$EODWLRQ&DWKHWHU LIWKHSK\VLFLDQFDQQRWUHWUDFWWKHFDWKHWHUXVLQJWKHQRUPDOF DWKHWHUUHWUDFWLRQF\FOH"
41,page_41,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO )LJXUH 0DQXDO5HWUDFWLRQ.LW  $GGLWLRQDO6W XG\'HYLFHV 0HGWURQLFPD\LQFRUSRUDWHDGGLWL RQDOFRPSRQHQWVVRIWZDUHDQG GHYLFHVLQWRWKLVFOLQ LFDOVWXG\DVWKH\ UHFHLYHDSSURSULDWHOLFHQVHRUUHJXODWRU\DSSURYDODQGDUHUHOH DVHGFRPPHUFLDOO\E\ 0HGWURQLFLQWKH UHJLRQZKHUHWKH\Z LOOEHXVHGSURYLGLQJWKDWWKHVFLHQWLILFVR XQGQHVVRIWKHVWXG\ LVQRWDGYHUVHO\ DIIHFWHGDVHYDOXDWHGE\0HGWURQLF 3URGXFW7UDLQLQJ5HTXLUHPHQWV 3K\VLFLDQVSHUIRUPLQJWKHFU\RDE ODWLRQSURFHGXUHPXVWKDYHEHHQ WUDLQHGLQWKHKDQGOLQJRI$UFWLF)URQW $GYDQFH&DUGLDF&U\R$EODWLRQ&DWKHWHUDQG&U\R&DWK&DUGLDF&U\ R$EODWLRQ6\VWHP7KH\PXVWEH TXDOLILHGE\0HGWURQLF$)6ROXWLRQV7UDLQLQJDQG(GXFDWLRQ 86 21/< DQGPXVWKDYHSHUIRUPHGDWOHDVW DEODWLRQSURFHGXUHVZLWK$UFW LF)URQWRU$UFWLF)URQW$GYDQF HDQGDVVRFLDWHGSURGXFWV 3DFNDJLQJ ,QWKH86DQG(XURSHWKH$UFWLF )URQW$GYDQFH&DUGLDF&U\R$EO DWLRQ&DWKHWHUVZLOOQRWEHODEHOHGDV LQYHVWLJDWLRQDO7KHVHGHYLFH VZLOOEHFRQVLGHUHGLQYHVWLJDWLR QDOXSRQRSHQLQJSHU WKH&,3 86RQO\  &RPPHUFLDOO\DYDLODEOHSURGXF WVZLOOEHXVHGIRUWKHVWXG\ ,QYHVWLJDWLRQDO'HYLFH6WRUDJH +DQGOLQJDQG7UDFHDELOLW\ 7KH$UFWLF)URQW$GYDQFH&DUGLD F&U\R$EODWLRQ&DWKHWHUVXVHGL QWKLVVWXG\DUHFRPPHUFLDOO\DYDLODEOH LQWKH86DQG(XURSH WKH\ZLOOQ RWEHODEHOHGDVLQYHVWLJDWLRQ DODQGZLOOQRWEHSURYLGHGWRWKH LQYHVWLJDWLRQDOFHQWHUV 7KH$UFWLF)URQW$GYDQFH&DUGLD F&U\R$EODWLRQ&DWKHWHUZLOOEH FRQVLGHUHGLQYHVWLJDWLRQDOLQWKH86 ZKHQRSHQHGZLWKWKHLQWHQWWRXV HLQWKLVVWXG\7KHFDWKHWHU LVPDUNHWUHOHDVHGDQGZLOOEHXVHG ZLWKLQWKHDSSURYHGLQGLFDWLRQLQ(XURSHWKHUHIRUHZLOOEHFR QVLGHUHGQRQLQYHVWLJDWLRQDOLQ(XURSH ,QWKH86GHYLFHWUDFNLQJLQIRU PDWLRQZLOOEHHQWHUHGLQWRWKH VWXG\GDWDEDVHIRUDQ\FDWKHWHUWKDWLV FRQVLGHUHGLQYHVWLJDWLRQDOLQWKLVVWXG\7KHGHYLFHWUDFNLQJ LQIRUPDWLRQPXVWEHPDLQWDLQHGDQG XSGDWHGZKHQWKHLQYHVWLJDWLRQDOFDWKHWHULVGLVSRVHGRIRUUHW XUQHGWR0HGWURQLF"
42,page_42,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 42 of 130 Version 5.0 STOP AF First Page 42 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential NOTE: this is a deviation to Section 9.8 of the ISO standard because device accountability for the Arctic Front Advance™ Cardiac CryoAblation Catheters will not be performed in Europe and only upon package opening with the intent of using the catheter for a study subject in the US."
43,page_43,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 43 of 130 Version 5.0 STOP AF First Page 43 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 8. Investigator/Investigator Center Selection All clinical Investigators managing the subject’s arrhythmia must be qualified practitioners and experienced in the diagnosis and treatment of subjects with atrial arrhythmias. Investigators performing the cryoablation procedure must have been trained in the handling of Arctic Front Advance ™ Cardiac CryoAblation Catheters. The role of the Principal Investigator is to implement and manage the day -to-day conduct of the clinical investigation as well as ensure data integrity and the rights, safety and well- being of the subjects involved in the clinical investigation. The minimum required criteria for a Principal Investigator and proposed investigational center are listed below: • Investigator/site is qualified by training, education, and relevant experience appropriate to the use of the product and a ssociated procedures. • Investigator/site expects to have adequate time and resources to conduct the study throughout the duration of the study. • Investigator/site has access to an adequate number of eligible subjects. • Ability to comply with applicable Institutional Review Board (IRB)/Ethics Committee (EC) and regulatory requirements . • Investigator is not debarred, disqualified, or working under sanctions in applicable regions. Center personnel training will be completed prior to participation in this clini cal study."
44,page_44,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 44 of 130 Version 5.0 STOP AF First Page 44 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 9. Center Activation During the activation process (prior to subject enrollment), Medtronic will train center personnel on the CIP, relevant standards and regulations, informed consent, and on data collection and reporting tools. If new members j oin the study center team, they will receive training on the applicable clinical study requirements relevant to their role before contributing to the clinical study. Prior to performing study related activities, all local regulatory requirements shall be fulfilled, including, but not limited to the following: • IRB/MEC approval (and membership roster/voting list) of the current version of the CIP, Patient Informed Consent Form, subject facing materials, Report of Prior Investigation, Investigator Brochure a s required by local laws and other materials, as necessary. • Regulatory authority approval or notification (as required per local law) • Fully executed Clinical Trial Agreement (CTA) and Investigator Statement where applicable • Financial Disclosure of Investigators • Curriculum Vitae (CV) of Investigators and key members of the investigation center team (as required by local law) (in Europe, CVs are required for the Principal Investigator and all center members who have been delegated tasks) • Documentation of delegated tasks • Documentation of study training Documentation of delegated tasks must be completed prior to any person other than the Principal Investigator performing study activities. Additional requirements imposed by the IRB/MEC and regulatory authority shall be followed. In addition, all participating center staff must be trained on the current version of the CIP and must be delegated by the Principal Investigator to perform study related activities. Medtronic will provide each study center wit h documentation of study center/Investigator readiness in the form of a center readiness letter; this letter must be received prior to subject enrollment. Additional center personnel included after the initial activation will be notified when all requireme nts have been completed."
45,page_45,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 6HOHFWLRQRI6XEMHFWV 6WXG\3RSXODWLRQ 7KHVWXG\SRSXODWLRQLQFOXGHVDGX OWSDWLHQWVZLWKUHFXUUHQWV\P SWRPDWLFSDUR[\VPDODWULDOILEULOODWLRQ 7KH$)FODVVLILFDWLRQVWKDWZLOOEHXVHGIRUWKLVVWXG\DUHGHI LQHGLQWKH+56(+5$(&$6([SHUW &RQVHQVXV6WDWHPHQWRQ&DWKHWHU DQG6XUJLFDO$EODWLRQRI$WULDO )LEULOODWLRQ &DONLQVHWDO  3DUR[\VPDO$)LVGHILQHGDV$)WK DWWHUPLQDWHVVSRQWDQHRXVO\RU ZLWKLQWHUYHQWLRQZLWKLQGD\VRIRQVHW 3DWLHQWVLQSHUVLVWHQW$)DUHH[F OXGHGIURPWKHVWXG\3HUVLVW HQW$)LVGHILQHGDVFRQWLQXRXV$)WKDWLV VXVWDLQHGEH\RQGGD\V 6XEMHFW(QUROOPHQW  3DWLHQWVZLOOEHVFUHHQ HGWRHQVXUHWKH\P HHWDOORIWKHLQFOXV LRQFULWHULDDQGQRQ HRIWKHH[FOXVLRQ FULWHULDSULRUWRVWXG\HQUROOPH QW,QVWLWXWLRQDO5HYLHZ%RDUG ,5% (WKLFV&RPPLWWHH (& DQG0HGWURQLF DSSURYDORIWKLV&,3DQGWKH,QIRU PHG&RQVHQW)RUP ,&) PXVWE HREWDLQHGSULRUWRHQUROOLQJVXEMHFWVLQ WKHVWXG\6XEMHFWVDUHFRQVLGH UHGHQUROOHGLQWKHVWXG\XSRQ VLJQLQJDQGGDWLQJWKH,&)6XEMHFWVPXVW SURYLGHLQIRUPHGFRQVHQW ,& EH IRUHDQ\VWXG\UHODWHGSURFHGXU HVRFFXU ,QFOXVLRQ&ULWHULD x$GLDJQRVLVRIV\PSWRPDWLFSDUR[\VPDO$)ZLWKWKHIROORZLQJGRF XPHQWDWLRQ   SK\VLFLDQ¶VQRWH LQGLFDWLQJUHFXUUHQWVHOIWHUPLQ DWLQJ$)RUSDUR[\VPDO$) DQG   DQ\(&*GRFXPHQWHG$) ZLWKLQPRQWKVSUL RUWRHQUROOPHQW x$JH ([FOXVLRQ&ULWHULD x+LVWRU\RI$)WUHDWPHQWZLWK FODVV,RU,,,DQWLDUUK\WKPLFGUXJ LQFOXGLQJVRWDOROZLWKWKH LQWHQWLRQWRSUHYHQWDQ$)UHFXUUHQFH+RZHYHUSDWLHQWVSUHWU HDWHGZLWKDERYH$$'IRUOHVV WKDQGD\VZLWK WKHLQWHQWLRQWRFRQYHUWDQ$)HSLVRGHDUHDOO RZHG x3ULRUSHUVLVWHQW$) FRQWLQXRX V$)WKDWLVVXVWDLQHG!GD\V  x/HIWDWULDOGLDPHWHUJUHDWHUWKDQFP x3ULRUOHIWDWULDODEODWLRQRUO HIWDWULDOVXUJLFDOSURFHGXUH x3UHVHQFHRUOLNHO\LPSODQWRID SHUPDQHQWSDFHPDNHUELYHQWULFX ODUSDFHPDNHUORRSUHFRUGHU RUDQ\W\SHRILPSODQWDEOHFDUGL DFGHILEULOODWRU ZLWKRUZLWKR XWELYHQWULFXODUSDFLQJIXQFWLRQ  x3UHVHQFHRIDQ\SXOPRQDU\YHLQVWHQWV x.QRZQSUHVHQFHRIDQ\SUHH[LVW LQJSXOPRQDU\YHLQVWHQRVLV x3UHH[LVWLQJKHPLGLDSKUDJPDWLFSDUDO\VLV x3UHVHQFHRIDQ\FDUGLDFYDOYHSURVWKHVLV x0RGHUDWHRUVHYHUHPLWUDOYDO YHUHJXUJLWDWLRQRUVWHQRVLV x$Q\FDUGLDFVXUJHU\P\RFDUGLDOLQIDUFWLRQ3&,37&$RUFRURQ DU\DUWHU\VWHQWLQJZKLFK RFFXUUHGGXULQJWKH GD\LQWHUYDOSUHFHGLQJWKHGDWHWKHVXEM HFWVLJQHGWKH,QIRUPHG &RQVHQW)RUP x8QVWDEOHDQJLQD x1<+$FODVV,,,RU,9FRQJHVWLYHKH DUWIDLOXUHDQGRUNQRZQOHIW YHQWULFXODUHMHFWLRQIUDFWLRQ /9() OHVVWKDQ"
46,page_46,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 46 of 130 Version 5.0 STOP AF First Page 46 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential • Diagnosis of primary pulmonary hypertension • Rheumatic heart disease • Thrombocytosis, thrombocytopenia • Contraindication to anticoagulation thera py • Active systemic infection • Hypertrophic cardiomyopathy • Cryoglobulinemia • Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe obstructive sleep apnea, and acute alcohol toxicity. • Any cerebral ischemic event (strokes or TIAs) which occurred during the 180 day interval preceding the date the subject signed the Informed Consent Form, or any known unresolved complications from previous stroke/TIA • Existing thrombus • Pregnancy • Patient with life expectancy that makes it unlikely 12 months o f follow-up will be completed. • Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of this study not pre -approved by Medtronic • Patients with contraindications to a Holter monitor • Unwilling or unable to comply fully with study procedures and follow -up"
47,page_47,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 6WXG\3URFHGXUHV 3ULRUWRSHUIRUPLQJVWXG\UHODWHGSURFHGXUHVDOOVLWHVPXVWKD YH,5%(&DSSURYDODVZHOODV GRFXPHQWDWLRQIURP0HGWURQLFRIFHQWHUUHDGLQHVV 6FKHGXOHRI(YHQWV 7KHYLVLWVFKHGXOHDQGGDWDFROOH FWLRQUHTXLUHPHQWVDUHVXPPDUL ]HGLQ7DEOH 7DEOH 9LVLW6FKHGXOHDQG'DWD&ROOHFWLRQ5HTXLUHPHQWV6XPPDU \%DVHOLQH 3URFHGXUH+RVSLWDO 'LVFKDUJH 0 0  0 8QVFKHGXOHG 5HDEODWLRQ &URVVRYHU$EODWLRQ7UHDWPHQW $UP2QO\ ,QIRUPHG&RQVHQW ;      5DQGRPL]DWLRQ ;      ,QFOXVLRQ([FOXVLRQ ;      0HGLFDO+LVWRU\ ; 3K\VLFDO([DP ;      3UHJQDQF\6FUHHQLQJ;       5HYLHZ0HGLFDWLRQV ; ; ; ; ; ; ; 5HYLHZRI$)6\PSWRPV ; ; ; ; ; ; &ROOHFW+HDOWK&DU H8WLOL]DWLRQ ,QIRUPDWLRQ  ; ; ; ; ; /HDG(&* ; ; ; ; ; ; (4' $)(47 ;   ;  ; 7UDQVWKRUDFLF(FKRFDUGLRJUDP 77( ;        7UDQVHVRSKDJHDO (FKRFDUGLRJUDP 7(( ;      ;  5HTXLUHGRQO\IRUIHPDOHVXEMHFWVRIFKLOGEHDULQJSRWHQWLDO 2QO\UHTXLUHGLIGDWDQRWDYDLODEOHIURPZLWKLQSULRUPRQWKV IURPFRQVHQWGDWH 7((PXVWEHSHUIRUPHGLQDOOVXEMHFWVZKRSUHVHQWWRWKHDEODW LRQSURFHGXUHLQDWULDOILEULOOD WLRQODVWLQJPRUHWKDQKRXUV LQ GXUDWLRQ RURIDQXQNQRZQGXUDWLRQ +RZHYHUWKH7((LVQRW UHTXLUHGLIWKHVXEMHFWKDVDGHTXDWHV\VWHPLFDQWLFRDJXODWLRQW KDW KDVEHHQPDLQWDLQHGIRUDWOHDVW ZHHNVSULRUWRSUHVHQWLQJWR WKHDEODWLRQSURFHGXUHLQ$) 7((PXVWEHSHUIRUPHGLIVXEMHF WV KDYHD&+$'69$6FDQGSUHVHQWWRWKHSURFHGXUHZLWKDVXE WKHUDSHXWLF,15  RULIWKHVXEMHFWKDVKDGDVLJQLILFDQW  LQWHUUXSWLRQRI12$&V$VLJQLILFDQWLQWHUUXSWLRQRI12$&VLVG HILQHGDVDQ\PLVVHGGRVHZLWKLQ GD\VSULRUWRWKHDEODWLRQ SURFHGXUH"
48,page_48,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  %DVHOLQH 3URFHGXUH+RVSLWDO 'LVFKDUJH 0 0  0 8QVFKHGXOHG 5HDEODWLRQ &URVVRYHU$EODWLRQ7UHDWPHQW $UP2QO\ $EODWLRQ3URFHGXUH'DWD ;     ; KRXUFRQWLQXRXVDPEXODWRU\ (&*PRQLWRULQJ ;    3DWLHQW$FWLYDWHG$PEXODWRU\ (&*0RQLWRULQJ ;   $ G Y H U V H  ( Y H Q W V  ; ; ; ;  ; ; ;  ;  'HYLFH'HILFLHQFLHV $VWKH\RFFXU 6WXG\'HYLDWLRQV $VWKH\RFFXU &KHVW;UD\ WUHDWPHQWDUPRQO\ ,ISKUHQLFQHUYHLQMXU\LVGHW HFWHGGXULQJWKHSURFHGXUH WKHVXEMHFWZLOOEHHYDOXDWHG ZLWKLQVSLUDWLRQH[SLUDWLRQ FKHVW[UD\DW3+'DQGDOOIR OORZXSYLVLWVXQWLOUHVROYHG 05,RU&76FDQ WUHDWPHQWDUPRQO\ 5HTXLUHGRQO\IRUVXEMHFWVZ LWKVXVSHFWHG39VWHQRVLV 0RGHVRI'DWD&ROOHFWLRQ 0XOWLSOHPRGHVRIGDWDFROOHFWLR QPD\EHHPSOR\HGWRVXSSRUWWK HFROOHFWLRQRIUHTXLUHGYLVLWGDWD7KLV LQFOXGHVVXFKPHWKRGVDV  x,QRIILFHSDWLHQWFOLQLFYLVLW x'LUHFWWRSDWLHQWFRQWDFW LH WHOHSKRQHHPDLOPDLOFRQWDFW HWF  x5HPRWHWHFKQRORJ\WUDQVPLVVLRQVXSORDGV 0HGLFDWLRQV ,QIRUPDWLRQUHJDUGLQJGUXJVSUHVF ULEHGWRWUHDWD WULDODUUK\WKP LDVZLOOEHFROOHFWHGLQFOXGLQJWKHSXUSRVH IRUWKHLUXVHUHDVRQIRUPRGLILF DWLRQDQGVWDUW DQGVWRSGDWHV ,QIRUPDWLRQUHJDUGLQJDQWLFRDJXODWLRQ PHGLDWLRQVZLOOEHFROOHFWHGLQFO XGLQJVWDUWDQGVWRSGDWHV &RQWURO$UP $$' 6XEMHFWVPXVWLQLWLDWHD& ODVV,RU,,,$$'ZLWKLQGD\VRI UDQGRPL]DWLRQ,WLV UHFRPPHQGHGWKDW$$'VEHLQLWLD WHGDVVRRQDVSRVVLEOHDIWHUUD QGRPL]DWLRQZLWKDWDUJHWRIZLWKLQ GD\V7KHLQYHVWLJDWRUVKRXOGFK RRVHWKHDSSURSULDWH$$'SHUK LVRUKHUVWDQGDUG RIFDUH KRZHYHU DPLRGDURQHVKRXOGRQO\EHXVHGLIRWKHU$$'VZHUHQRWWROHUDWHG RUIDLOHG7KH$+$$&&+56  6XEMHFWVVKDOOVXEPLW(&*WUDQVPLVVLRQVZHHNO\DQGZKHQHYHUV\ PSWRPVRFFXUDIWHUWKH$$'RSWLPL]DWLRQSRVWDEODWLRQEODQNLQJ SHULRGVWKURXJKPRQWKIROORZXS"
49,page_49,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH  RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO *XLGHOLQHIRUWKH0DQDJHPHQWRI3DWLHQWVZLWK$)VKRXOGEHFRQV XOWHGIRU$$'SUHVFULSWLRQV 0RGLILFDWLRQVWR$$'V W\SHRUG RVDJHLQFUHDVH PD\EHPDGHIRU XSWR GD\VDIWHU$$'LQLWLDWLRQ7KLV LVUHIHUUHGWRDVWKH$$'RSWLPL] DWLRQSHULRG'RVLQJRI$$'V FDQEHLQGLYLGXDOO\WD LORUHGXQWLOWKHHQGRI WKH$$'RSWLPL]DWLRQSHULRG$IWH UWKHRSWLPL]DWLRQSHULRGIXU WKHU$$'WKHUDS\RSWLPL]DWLRQRUFKDQJH VKRXOGEHDYRLGHGRUDWOHDVWD OORZHGRQO\XSWRSK\VLFLDQV¶GL VFUHWLRQWRJXDUDQWHHWKHVDIHW\RIWKH SDWLHQWV7KHSRVVLEOHFRQFRPLWD QWXVHRIEHWDEORFNHUVFDQVW LOOEHRSWLPL]HGDIWHUWKHRSWLPL]DWLRQ SHULRG 7UHDWPHQW$UP &U\RDEODWLRQ 6XEMHFWVPD\EHSUHVFULEHG&ODVV,RU,,,$$'VIRUXSWRG D\V SRVWDEODWLRQSURFHGXUH DWWKHGLVFUHWLRQRIWKH,QYHVWLJDWRU 6XEMHFWVPXVWVWRSWDNLQJDOO&ODVV,RU,,, $$'VEHIRUHGD\SRVWDEODWLRQ8VHRIDPLRGDURQHLVQRWSHU PLWWHG $QWLFRDJXODWLRQUHTXLUHPHQWVIRUDOOVXEMHFWV  $QWLFRDJXODWLRQSUHSURFHGXUHVKRXOGEHGHWHUPLQHGEDVHGXSRQW KHVXEMHFWV&+$ '69$6FVFRUH D2UDODQWLFRDJXODQWVDUHUHTXLUHG LIWKHVXEMHFWKDVKDGDSULRU VWURNHRU7,$RULIWKHVXEMHFW KDVD&+$ '69$6FVFRUH:KHQDQWLFRDJXO DWLRQLVUHTXLUHGVXEMHFWVPXV WWDNHLWIRU DWOHDVWGD\VSULRUWRD QDEODWLRQSURFHGXUH E2UDODQWLFRDJXODQWVDUHQRWUHTXL UHGIRUVXEMHFWVZLWKQRQYDOYX ODU$)DQGD&+$ '69$6F VFRUHRIRU 1RWH 7((PXVWEHSHUIRUPHGZLWKLQRQHGD\SULRUWRWKHFU\RDE ODWLRQSURFHGXUHLIVXEMHFWVKDYHD &+$'69$6FDQGSUHVHQWWRWKHSURFHGXUHZLWKDVXEWKHUDSHXWLF, 15  RULIWKHVXEMHFWKDV KDGDVLJQLILFDQWLQWHUUXSWLRQRI12$&V$VLJQLILFDQWLQWHUUX SWLRQRI12$&VLVGHILQHGDVDQ\PLVVHG GRVHZLWKLQGD\VSULRUW RWKHDEODWLRQSURFHGXUH 6XEMHFW&RQVHQW 3DWLHQWLQIRUPHGFRQVHQW ,& LVGHILQHGDVDOHJDOO\HIIHFWLYH GRFXPHQWHGFRQILUPDWLRQRIDVXEMHFW¶V RU WKHLUOHJDOO\DXWKRUL]HGUHSUHVHQ WDWLYH8621/< YROXQWDU\DJU HHPHQWWRSDUWLFLSDWHLQDSDUWLFXODU FOLQLFDOVWXG\DIWHULQIRUPDWLR QKDVEHHQJLYHQW RWKHVXEMHFW RQDOODVSHFWVRIWKHFOLQLFDOVWXG\WKDWDUH UHOHYDQWWRWKHVXEMHFW¶VGHFLVLR QWRSDUWLFLSDWH7KLVSURFHVV LQFOXGHVREWDLQLQJDQ,QIRUPHG&RQVHQW )RUP ,&) DQGDQ$XWKRUL]DWLRQ WR8VHDQG'LVFORVH3HUVRQDO+H DOWK,QIRUPDWLRQWKD WKDVEHHQDSSURYHG E\WKHVWXG\FHQWHU¶V,5%(&DQG VLJQHGDQGGDWHGE\WKHVXEMHF W RUWKHLUOHJDOO\DXWKRUL]HG UHSUHVHQWDWLYH8621/< $VXEM HFWPD\RQO\FRQVHQWDIWHULQIR UPDWLRQKDVEHHQJLYHQWRWKHVXEMHFWRQ DOODVSHFWVRIWKHFOLQLFDOLQYHVW LJDWLRQWKDWDUHUHOHYDQWWR WKHVXEMHFW¶VGHFLVLRQWRS DUWLFLSDWH,QIRUPHG FRQVHQWPD\EHJLYHQE\WKHLUOH JDOO\DXWKRUL]HGUHSUHVHQWDWLYH  8621/< RQO\LIDV XEMHFWLVXQDEOHWR PDNHWKHGHFLVLRQWRSDUWLFLSDWH LQDFOLQLFDOLQYHVWLJDWLRQ, QVXFKFDVHVWKHVX EMHFWVKDOODOVREH LQIRUPHGDERXWWKHFOLQLFDOLQYH VWLJDWLRQZLWKLQKLVKHUDELOLW \WRXQGHUVWDQG  3ULRUWRHQUROOLQJVXEMHFWVWKH,&)PXVWKDYHEHHQDSSURYHGE\ HDFKFHQWHU¶V,5%(&(DFKVLWHPXVW DOVRXVHDQ$XWKRUL]DWLRQWR8VHDQG'LVFORVH3HUVRQDO+HDOWK, QIRUPDWLRQ5HVHDUFK$XWKRUL]DWLRQRWKHU SULYDF\ODQJXDJHDVUHTXLUHGE\ ODZ7KH,&)PXVWEHFRQWUROOHG  LHYHUVLRQHGDQGGDWHG WRHQVXUHLWLV FOHDUZKLFKYHUVLRQ V ZHUHDSSU RYHGE\WKH,5%(&$Q\PRGLILF DWLRQVWRWKHVDPSOH,&)PXVWEH UHYLHZHGDQGDSSURYHGE\0HGWURQL FDQGWKH,5%(&UHYLHZLQJWKH DSSOLFDWLRQSULRUWRHQUROOLQJVXEMHFWV  7KH,QYHVWLJDWRUPXVWQRWLI\WKH VXEMHFW 8621/< RUWKHLUOHJ DOO\DXWKRUL]HGUHSU HVHQWDWLYH RIDQ\ VLJQLILFDQWQHZILQGLQJVDERXWWKHVWXG\WKDWEHFRPHDYDLODEOH GXULQJWKHFRXUVHRIWKHVWXG\ZKLFKDUH SHUWLQHQWWRWKHVDIHW\DQGZHOO EHLQJRIWKHVXEMHFW7KLVFRX OGLPSDFWDVXEMHFW ¶VZLOOLQJQHVVWR"
50,page_50,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 50 of 130 Version 5.0 STOP AF First Page 50 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential participate in the study. If relevant, approval may be requested from subjects to confirm their continued participation. Prior to initiation of any study -specific procedures, documented IC must be obtained from the subject (or their legally authorized representative, US ONLY ). Likewise, privacy or health information protection regulation may require subjects to sign additional forms to authorize centers to submit subject information to the study sponsor. The IC process must be conducted by the principal Investigator or an authorized designee, and the ICF and the Authorization to Use and Disclose Personal Health Information/Research Authorization/other privacy language as required by law must be given to the subject (or their legally authorized representa tive, US ONLY ) in a language he/she is able to read and understand. The process of IC must be conducted without using coercion, undue or improper influence on, or inducement of the subject to participate by the Investigator or other center personnel. The informed consent process shall not waive or appear to waive the subject’s legal rights. The language used shall be as non -technical as possible and must be understandable to the subject and the impartial witness, where applicable. The subject must have ample time and opportunity to read and understand the ICF to inquire about details of the study, and to decide whether or not to participate in the clinical study. All questions about the study should be answered to the satisfaction of the subject. When the s ubject decides to participate in the clinical study, the ICF and the Authorization to Use and Disclose Personal Health Information/Research Authorization/other privacy language as required by law must be signed and personally dated by the subject (or their legally authorized representative, except in Europe) and either the Investigator or the Investigator’s authorized designee, as required by local law. If applicable, witness shall also sign and personally date the consent form to attest that the informatio n in the ICF was accurately explained and clearly understood by the subject, and that IC was freely given. In Europe, include a personally dated signature by the Principal Investigator or authorized designee responsible for conducting the informed consent process. The Principal Investigator or designee must conduct the informed consent discussion. A copy of the ICF and the Authorization to Use and Disclose Personal Health Information/Research Authorization/other privacy language as required by law, signed and dated as required by law, must be provided to the subject. If consent is obtained the same day the subject begins participating in study -related procedures, it must be documented in the subject’s case history that consent was obtained prior to participation in any study related procedures. It is best practice for the IC process to be documented in the subject’s case history, regardless of circumstance. In the event the subject cannot read and/or write, a witnessed (impartial third party) ICF will be allowed, provided detailed documentation of the process is recorded in the subject’s case history and the witness signs and dates the ICF to attest that the information was accurately explained and that informed consent was freely given . In Europe, wh en a subject cannot read and/or write, an independent witness shall be present throughout the process, the written ICF and any other information shall be read aloud and explained to the prospective subject. The subject should “make his mark” (sign or other wise physically mark the document so as to indicate consent) on the ICF as well. The ICF should document the method used for communication with the prospective subject and the specific means by which the prospective subject communicated agreement to partic ipate in the study."
51,page_51,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 7KHRULJLQDORIWKHVLJQHG,&)DQGWKH$XWKRUL]DWLRQWR8VHDQG 'LVFORVH3HUVRQDO+HDOWK ,QIRUPDWLRQ5HVHDUFK$XWKRUL]DWL RQRWKHUSULYDF\ODQJXDJHDVUH TXLUHGE\ODZPXVWEHILOHGLQWKH KRVSLWDOFOLQLFDOFKDUWDQGRUZL WKWKHVXEMHFW¶VVWXG\GRFXPHQ WV7KH,&)DQGWKH$XWKRUL]DWLRQWR8VH DQG'LVFORVH3HUVRQDO+HDOWK,QIR UPDWLRQ5HVHDUFK$XWKRUL]DWLRQ RWKHUSULYDF\ODQJXDJHDVUHTXLUHGE\ ODZVKRXOGDOVREHDYDLODEOHIRUPRQLWRULQJDQGDXGLWLQJ$Q\0 HGWURQLF)LHOGSHUVRQQHOZKRVXSSRUWWKH VWXG\SURFHGXUHPXVWEHDEOHWR UHYLHZWKHVXEMHFW¶VVLJQHGDQG GDWHG,&)DQGYHULI\LWVFRPSOHWHQHVV SULRUWRSURFHHGLQJZLWKWKHSUR FHGXUH,QWKHH YHQWWKH0HGWUR QLF)LHOGSHUVRQQHOLGHQWLI\DQ,&)DV EHLQJLQFRPSOHWHWKHVWXG\SURF HGXUHZLOOQRWEHDOORZHGWRRF FXUXQWLOWKHFRQVHQWRIWKHVXEMHFWFDQEH DGHTXDWHO\DQGDSSURSULDWHO\REWDLQHG 5DQGRPL]DWLRQDQG7 UHDWPHQW$VVLJQPHQW (QUROOHGVXEMHFWVDUHHOLJLEOHIRU UDQGRPL]DWLRQDIWHUDOOLQFO XVLRQDQGQRQHRIWKHH[FOXVLRQFULWHULDDUH PHWDQGDIWHUWKHEDVHOLQH4R/TXHVWLRQQDLUHVDUHFRPSOHWHG6 XEMHFWVZLOOEHUDQG RPL]HGLQD  IDVKLRQWRXQGHUJRDFU\RDEODWLRQSURFHGXUH WUHDWPHQWDUP RU UHFHLYH$$'WKHUDS\ FRQWURODUP  6HH6HFWLRQIRUFRQWURODUPSURFHGXUHVDQG6HFWLRQ IRUWUHDWPHQWDUPSURFHGXUHV 6XEMHFWVZLOOEHUDQGRPL]HGXVLQJDQHOHFWURQLFUDQGRPL]DWLRQV \VWHP7KHUDQGRPL] DWLRQVFKHGXOHZLOO EHVWUDWLILHGE\VWXG\VLWHWRH QVXUHWKDWZLWKLQHDFKVWXG\VL WHUDQGRPL]DWLRQLVDSSUR[LPDWHO\  6XEMHFWVZLOOEHDQDO\]HGDFFRUGLQ JWRDPRGLILHGLQWHQWLRQWR WUHDWSURWRFRO VXEMHFWVZKRZLWKGUDZWKHLU LQIRUPHGFRQVHQWSULRUWRWKHLQGH[FU\RDEODWLRQSURFHGXUHRUL QLWLDWLRQRI$$'WKHUDS\ZLOOEHH[FOXGHG IURPWKHDQDO\VLVRIWKHSULPDU\ VDIHW\DQGHIILFDF\HQGSRLQWV 2WKHUZLVHWKHVWDQGDUGLQWHQWLRQWRWUHDW SURWRFROLVDSSOLHG V XEMHFWVZKRUHFHLYHH LWKHUWKHUDS\UHJDU GOHVVRIZKDWLWDFWXDOO\LVZLOOEHDQDO\]HG DFFRUGLQJWRWKHLUUDQGRPL]DWLRQ VWDWXV7KLVDOORZVIRUWKHSU RWHFWLRQRIWKHEHQHILWVRIUDQGRPL]DWLRQ ZKLOHDYRLGLQJWKHSUREOHPRIDWW ULWLRQDQGDGYHUVHHYHQWVRFFX UULQJLQWKHWLPHEH WZHHQUDQGRPL]DWLRQ DQGWKHLQLWLDWLRQRIWUHDWPHQW ZKLFKGXHWRWKHSUDFWLFDOLW\ RIVFKHGXOLQJFDQEHXSWRGD\V$OO UDQGRPL]HGVXEMHFWVVKRXOGEHHQFRXUDJHGWRFRPSO\ZLWKWKHVWX G\SURFHGXUHVXQWLOVWXG\FORVXUH 'HVFULSWLRQRI$OO6WXG\3URFHGXUHVDQG9LVLWV (QUROOPHQW %DVHOLQH 7KHSDWLHQWLVFRQVLGHUHGDVXEM HFWHQUROOHGLQWKHVWXG\XSRQFRP SOHWLRQRIWKH,&SURFHVV7KHGDWH WKHVXEMHFWVLJQHGWKH,&)DQG+,3$$GDWDSURWHFWLRQDXWKRUL]DW LRQRURWKHUSULYDF\ODQJXDJHZKHUH UHTXLUHGE\ODZPXVWEHGRFXPHQWHGLQWKHVXEMHFW¶VPHGLFDOUHF RUGV $OOEDVHOLQHDVVHVVPHQWVPXVWEH SHUIRUPHGSULRUWRWUHDWPHQW FU\RDEODWLRQSURFHGXUHRULQLWLDWLRQRI $$'V 7KHIROORZLQJHYDOXDWLRQ VZLOOEHSHUIRUPHGDIWHUWKHVX EMHFWVLJQVWKH,&)XQOHVVSUHYLRXVO\ SHUIRUPHGDVSDUWRIURXWLQHFOLQ LFDOHYDOXDWLRQVZLWKLQWKHVS HFLILHGZLQGRZV  :LWKLQPRQWKVSULRUWRWKHGDWHWKHVXEMHFWVLJQHGWKH,QIRUP HG&RQVHQW)RUP  x7UDQVWKRUDFLFHFKRFDUGLRJUDP 77( IRUWKHFROOHFWLRQRIOHIW DWULDOVL]HOHIWYHQWULFXODUHMHFWLRQ IUDFWLRQDQGPLWUDOYDOYHLPSDL UPHQW$UHSHDW77(SURFHGXUH IRUWKHSXUSRVHRIWKLVVWXG\LV QRWUHTXLUHGLID77(ZDVSHUIRUPHGZLWKLQPRQWKVRIWKHGDWH WKHVXEMHFWVLJQHGWKH,QIRUPHG &RQVHQW)RUPDQGDOO GDWDDUHDYDLODEOH "
52,page_52,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO :LWKLQGD\VSULRUWRWKHGDWH WKHVXEMHFWVLJQHGWKH,QIRUPH G&RQVHQW)RUP  x3K\VLFDOH[DPLQDWLRQ x&+$'69$6F6FRUH xOHDG(&* x'HPRJUDSKLFV x0HGLFDOKLVWRU\  $IWHUWKHGDWHWKHVXEMHFWVLJQHGWKH,QIRUPHG&RQVHQW)RUPEX WSULRUWRFU\RDEODWLRQSURFHGXUHRU$$' WUHDWPHQW  1RWH 7KHWLPHEHWZHHQUDQGRPL]DWLRQDQGWKHSURFHGXUH$$'LQLW LDWLRQPXVWQRWH[FHHGGD\V,WLV UHFRPPHQGHGWKDW$$'LQLWLDWLRQRFFXUZLWKLQGD\VRIUDQGRPL ]DWLRQ,WLVUHFRPPHQGHGWKDWWKH FU\RDEODWLRQSURFHGXUHRFFXUZLWKLQGD\VRIUDQGRPL]DWLRQ x$VVHVVPHQWRIDOOIDFWRUVVSHFLILH GIRUHYDOXDWLRQXQGHU,QFOXV LRQ&ULWHULDDQG([FOXVLRQ&ULWHULD 6HFWLRQDQG LQFOXGL QJ77( UHTXLUHGSULRUWRUDQGR PL]DWLRQ  x(4'DQG$)(474XHVWLRQQDLUHV UHTXLUHGSULRUWRUDQGRPL]DWLRQ  x5DQGRPL]DWLRQ x3UHJQDQF\VFUHHQ UHTXLUHGRQO\ IRUIHPDOHVXEMHFWVRIFKLOGEHD ULQJSRWHQWLDO  x)RUWKLVVWXG\DZRPDQRIFKLO GEHDULQJSRWHQWLDOLVGHILQHGDV DSUHPHQRSDXVDOIHPDOHFDSDEOH RIEHFRPLQJSUHJQDQW QRWVW HULOL]HGRUSRVWPHQRSDXVDO  x5HYLHZRI$)V\PSWRPV x5HYLHZRIPHGLFDWLRQVWRWUHDWDWULDODUUK\WKPLDVDQGDQWLFRDJX ODWLRQPHGLFDWLRQV x7UDQVHVRSKDJHDO(FKRFDUGLRJUDP 7((  WUHDWPHQWDUPRQO\  x7((PXVWEHSHUIRUPHGLQDOOVXEM HFWVZKRSUHVHQWWRWKHDEODWL RQSURFHGXUHLQDWULDOILEULOODWLRQ ODVWLQJPRUHWKDQKRXUVLQGXUDWLRQ RURIDQXQNQRZQGXUDWL RQ +RZHYHUWKH7((LV QRWUHTXLUHGLIWKHVXEMHFWKDVDGHTXDWHV\VWHPLFDQWLFRDJXODWL RQWKDWKDVEHHQPDLQWDLQHG IRUDWOHDVWZHHNVSULRUWRSUH VHQWLQJWRWKHDEODWLRQSURFHG XUHLQ$) x7((PXVWEHSHUIRUPHGLIVXEMHFWVKDYHD&+$'69$6FDQGS UHVHQWWRWKHSURFHGXUH ZLWKDVXEWKHUDSHXWLF ,15  RULIWKHVXEMHFWKDVKDGDV LJQLILFDQWLQWHUUXSWLRQRI 12$&V$VLJQLILFDQWLQWHUUXSW LRQRI12$&VLVGHILQHGDVDQ\P LVVHGGRVHZLWKLQGD\V SULRUWRWKHDEODWLRQSURFHGXUH x3HUIRUPDQFHRID7((LQVXEMHFW VZKRDUHLQVLQXVUK\WKPDWWKH WLPHRIDEODWLRQRUHOLJLEOH VXEMHFWVWKDWKDYHEHHQLQ$)IRUKRXUVRUOHVVSULRUWR$) DEODWLRQPD\EHFRQVLGHUHGEXW LVQRWPDQGDWRU\ x7KHVXEMHFWZLOOQRWSURFHHGZLWK WKHVWXG\DEODWLRQSURFHGXUH DQGZLOOEHH[LWHGIURPWKH VWXG\LIDFDUGLDFWKURPEXVLVYLVXDOL]HG x7((ZKHQUHTXLUHGPXVWEHSHUI RUPHGZLWKLQG D\RIWKHDEODW LRQSURFHGXUH RQWKHGD\RI RUZLWKLQWKHGD\SULRUWR  &RQWURO$UP$$',QLWLDWLRQ 6XEMHFWVPXVWLQLWLDWHD&OD VV,RU,,,$$'ZLWKLQGD\VRIU DQGRPL]DWLRQ,WLVUHFRPPHQGHGWKDW$$'V EHLQLWLDWHGDVVRRQDVSRVVLEOH DIWHUUDQGRPL]DWLRQZLWKDWD UJHWRIZLWKLQGD\V7KHLQYHVWLJDWRU VKRXOGFKRRVHWKHDSSURSULDWH$$ 'SHUKLVRUKHUVWDQGDUGRIFD UH KRZHYHUDPLRGDURQHVKRXOGRQO\EH XVHGLIRWKHU$$'VZHUHQRWWROHU DWHGRUIDLOHG7KH$+$ $&&+56*XLGHOLQHIRUWKH0DQDJHPHQW RI3DWLHQWVZLWK$)VKRXOGEHFR QVXOWHGIRU$$'SUHVFULSWLRQV 0RGLILFDWLRQVWR$$'V W\SHRUGRVDJH LQFUHDVH PD\EHPDGHIRUXSWR GD\VDIWHU$$'LQLWLDWLRQ 7KLVLVUHIHUUHGWRDVWKH$$'RSWLPL]DWLRQ"
53,page_53,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO SHULRG'RVLQJRI$$'VFDQEHLQ GLYLGXDOO\WDLORUHGXQWLOWKH HQGRIWKH$$'RSWLPL]DWLRQSHULRG$IWHUWKH RSWLPL]DWLRQSHULRGIXUWKHU$$' WKHUDS\RSWLPL]DWLRQRUFKDQJH VKRXOGEHDYRLGHGRUDWOHDVWDOORZHG RQO\XSWRSK\VLFLDQV¶GLVFUHWLRQWRJXDUDQWHHWKHVDIHW\RIWK HSDWLHQWV7KHSRVVLEOHFRQFRPLWDQWXVHRI EHWDEORFNHUVFDQVWLOOEHRSWLPL ]HGDIWHUWKHRSWLPL]DWLRQSHU LRG5HDVRQIRU$$'PRGLILFDWLRQPXVWEH GRFXPHQWHG &URVVRYHUVIURP$$'WKHUDS\WRF U\RDEODWLRQZLOOEHDOORZHGRQO \LIWKHVXEMHFWLQW KHFRQWUROJURXSLV GHHPHGDWUHDWPHQWIDLOXUH&UR VVRYHUVPXVWEHSUHDSSURYHGE\ WKH0HGWURQLF&OLQLFDO6WXG\0DQDJHU $SSURYDOZLOOEHJUDQWHGDIWHUYH ULILFDWLRQWKDWWKHVXEMHFWLV DQHIILFDF\IDLOXUH 7UHDWPHQWIDLOXUHLVGHIL QHGLQVHFWLRQ 7UHDWPHQW$UP&U\RDEODWLRQ3URFHGXUH :LWKLQGD\VRIUDQGRPL]DWLRQSHUIRUPWKHSXOPRQDU\YHLQLVR ODWLRQSURFHGXUHXVLQJWKH$UFWLF)URQW $GYDQFH&DUGLDF&U\R$EODWLRQ&DWKHWHU ,IQHHGHGD)UHH]RU 0$;&DUGLDF&U\R$EODWLRQ&DWKHWHUPD\DOVREHXWLOL]HGIRUJDSDEO DWLRQWR FRPSOHWHHOHFWULFDOLVRODWLRQRI WKHSXOPRQDU\YHLQVDQGFUHDWL RQRIDEODWLRQOLQHV EHWZHHQWKHLQIHULRU YHQDFDYDDQGWKHWULFXVSLGYDOYH7KH,QYHVWLJDWRULVWRSHUI RUPWKHSURFHGXUHDFFRUGLQJWRWKH SURFHGXUDOVWHSVLQWKLV&,3DQG WKH,QVWUXFWLRQVIRU8VHIRUW KHFDWKHWHUV$SSURSULDWHVHGDWLRQDQG YHQRXVDFFHVVVKRXOGEHDWWDLQHGD WWKH,QYHVWLJDWRU¶VVWDQGDUG SUDFWLFHDFFRUGLQJWR WKHLULQVWLWXWLRQ¶V SUHHVWDEOLVKHGSURFHGXUHVJXLGHOLQHVDWWKHWLPHRIWKHSURFHG XUH 7KHXVHRIDQ\QRQVWXG\GHYLFH LQWKHOHIWDWULXPLVQRWSHUPL WWHG 2QO\WKH0HGWURQLF)OH[&DWKVKHD WKIDPLO\VKRXOGEHXVHGZLWKW KH$UFWLF)URQW$GYDQFH&DUGLDF &U\R$EODWLRQ&DWKHWHU7KHXVHRIRWKHUVKHDWKVPD\GDPDJHWKH GHYLFH7KH,QYHVWLJDWRUPD\FKRRVH FRPSDWLEOHJXLGHZLUHVDQGPDSSLQJ FDWKHWHUVDWKLVRUKHUGLVFU HWLRQ  (VRSKDJHDO9LVXDOL]DWLRQDQG7HPSHUDWXUH0RQLWRULQJ  (QVXUHDQHVRSKDJHDOWHPSHUDWXUH PRQLWRULVXVHGIRUHDFKFU\RD EODWLRQDSSOLFDWLRQ7KHFU\RDSSOLFDWLRQ PXVWEHFHDVHGLIWKHWHPSHUDWXUHUHDFKHV&  3UHSURFHGXUH$QWLFRDJXODWLRQ &XUUHQWUHFRPPHQGDWLRQVIRUDQWLFRDJXODWLRQDUHIRXQGLQWKH +56(+5$(&$6([SHUW&RQVHQVXV 6WDWHPHQWRQ&DWKHWHUDQG6XUJLF DO$EODWLRQRI$WULDO)LEULOODW LRQ &DONLQVHWDO $QWLFRDJXODWLRQ SUHSURFHGXUHVKRXOGEHGHWHUPLQH GEDVHGXSRQWKHVXEMHFWV&+$ '69$6FVFRUH2UDODQWLFRDJXODQWV DUHUHTXLUHGLIWKHVXEMHFWKDVKDGDSULRUVWURNHRU7,$RUL IWKHVXEMHFWKDVD&+$ '69$6FVFRUH :KHQDQWLFRDJXODWLRQLVUHTXLUHG VXEMHFWVPXVWWDNHLWIRUDW OHDVWGD\VSULRUWRDQDEODWLRQ SURFHGXUH2UDODQWLFRDJXODQWVDUHQRWUHTXLUHGIRUVXEMHFWVZ LWKQRQYDOYXODU$)DQGD&+$ '69$6F VFRUHRIRU  ,QWUDSURFHGXUH$QWLFRDJXODWLRQ  +HSDULQVKRXOGEHDGPLQLVWHUHGS ULRUWRRULPPHGLDWHO\IROORZLQ JWUDQVVHSWDOSXQFWXUHGXULQJ$)DEODWLRQ SURFHGXUHVDQGDGMXVWHGWRDFKLHYHDQGPDLQWDLQDQ$&7RI GXULQJWKHSURFHGXUHZLWK$&7 UHFRPPHQGHGWREHFKHFNHGDW PLQXWHVLQWHUYDOV$GPLQLVWUDW LRQRISURWDPLQHIROORZLQJDEODWLRQWR UHYHUVHKHSDULQVKRXOGEHFRQVLGHUHG"
54,page_54,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 54 of 130 Version 5.0 STOP AF First Page 54 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 11.5.3.4. Post-procedure Anticoagulation Systemic oral anticoagulation should be initiated on the day of the procedure and is recommended for at least two months following an AF ablation procedure. Decisions regarding the continuation of systemic anticoagulation agents more than two months following ablation should be based on the patient’s risk factors for stroke as estimated by the CHA 2DS2-VASc score and not on the presence or type of AF . Discontinuation of systemic anticoagulation therapy post ablation is not recommended in patients who are at high risk of stroke as estimated by the CHA 2DS2-VASc score. 11.5.3.5. Diaphragm Movement a. Prior to the first cryoablation application, the Investigator will make a fluoroscopic recording of inspiratory and expiratory movement of the diaphragm. b. Continuous phrenic nerve pacing with abdominal palpitation m ust be performed for all right pulmonary vein cryoapplications and should be considered for all cryoapplicat ions. Additional methods of phrenic n erve monitoring are encouraged, such as diaphragmatic compound motor action potential (CMAP) . c. After the last cryoablation application, the Investigator will make a fluoroscopic recording of inspiratory and expiratory m ovement of the diaphragm. 11.5.3.6. Balloon Pulmonary Vein (PV) Cryoablation a. Every effort consistent with subject welfare will be made to treat all PVs or their anomalous equivalents. b. The catheter will be advanced into the left atrium over the mapping catheter or gu idewire and inflated. Once inflated, the catheter will be tracked over the Achieve™ catheter and positioned at the entrance of the PV. c. Assess the positioning, contact and occlusion of the PV by the catheter’s balloon by injection of contrast material, ult rasound imaging, or other technique. Reposition as needed. d. Each pulmonary vein must be assessed for entrance block and, where assessable, exit block to demonstra te electrical isolation. e. It is recommended that the Investigator use cryoapplications of three (3) minutes each. Once PV isolation has been achieved, one (1) additional application of three (3) minutes at the same PV should be performed; however, it is up to the operator’s discretion to assess application time and necessity of the additional freeze given factors such as time to isolation of prior application(s) , temperature of prior application(s) , risk of collateral damage, etc. f. Upon the Investigator’s assessment of procedure completion, isoproterenol and/or adenosine may be used to assess pulmonary vein isolation."
55,page_55,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 55 of 130 Version 5.0 STOP AF First Page 55 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 11.5.3.7. Other Ablations During Index Procedure a. Ablation of the cavotricuspid isthmus is required in subjects with a history of typical atrial flutter or inducible cavotricuspid isthmus depend atrial flutter. Complete an assessment for bi-directional block if this procedure is performed. Any commercially released catheter deemed appropriate for the procedure may be used. b. The following are not allowed: • Left atrial non -PVI ablations including but not limited to, ablation of linear lesions, complex fractionated electrograms or non -PV triggers • Ablation using any non- study device in the left atrium 11.5.3.8. Cardioversion a. Electrical or pharmacological cardioversion to sinus rhythm must be attempted following the PVI portion of the procedure if sinus rhyt hm wasn’t restored. Cardioversion may be performed prior to PVI if needed. 11.5.3.9. Procedure Documentation During the procedure the investigator will document the following: • Catheter s used (i.e. Arctic Front Advance ™, Freezor ® MAX and Achieve ™ Mapping Catheter, etc.) • Minimum temperature for each cryoapplication • Duration of each cryoapplication • Vein location for each cryoapplication (e.g. right superior PV) • Use of phrenic nerve pacing or other phrenic nerve monitoring technique for each cryoapplication, specifically those cryoapplications surrounding the RS and RI PVs • Demonstrated electrical block and, if real-time signals are available, time to isolation • Adjunctive catheters, mapping or visualization devices, sedation type, procedure information , esophageal temperature, ACT, cardioversion use and fluoroscopy time will be collected ."
56,page_56,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  +RVSLWDO'LVFKDUJH  $WRUVKRUWO\EHIRUHKRVSLWDOG LVFKDUJHWKHIROORZLQJZLOOEH SHUIRUPHGDQGFROOHFWHG  x$GYHUVHHYHQWDVVHVVPHQW x,QWKHFDVHRIVXVSHFWHG39VWHQ RVLV0DJQHWLF5HVRQDQFH,PDJLQ J 05, RU&RPSXWHUL]HG 7RPRJUDSK\6FDQQLQJ &7VFDQ LVUHTXLUHG x5HYLHZPHGLFDWLRQV xOHDG(&* x&KHVW;UD\ )RUDQ\VXEMHFWZK RVHSRVWSURFHGXUDOIOXRURVFRS\ GHPRQVWUDWHGVWXG\UHODWHG 31,DIROORZXSFKHVW;UD\LQFOXGLQJLQVSLUDWLRQDQGH[SLUDW LRQILOPVZLOOEHSHUIRUPHG x5HYLHZVWXG\UHTXLUHPHQWVZLWKWKHVXEMHFWWRKHOSHQVXUHFRPSO LDQFHZLWKIROORZXS SURFHGXUHV x(YDOXDWHWKHVXEMHFW ¶VQHXURORJLFDOVWDWXVSHULQVWLWXWLRQDOVW DQGDUGRIFDUHWR GHWHUPLQHLID IRUPDOQHXURORJLFDOFRQVXOWDWLRQ VKRXOGEHSHUIRUPHGIRUVWURNH DVVHVVPHQW5HSRUWDQ\ DGYHUVHHYHQWVWKDWUHVXOWIURPWKHQHXURORJLFHYDOXDWLRQDQGF RQVXOWDWLRQLIDSSOLFDEOH 0HGLFDWLRQ&RPSOLDQFH  ,QIRUPDWLRQUHJDUGLQJPHGLFDWLRQ VSUHVFULEHGIRUDQWLFRDJXODWLR QRUWRWUHDWDWULDODUUK\WKPLDVZLOOEH FROOHFWHGWKURXJKVWXG\H[LW 7KHIROORZLQJLQIRUPDWLRQZLOOE HFROOHFWHGIRUPHGLFDWLRQVWRWUHDWDWULDO DUUK\WKPLDV PHGLFDWLRQQDPHS XUSRVHIRUXVHVWDUWDQGVWRS GDWHVGRVHGRVDJHFKDQJHV DQG UHDVRQVIRUFKDQJHV DQGURXWH RIDGPLQLVWUDWLRQ'DWDFROOHF WLRQIRUDQWLFRDJXODWLRQPHGLFDWLRQZLOOEH OLPLWHGWRPHGLFDWLRQQDPHDQGVWDUWDQGVWRSGDWHV &RQWURO$UP $$'  6XEMHFWVPXVWLQLWLDWHD&OD VV,RU,,,$$'ZLWKLQGD\VRIU DQGRPL]DWLRQ,WLVUHFRPPHQGHGWKDW$$'V EHLQLWLDWHGDVVRRQDVSRVVLEOH DIWHUUDQGRPL]DWLRQZLWKDWD UJHWRIZLWKLQGD\V7KHLQYHVWLJDWRU VKRXOGFKRRVHWKHDSSURSULDWH$$ 'SHUKLVRUKHUVWDQGDUGRIFD UH KRZHYHUDPLRGDURQHVKRXOGRQO\EH XVHGLIRWKHU$$'VZHUHQRWWROHU DWHGRUIDLOHG7KH$+$ $&&+56*XLGHOLQHIRUWKH0DQDJHPHQW RI3DWLHQWVZLWK$)VKRXOGEHFR QVXOWHGIRU$$'SUHVFULSWLRQV 0RGLILFDWLRQVWR$$'V W\SHRUGRVDJH LQFUHDVH PD\EHPDGHIRUXSWR GD\VDIWHU$$'LQLWLDWLRQ 7KLVLVUHIHUUHGWRDVWKH$$'RSWLPL]DWLRQ SHULRG'RVLQJRI$$'VFDQEHLQ GLYLGXDOO\WDLORUHGXQWLOWKH HQGRIWKH$$'RSWLPL]DWLRQSHULRG$IWHUWKH RSWLPL]DWLRQSHULRGIXUWKHU$$' WKHUDS\RSWLPL]DWLRQRUFKDQJH VKRXOGEHDYRLGHGRUDWOHDVWDOORZHG RQO\XSWRSK\VLFLDQV¶GLVFUHWLRQWRJXDUDQWHHWKHVDIHW\RIWK HSDWLHQWV7KHSRVVLEOHFRQFRPLWDQWXVHRI EHWDEORFNHUVFDQVWLOOEHRSWLPL ]HGDIWHUWKHRSWLPL]DWLRQSHU LRG &U\RDEODWLRQ 7UHDWPHQW$UP 3HUSK\VLFLDQGLVFUHWLRQFODVV,RU,,,DQWLDUUK\WKPLFLQFOXG LQJVRWDOROPHGLFDWLRQXVHLVSHUPLWWHGIRUXS WRGD\VIROORZLQJWKHDEODWLR QSURFHGXUH8VHRIDPLRGDURQH LVQRWSHUPLWWHG3U HVFULSWLRQVIRUWKHVH GUXJVPXVWQRWDOORZDTXDQWLW\ WKDWZLOOODVWORQJHUWKDQG D\VSRVWSURFHGXUH,WLVUHFRPPHQGHG WKDWVLWHSHUVRQQHOFRQWDFWVXEMHF WVRQGD\SRVWDEODWLRQSU RFHGXUHWRHQVXUHWKH\KDYHVWRSSHG WDNLQJFODVV,RU,,,DQWLDUUK\WKPLFGUXJV&ODVV,RU,,,DQW LDUUK\WKPLFGUXJXVHDIWHUWKH GD\EODQNLQJ SHULRGZLOOEHFRQVLGHUHGDSULPDU\HQGSRLQWIDLOXUH 6\VWHPLFRUDODQWLFRDJXODWLRQVKRXOGEHLQLWLDWHGRQWKHGD\RI WKHSURFHGXUHDQGL VUHFRPPHQGHGIRUDW OHDVWWZRPRQWKVIROORZLQJDQ$) DEODWLRQSURFHGXUH'HFLVLRQV UHJDUGLQJWKHFRQWLQXDWLRQRIV\VWHPLF DQWLFRDJXODWLRQDJHQWVPRUHWKDQWZRPRQWKVIROORZLQJDEODWLRQ VKRXOGEHEDVHGRQW KHSDWLHQW¶VULVN IDFWRUVIRUVWURNHDVH VWLPDWHGE\WKH&+$ '69$6FVFRUHDQGQRWRQWKHSUHVHQFHRUW\SHRI$)"
57,page_57,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 'LVFRQWLQXDWLRQRIV\VWHPLFDQWLFRDJXODWLRQWKHUDS\SRVWDEODWL RQLVQRWUHFRPPHQGHGLQSDWLHQWVZKR DUHDWKLJKULVNRIVWURNH DVHVWLPDWHGE\WKH&+$ '69$6FVFRUH  $OO6XEMHFWV  $OORWKHUPHGLFDWLRQV WKRVHWKDW DUHQRWVSHFLILHGDERYH DUH SHUPLWWHGLQWKHVWXG\ ZLWKWKHH[FHSWLRQ RILQYHVWLJDWLRQDOGUXJVWKDWPD \FRQIRXQGWKHVWXG\UHVXOWV %HWDEORFNHUVPD\EHSUHVFULEHGSHU VWDQGDUGRIFDUH 6XEVHTXHQW$EODWLRQ3URFHGXUHV  $Q\VXEVHTXHQWDEODWLRQLQWKHOH IWDWULXPRU$)VXUJHU\ZLOOE HFRXQWHGDVDQHQGSRLQWIDLOXUH7KHUHLV QR GD\EODQNLQJSHULRGIRUUHSHDWDEODWLRQ6XEVHTXHQWDEOD WLRQVDQG$)VXUJHULHVZLOOEH GRFXPHQWHGRQDQH&5) 6XEVHTXHQWDEODWLRQVLQWKHULJKWDWULXPDUHDOORZHG HJW\SL FDODWULDOIOXWWHUDEODWLRQ  &DUGLRYHUVLRQV  (OHFWULFDOO\DQGSKDUPDFRORJLFD OO\FDUGLRYHUWLQJ WKHVXEMHFWWR VLQXVUK\WKPLVDOORZHG LQWKH GD\SRVW SURFHGXUHEODQNLQJSHULRG WUHD WPHQWDUP $$'RSWLPL]DWLRQSHUL RG FRQWURODUP DWWKH GLVFUHWLRQRIWKH ,QYHVWLJDWRU(OHFWULFDOO\RUS KDUPDFRORJLFDOO\FDUGLRYHUWLQJ WKHVXEMHFWWRVLQX VUK\WKPDIWHUWKH EODQNLQJSHULRG$$'RSWLPL]DWLR QSHULRGZLOOEHFRXQWHGDVDQH IILFDF\HQGSRLQWIDLOXUH 6FKHGXOHG)ROORZXS9LVLWV  $IWHUWKHLQGH[FU\RDEODWLRQSURF HGXUH WUHDWPHQWDUP RU$$'LQL WLDWLRQ FRQWURODUP LVUHSRUWHGLQWKH VWXG\GDWDEDVHWKHGDWDEDVHZLOOFDOFXODWHWKHWDUJHWGDWHVDQ GZLQGRZVIRUHDFKYLVLW WRWKHVLWH6KRXOG DVXEMHFWPLVVDYLVLWRUWKHY LVLWIDOORXWVLGHWKHSUHVSHFLI LHGZLQGRZDVWXG\GHYL DWLRQPXVWEHUHSRUWHG DQGWKHRULJLQDOIROORZXSVFKHGXOHPDLQWDLQHGIRUVXEVHTXHQWY LVLWV 'DWDDQDO\VHVLQFOXGHIROORZXSY LVLWVUHJDUGOHVVRIZKHWKHUW KHYLVLWRFFXUVZLWKLQWKHZLQGRZ 7KHUHIRUHDODWHYLVLWLVSUHIHUU HGRYHUDPLVVHGYLVLWEXWPX VWEHDFFRPSDQLHGE\DGHYLDWLRQ)ROORZXS YLVLWZLQGRZVDUHOLVWHGLQ7DEOH DQGDUHEDVHGRQGD\VSRVW LQGH[SURFHGXUHRU$$'LQLWLDWLRQ "
58,page_58,
59,page_59,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 59 of 130 Version 5.0 STOP AF First Page 59 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 11.5.8.2. Three Month Office Visit • Review medications • Adverse event assessment • Review symptoms suggestive of recurrent AF/AT/AFL • Health care utilization assessment - collect information about hospitalizations or emergency department visits experienced by the subject since the last visit • 12 lead ECG • Provide the subject with patient-activated ambulato ry monitoring equipment ; provide instructions for and weekly and symptomatic transmissions. • Chest X-ray o For any subject whose post -procedural fluoroscopy demonstrated study -related PNI, a follow-up chest X- ray, including inspiration and expiration films, w ill be performed if the PNI was unresolved at the one month visit • In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or Computerized Tomography Scanning (CT scan) is required. It is not required at this visit if it was already completed at an earlier visit and PV stenosis was confirmed. 11.5.8.3. Six Month Office Visit • Review medications • Adverse event assessment • Review symptoms suggestive of recurrent AF/AT/AFL • Health care utilization assessment - collect information about hospitalizations or e mergency department visits experienced by the subject since the last visit • 12 lead ECG • 24h continuous ECG monitoring with ambulatory monitoring equipment • EQ-5D and AFEQT Questionnaire s • Review the patient-activated ambulatory monitoring instructions with the subject . • Chest X-ray, including inspiration and expiration films, is required for subjects whose PNI was unresolved at the 3 month visit • In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or Computerized Tomography Scanning (CT scan) is required. It is not required at this visit if it was already completed at an earlier visit and PV stenosis was confirmed."
60,page_60,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 60 of 130 Version 5.0 STOP AF First Page 60 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 11.5.8.4. Twelve month Office Visit • Review medications • Adverse event assessment • Review symptoms suggestive of recurr ent AF/AT/AFL • Health care utilization assessment - collect information about hospitalizations or emergency department visits experienced by the subject since t he last visit • 12 lead ECG • 24h continuous ECG monitoring with ambulatory monitoring equipment . The subject will be instructed to apply the continuous monitoring patches and complete the 24 hours of continuous monitoring within 7 days prior to the 12 month visit. It is recommended that the study personnel call the subject to remind them of this requirement. If the subject is not able to apply the device prior to the visit, it may be applied by study personnel at the 12 month visit. • EQ-5D and AFEQT Quest ionnaires • Collect the ambulatory monitoring equipment and return to Medtronic (or designee). If the subject did not perform the continuous monitoring prior to the 12 month visit, apply the device to the subject to complete 24 hour continuous monitoring. Give the subject instructions on how to return the equipment. • Chest X-ray, including inspiration and expiration films, is required for subjects whose PNI was unresolved at the 6 month visit • In the case of suspected PV stenosis, Magnetic Resonance Imaging (MRI) or Computerized Tomography Scanning (CT scan) is required. It is not required at this visit if it was already completed at an earlier visit and PV stenosis was confirmed. • Inform the subject they have completed the study"
61,page_61,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  8QVFKHGXOHG2IILFH9LVLWV  $QXQVFKHGXOHGYLVLWLVGHILQHGDVD Q\XQSODQQHGFDUGLRYDVFXODU UHODWHGRIILFHYLVLWDWWKHVWXG\VLWHWKDW LVSHUIRUPHGE\SHUVRQQHOSDUWLFLS DWLQJLQWKHVWXG\DQGRFFXUV EHWZHHQ&,3UHTXLUHGYLVLWV6XEPLWWR WKHFRUHODEDQ\OHDG(&*RUFRQWLQXRXVPRQLWRULQJFRPSOHWHG LQFRQMXQFWLRQZLWKDQXQVFKHGXOHG RIILFHYLVLW7KHIROORZLQJL QIRUPDWLRQLVUHTXLUHGWREHFROO HFWHGDWXQVFKHGXOHGIROORZXSYLVLWV  x5HYLHZPHGLFDWLRQV x$GYHUVHHYHQWDVVHVVPHQW x5HYLHZV\PSWRPVVXJJHVWLYHRIUHFXUUHQW$)$7$)/ x+HDOWKFDUHXWLOL]DWLRQDVVHVVPHQW FROOHFWLQIRUPDWLRQDERXWK RVSLWDOL]DWLRQVRUHPHUJHQF\ GHSDUWPHQWYLVLWVH[SHU LHQFHGE\WKHVXEMHF WVLQFHWKHODVWYLV LW xOHDG(&* 5H$EODWLRQ&URVVRYHU$EODWLRQ  x2EWDLQDSSURYDOIURP0HGWURQLFIR UFURVVRYHUDEODWLRQV QRWUHT XLUHGIRUWUHDWPHQWDUP UHDEODWLRQ  x3HUIRUPWKHIROORZLQJDVVHVVPHQW VSULRUWRWKHFU\RDEODWLRQ  R5HYLHZPHGLFDWLRQV R$GYHUVHHYHQWDVVHVVPHQW R5HYLHZV\PSWRPVVXJJHVWLYH RIUHFXUUHQW$)$7$)/ R(4'DQG$)(474XHVWLRQQDLUHV R+HDOWKFDUHXWLOL]DWLRQDVVHVVPHQW FROOHFWLQIRUPDWLRQDERXWK RVSLWDOL]DWLRQVRU HPHUJHQF\GHSDUWPHQWYLVLWVH[SH ULHQFHGE\WKHV XEMHFWVLQFHWK HODVWYLVLW x3URFHGXUH'DWD  R&DWKHWHUVXVHG LH$UFWLF)URQW$GYDQFH)UHH]RU0$;DQG$F KLHYH0DSSLQJ &DWKHWHUHWF  R0LQLPXPWHPSHUDWXUHIRUHDFKFU\RDSSOLFDWLRQ R'XUDWLRQRIHDFKFU\RDSSOLFDWLRQ R9HLQORFDWLRQIRUHDFKFU\RDSSOLFDWLRQ HJULJKWVXSHULRU39  R8VHRISKUHQLFQHUYHSDFLQJRURWKHUSKUHQLFQHUYHPRQLWRULQJW HFKQLTXHIRUHDFK FU\RDSSOLFDWLRQVSHFLILFDOO\WKR VHFU\RDSSOLFDWLRQVVXUURXQGLQ JWKH56DQG5,39V R'HPRQVWUDWHGHOHFWULFDOEORFNDQ GLIUHDOWLPHVLJQDOVDUHDYD LODEOHWLPHWRLVRODWLRQ R$GMXQFWLYHFDWKHWHUVPDSSLQJRU YLVXDOL]DWLRQGHYLFHVVHGDWLR QW\SHSURFHGXUH LQIRUPDWLRQHVRSKDJHDOWHPSHUDW XUH$&7FDUGLRYHUVLRQXVHDQG IOXRURVFRS\WLPHZLOO EHFROOHFWHG R3XOPRQDU\YHLQLVRODWLRQVWDWVI URPSUHYLRXVDEODWLRQ UHDEODW LRQVRQO\  OHDG(OHFWURFDUGLRJUDPV  $OOVWXG\UHTXLUHGOHDG(&* VZLOOEHVHQWWRWKHFRUHODE 7KHFRUHODEZLOOEHUHVSRQVLEOHIRU DGMXGLFDWLRQRIDWULDODUUK\WKPLDVIRUWKHSULPDU\REMHFWLYHRI WKHVWXG\7KHFRUHODEZLOOVHQGWKH UHVXOWVRIDOO(&*DQDO\VHVWRWK H,QYHVWLJDWRUVIRUDSSURSULDW HIROORZXSLIQHFHVVDU\DQGDVVHVVPHQW IRUDGYHUVHHYHQWUHSRUWLQJ&R SLHVRIDGGLWLRQDOVRXUFHGRFXP HQWVPD\EHUHTXHVWHG $PEXODWRU\0RQLWRULQJ 0DUNHWUHOHDVHGDPEXODWRU\PRQLWRULQJHTXLSPHQWZLOOEHGLVWUL EXWHGE\DFRUHODE WRFHQWHUVDIWHU DFWLYDWLRQKDVRFFXUUHG6XEM HFWVZLOOEHSURYLGHGZLWKDVPDO OSDWLHQWDFWLYDWHGHOHFWURQLFDPEXODWRU\"
62,page_62,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO PRQLWRULQJGHYLFHDIWHUWKH$$'R SWLPL]DWLRQ FRQWURODUP RUS RVWDEODWLRQEODQNLQJSHULRG WUHDWPHQW DUP HQGV7KLVGHYLFHZ LOOVHUYHWZRIXQFWLRQV  xKRXUFRQWLQXRXVPRQLWRULQJ 7KLVLVWUDGLWLRQDOO\GRQHXVLQ JD+ROWHUPRQLWRU7KH LQYHVWLJDWLYHVLWHSH UVRQQHOZLOODSSO\WKHGH YLFHSDWFKHVIRU WKHVXEMHFWGXULQJWKHVXEMHFW¶V PRQWKYLVLWDQGWUDLQW KHVXEMHFWKRZWRDS SO\WKHGHYLFH7KH VXEMHFWZLOOEHDVNHGWRDSSO\WKH FRQWLQXRXVPRQLWRULQJSDWFKHVWKHPVHOYHVSULRUWRWKHPRQWK VWXG\YLVLW$GGLWLRQDOO\ VXEMHFWVPD\EHDVNHGWRSHUIRUPKRXUFRQWLQXRXVPRQLWRULQJ RQWKHLURZQLIWKH\PLVVD VFKHGXOHGVWXG\YLVLW x3DWLHQWDFWLYDWHGPRGH 6XEMHFW VZLOOEHDVNHGWRWUDQVPLW(&* GDWDZHHNO\DQGZKHQHYHUWKH\ H[SHULHQFH$)V\PSWRPV7KLVPRGHGRHVQRWUHTXLUHDGKHVLYHSD WFKHV WKHVXEMHFWVLPSO\ KROGVWKHGHYLFHWRKLVRUKHUF KHVWIRUDVKRUWSHULRGRIWLPH  ,QERWKPRGHVWKHGDWDDXWRPDWL FDOO\WUDQVPLWVWRWKHFRUHODE YLDDVHFXUHGFHOOSKRQHFRQQHFWLRQ 7KHFRUHODEZLOOPDQDJHPDLQWHQDQ FHFDOLEUDWLRQDQGWUDFNLQJ RIWKHDPEXODWRU\PRQLWRULQJHTXLSPHQW 7KHFRUHODEZLOOEHUHVSRQVLEOHI RUDGMXGLFDWLRQRIUK\WKPGRF XPHQWDWLRQIRUWKH SULPDU\HIILFDF\ REMHFWLYHRIWKHVWXG\7KHF RUHODEZLOOVHQGW KHUHVXOWVRI DOODPEXODWRU\PRQLWRULQJDQDO\VHVWRWKH ,QYHVWLJDWRUVIRUDSSURSULDWHIROORZXSLIQHFHVVDU\DQGDVVH VVPHQWIRUDGYHUVHHYHQWUHSRUWLQJ 6XEMHFWVZLOOUHWXUQWKHDPEXODWR U\PRQLWRULQJHTXLSPHQWDWWKH PRQWKIROORZXSYLVLW 6WXG\([LW 6XEMHFWVZLOOEHH[LWHGIURPWKH VWXG\XSRQFRPSOHWLRQRIWKH PRQWKIROORZXSYLVLW)RULQIRUPDWLRQ DERXWVXEMHFWZLWKGUDZDODQGGLVF RQWLQXDWLRQVHHVHFWLRQ  $VVHVVPHQWRI(IILFDF\ 7KHSULPDU\HIILFDF\REMHFWLYHLVEDVHGRQWKHGDWDFROOHFWHGD VGLVFXVVHGLQVHFWLRQDQG $VVHVVPHQWRI6DIHW\ 7KHVHFRQGDU\VDIHW\REMHFWLYHL VEDVHGRQWKH$ GYHUVH(YHQWGD WDFROOHFWHG)XUWKHULQIRUPDWLRQRQWKH FROOHFWLRQDQGDVVHVVPHQWRIVD IHW\GDWDLVGLVFXVVHGLQVHFWLR Q 5HFRUGLQJ'DWD 7KHVWXG\ZLOOFROOHFWGDWDXVLQJ DQHOHFWURQLFGDWDPDQDJHPHQW V\VWHPIRUFOLQLFDOVW XGLHV&HQWHUVZLOO HQWHUGDWDRQWRH&5)VZLWKLQW KHGDWDEDVH7KHFRUHODEZLOOD OVRHQWHUGDWDRQWR&5)VZLWKLQDVHSDUDWH HOHFWURQLFGDWDEDVH 3URFHGXUHVLQWKH&,3UHTXLUHVRXUFHGRFXPHQWDWLRQ6RXUFHGRFX PHQWDWLRQZLOOEHPDLQWDLQHGDWWKH VWXG\FHQWHU6RXUFHGRFXPHQWVZKLFKPD\LQFOXGHZRUNVKHHWV VXEMHFWPHGLFDOUHFRUGVDQG FRQVROHILOHVPXVWEHFUHDWHGDQGPDLQWDLQHGE\WKHLQYHVWLJDW LRQDOFHQWHUWHDP7KHGDWDUHSRUWHG RQWKHH&5)VVKDOOEHGHULYHGIU RPVRXUFHGRFXPHQWVDQGEHFRQV LVWHQWZLWKWKHVHVRXUFH GRFXPHQWVDQGDQ\GLVFUHSDQFLH VVKDOOEHH[SODLQHGLQZULWLQJ 7KHH&5)PD\EHFRQVLGHUHGVRXUFH IRUWKHIROORZLQJGDWDFROOHFWLRQHOHPHQWV  x7LPHRILVRODWLRQRIWKH FU\RDEODWLRQFDWKHWHU x(VRSKDJHDOWHPSHUDWXUH x,QYHVWLJDWRUDVVHVVPHQWRIDGYHUVH HYHQWRUGHDWKUHODWHGQHVVD QGVHYHULW\"
63,page_63,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO x'DWHFHQWHUEHFDPHDZDUHRIWKH DGYHUVHHYHQWGHYLFHGHILFLHQF \RUGHDWK x5HDVRQIRUVWXG\GHYLDWLRQ x'DWDEDVHJHQHUDWHGSDWLHQWUHIHUHQFH,' :KHQFRSLHVRUSULQWRXWVRIWKHVRXUFHGRFXPHQWVDUHPDGHFHQ WHUSHUVRQQHOPXVWVLJQDQGGDWH DQ\FRSLHVRUSULQWRXWVRIRULJL QDOVRXUFHGRFXPHQ WVZLWKDVWDWHPHQWWKDWWKLVLVFR PSOHWHDQGWUXH UHSURGXFWLRQRIWKHRULJLQDOVRX UFHGRFXPHQW7KHVSRQVRURUD UHJXODWRU\DXWKRULW\PD\DXGLWRU LQVSHFWWKHVWXG\FHQWHUWRHYDOXDWHWKHFRQGXFWRIWKHVWXG\  7KHFOLQLFDO,QYHVWLJDWRU V LQ VWLWXWLRQ V VKDOODOORZVWXG\U HODWHGPRQLWRULQJDXGLWV,5%(&UHYLHZ DQGUHJXODWRU\LQVSHFWLRQE\SUR YLGLQJGLUHFWDFFHVVWRVRXUFH GDWDGRFXPHQWV)XUWKHUGHWDLORQ GDWDPDQDJHPHQWLVSURYLGHGLQ6HFWLRQ  'HYLDWLRQ+DQGOLQJ $VWXG\GHYLDWLRQLVGHILQHGDVD QHYHQWZLWKLQWKHVWXG\WKDW GLGQRWRFFXUDFFRUGLQJWRUHTXLUHPHQWV VSHFLILFWRWKH&,3RU&7$(YHU\DWWHPSWPXVWEHPDGHWRDYRLG VWXG\GHYLDWLRQV3ULRUDSSURYDOE\ 0HGWURQLFLVH[SHFWHGLQVLWXDWL RQVZKHUHWKH,QYH VWLJDWRUDQWLFLSDWHVFRQWHPSODWHVRUPDNHVD FRQVFLRXVGHFLVLRQWRGHYLDWH,QFRXQWULHVIROORZLQJ,62 SULRUDSSURYDOIRUVWXG\GHYLDWLRQV ZLOOEHUHSRUWHGWRORFDODXWKRUL WLHVDQGHWKLFVERDUGVSHUORF DOUHTXLUHPHQWV,IWKHGHYLDWLRQDIIHFWV VXEMHFW¶VULJKWVVDIHW\DQGZHOO EHLQJRUWKHVFLHQWLILFLQWH JULW\RIWKHVWXG\SULRUDSSURYDOIURPHWKLFV ERDUGDQGRUFRPSHWHQWDXWKRULW\  &$ LVDOVRUHTXLUHGGHSHQGL QJRQORFDOOHJLVODWLRQV3ULRUDSSURYDOLV QRWUHTXLUHGZKHQDGHYLDWLRQLV QHFHVVDU\WRSURWHFWWKHVDIHW \ULJKWVRUZHOOEHLQJRIDVXEMHFWLQDQ HPHUJHQF\RULQXQIR UHVHHQVLWXDWLRQVEH\RQGWKH,QYHVWLJDWRU¶V FRQWURO HJVXEMHFWIDLOXUHWRDWWHQG VFKHGXOHGIROORZXSYLVLWVLQDGY HUWHQWORVVRIGDWHGXHWRFRP SXWHUPDOIXQFWLRQLQDELOLW\WRSHUIRUP UHTXLUHGSURFHGXUHVGXHWRVXEM HFWLOOQHVV 6XEMHFWV¶IDLOXUH WRVXEPLWDPEXODWRU\PRQLWRULQJ WUDQVPLVVLRQVSHUWKH&,3GRQRW UHTXLUHDGHYLDWLRQWREHUHSR UWHG$PEXODWRU\PRQLWRULQJWUDQVPLVVLRQ FRPSOLDQFHZLOOEHWUDFNHGE\0HG WURQLFSHUVRQQHODQGWKH&RUH /DE )RUPHGLFDOO\MXVWLILDEOHFRQGLW LRQVZKLFKSUHHP SWDVXEMHFW¶V DELOLW\WRFRPSOHWHDVWXG\UHTXLUHG SURFHGXUHLWPD\EHSHUPLWWHGWRUHSRUWRQO\RQHGHYLDWLRQZKL FKZLOODSSO\WRDOOYLVLWVJRLQJIRUZDUG 7KLVPD\DOVRDSSO\IRURWKHUXQI RUHVHHQVLWXDWLRQV HJWKHV XEMHFWSHUPDQHQWO\UHI XVHVWRFRPSOHWHD VWXG\UHTXLUHGSURFHGX UHDQGWKHGDWDZLOOQRWFRQWULEXWHWRWK HSULPDU\HQGSRLQWDQDO\VLV +RZHYHU SULRUDSSURYDOIURP0HGWURQLFLVU HTXLUHGIRUVXFKVLWXDWLRQV $OOVWXG\GHYLDWLRQVPXVWEHUHS RUWHGWR0HGWURQLFUHJDUGOHVVR IZKHWKHUWKH\DUHPHG LFDOO\MXVWLILDEOH SUHDSSURYHGE\0HGWURQLFDQLQDGYHUWHQWRFFXUUHQFHRUWDNHQ WRSURWHFWWKHVXEMHFWLQDQHPHUJHQF\ 7KHGHVFULSWLRQRIWKHGHYLDWLRQ DQGMXVWLILFDWLRQPXVWEHGRFX PHQWHGDQGVXEPLWWHGWR0HGWURQLFYLD H&5)FRPSOHWLRQ  ,QWKHHYHQWWKHGHYLDWLRQLQYROYHVD IDLOXUHWRREWDLQDVLJQH G,QIRUPHG&RQVHQW)RUPRULVPDGHWR SURWHFWWKHOLIHRUSK\VLFDOZHOO EHLQJRIDVXEMHFWLQDQHPHU JHQF\WKHGHYLDWLRQPXV WEHUHSRUWHGWRWKH ,5%(&DVZHOODV0HGWURQLFZLWKLQ ILYH  ZRUNLQJGD\V5HSR UWLQJRIDOORWKHUVWX G\GHYLDWLRQVVKRXOG FRPSO\ZLWK,5%(&SROLFLHVDQ GRUORFDOODZVDQGPXVWEHUHSRU WHGWR0HGWURQLFDVVRRQDVSRVVLEOH XSRQWKHVLWHEHFRPLQJDZDUHRIWKHGHYLDWLRQ5HIHUWR 7DEOH IRUUHSRUWLQJUHTXLUHPHQWV 0HGWURQLFLVUHVSRQVLEOHIRUU HYLHZLQJGHYLDWLRQVDVVHVVLQJWK HLUVLJQLILFDQFHDQGLGHQWLI\LQJDQ\ QHFHVVDU\FRUUHFWLYHDQGRUSUHYHQWLYHDFWLRQV HJDPHQGWKH &,3FRQGXFWDGGLWLRQDOWUDLQLQJDQG WHUPLQDWHWKHLQYHVWLJDWLRQ 5 HSHWLWLYHRUVHULRXV,QYHVWLJDW RUFRPSOLDQFHLVVXHVPD\UHVXOWLQLQLWLDWLRQ"
64,page_64,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO RIDFRUUHFWLYHDFWLRQSODQZLWKWKH,QYHVWLJDWRUDQGFHQWHUD QGLQVRPHFDVHVPD\QHFHVVLWDWH VXVSHQGLQJDFHQWHU¶VDELOLW\ WRHQUROOXQWLOWKHSUREOHPLVUH VROYHGRUXOWLPDWHO \WHUPLQDWLQJWKH ,QYHVWLJDWRU¶VSDUWLFLSDWLRQLQ WKHVWXG\0HGWUR QLFZLOOSURYL GHFHQWHUVSHFLILFUHS RUWVWR,QYHVWLJDWRUV VXPPDUL]LQJLQIRUPDWLRQRQGHYLDWLRQVWKDWRFFXUUHGDWWKHLQYH VWLJDWLRQDOFHQWHURQDSHULRGLFEDVLV 6XEMHFW:LWKGUDZDORU'LVFRQWLQXDWLRQ $VXEMHFWFDQZLWKGUDZIURPWKHVWXG\DWDQ\WLPH,IWKHVXEM HFWZLVKHVWRH[LWIURPWKHVWXG\ LHWKH VXEMHFWUHYRNHVFRQVHQW WKHFHQWHULVUHTXLUHGWRGRFXPHQWWK HUHDVRQIRUH[LWRQDQH&5),QDGGLWLRQ FHQWHUVVKDOOIROORZWKHUHJXODWL RQVVHWIRUWKE\WKHLU,5%(&  3ULRUWRH[LWLQJDVXEMHFWIUR PWKHVWXG\LWLVUHFRPPHQGHGWR IROORZWKHVXEMHFW XQWLODOORQJRLQJGHYLFH DQGRUSURFHGXUHUHODWHGDGYHUVH HYHQWVDUHUHVROYHGRUXQUHVRO YHGZLWKQRIXUWKHUDFWLRQVSODQQHG$Q XQVFKHGXOHGRIILFHYLVLWVKRXOG EHDWWHPSWHGLIWKHVXEMHFWH[L WVWKHVWXG\RXWVLGH RIDVFKHGXOHGIROORZ XSYLVLW )ROORZLQJH[LWVXEMHFWVZLOOFRQ WLQXHWRUHFHLYHVWDQGDUGPHGL FDOFDUH8SRQH[LWLQJIURPWKHVWXG\QR IXUWKHUVWXG\GDWDZLOOEHFROOH FWHGRUVWXG\YLVLWVZLOORFFXU IRUWKHVXEMHFW$OOGDWD DYDLODEOHWKURXJKWKH WLPHRIWKHVXEMHFW¶VH[LW ZLOOEHXVHGIRUDQDO\VLV 5HDVRQVIRUVXEMHFWZLWKGUDZD ORUGLVFRQWLQXDWLRQLQFOXGH  x6XEMHFWLVORVWWRIROORZXS x6XEMHFWGLGQRWPHHWLQFOXVLRQH[ FOXVLRQFULWHULDDIWHUWKHGDW HWKHVXEMHFWVLJQHGWKH,QIRUPHG &RQVHQW)RUPDQGSULRUWRUDQGRPL]DWLRQ x7KHVXEMHFWZDVUDQGRPL]HGWRWKHWUHDWPHQWDUPEXWQRFU\REDO ORRQDEODWLRQSURFHGXUHZDV DWWHPSWHG x7KHVXEMHFWZDVUDQGRPL]HGWRWK HFRQWURODUPEXWQR$$'ZDVL QLWLDWHG x6XEMHFWFKRRVHVWRZLWKGUDZ HJ ,QIRUPHG&RQVHQW)RUPZLWKGU DZDOUHORFDWLRQWRDQRWKHU JHRJUDSKLFORFDWLRQ  x,QYHVWLJDWRUGHHPVZLWKGUDZDOQHF HVVDU\ HJPHGLFDOO\MXVWLI LHGLQFOXVLRQH[FOXVLRQFULWHULDQRW PHWIDLOXUHRI VXEMHFWWRPDLQWDLQDGHTXDWHVWXG\FRPSOLDQFH  x7KHVSRQVRURUUHJXODWRU\DXWK RULW\GHFLGHVWKHVWXG\ZLOOEHF ORVHGRUDSDUWLFXODUFHQWHUZLOOEH FORVHG 7KHIROORZLQJLQIRUPDWLRQLVUHTXLUHGWREHFROOHFWHGDWHDUO\ VWXG\H[LW  x5HDVRQIRUH[LWPXVWEHGRFXPHQWHGRQWKHH&5)DQGLQWKHVXEMH FW¶VPHGLFDOUHFRUG x$QXQVFKHGXOHGRIILFHYLVLWVKRXO GEHDWWHPSWHGLI WKHVXEMHFW H[LWVWKHVWXG\RXWVLGHRID VFKHGXOHGIROORZXSYLVLW ,QWKHFDVHWKDWWKH VXEMHFWLVGHWHUPLQHG WREHORVWWRIROORZ XSGHWDLOVRIDPLQLPXPRIWZRDWWHPSWV DQGWKHPHWKRGRIDWWHPSW HJRQHOHWWHUDQGRQHSKRQHUHFRU GRUWZROHWWHUV WRF RQWDFWWKHVXEMHFW PXVWEHUHFRUGHG,QDGGLWLRQI ROORZWKHUHJXODWLRQVVHWIRUW KE\WKHJRYHUQLQJ,5%(& "
65,page_65,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 5LVNVDQG%HQHILWV 3RWHQWLDO5LVNV 0HGWURQLFIROORZVULJRURXV4XDOLW\$VVXUDQFHDQG&RQWUROSURFHG XUHVWKURXJKRXWWKHOLIHRIDSURGXFW IURPWKHEXVLQHVVDQDO\VLVSKDVH WKURXJKGHYHORSPHQWPDUNHWUH OHDVHDQGSRVWPDUNHWVXUYHLOODQFH 7KHUHVLGXDOULVNVDVVRFLDWHGZLWK WKH$UFWLF)URQW$GYDQFH&D UGLDF&U\R$EODWLRQ&DWKHWHUKDYHEHHQ IRXQGWREHDFFHSWDEOHDQGKDYH EHHQPLWLJDWHGWRWKHIXOOHVWH [WHQWSRVVLEOH7KHSRWHQWLDOEHQHILWV UHODWHGWRWKHXVHRIWKH$UFWLF )URQW$GYDQFH&DUGLDF&U\R$EO DWLRQ&DWKHWHUKDYHEHHQGHWHUPLQHGWR RXWZHLJKDQ\SRWHQWLDOULVNV7 KHGHYLFHKDVQHYHUEHHQUHFDOO HG 7KHUHDUHSRWHQWLDOULVNVDQGVLG HHIIHFWVDVVRFLDWHGZLWK&ODV V,DQG,,,$$'V$FRPSO HWHOLVWRINQRZQ ULVNVDVVRFLDWHGZLWKWKHGUXJVXVHGLQWKLVVWXG\FDQEHIRXQG ZLWKLQWKHLUDSSURYHGODEHOLQJ 7KHUHDUHSRWHQWLDOULVNVDQGVLG HHIIHFWVDVVRFLDWHGZLWKDEOD WLRQSURFHGXUHV7K H,QYHVWLJDWRUVKDOO GHVFULEHULVNVLQIXUWKHUGHWDLOZ KHQDVNHGE\WKH VXEMHFW7K HULVNVPXVWEHFRQWLQXRXVO\PRQLWRUHG DVVHVVHGDQGGRFXPHQWHGE\WKH ,QYHVWLJDWRU3RVVLEOHDGGLWLRQ DOULVNVIRUSDUWLFLSDWLQJWKHVWXG\LQFOXGH WKHIROORZLQJ DOWKRXJKRWKHUVD UHSRVVLEOH DQGDUHIXUWKHUGH ILQHGLQ$SSHQGL[) x$QHPLDGHILFLHQF\RIUHGEORRGFHOOVRURIKHPRJORELQLQWKHEO RRGUHVXOWLQJLQZHDULQHVV x$Q[LHW\DIHHOLQJRIZRUU\QHUYRXVQHVVRUXQHDVH x%DFNSDLQSDLQIHOWLQWKHORZHURUXSSHUEDFN x%OHHGLQJHJEOHHGLQJLQWRW KHUHWURSHULWRQHDOVSDFH x%URQFKLWLVFRXJKSQHXPRQLDLQIODPPDWLRQRIWKHOXQJVFDQEHF DXVHGE\DYLUXVRUEDFWHULD x&DUGLDFWDPSRQDGHSUHVVXUHRQWKHKHDUWDVDUHVXOWRIIOXLGFR OOHFWLQJLQWKHVDF VXUURXQGLQJWKH KHDUW x&DUGLRSXOPRQDU\DUUHVWFHVVDWLRQ RIEORRGFLUFXODWLRQDQGRUUH VSLUDWLRQGXHWRG\VIXQFWLRQRIWKH KHDUWDQGRUOXQJV x&KHVWGLVFRPIRUWSDLQSUHVVXUHL QFOXGHVDUDQJHRIIHHOLQJIURP VKDUSVWDEELQJWRGXOODFKHLQ WKHFKHVW x&ROGIHHOLQJKDYLQJDORZR ULQDGHTXDWHWHPSHUDWXUH x&RPSOLFDWLRQVDVVRFLDWHGZLWKFRQW UDVWDJHQWVDGYHUVHHIIHFWVR IFRQWUDVWDJHQWVXVHGGXULQJWKH SURFHGXUH HJDOOHUJLFUHDFWLRQ RUUDGLRFRQWUDVWQHSKURSDWK\  x&RPSOLFDWLRQVDVVRFLDWHGZLWKPH GLFDWLRQVFRPPRQO\XWLOL]HGGXU LQJWKHSURFHGXUHNQRZQULVNV RIPHGLFDWLRQVFRPPRQO\XVHGGXULQJWKHSURFHGXUH HJQDUFRWL FVDQ[LRO\WLFVRWKHUSDLQ PHGLFDWLRQVDQWLYDVRVSDVPDJHQWV  x&RPSOLFDWLRQVDWFDWKHWHULQ VHUWLRQVLWHLQWKHJURLQ  R$9ILVWXODDQDEQRUPDOFRQQHFWLRQ EHWZHHQDQDUWHU\DQGDYHLQ LHFDXVHE\QHHGOH LQVHUWLRQWKURXJKWKHIHPRUDODUWHU\DQGYHLQ  R+HPDWRPD%UXLVLQJDFROOHFWLRQ RIEORRGLQWKHWLVVXHVXUURXQGL QJWKHFDWKHWH ULQVHUWLRQ VLWH R,QIHFWLRQORFDOL]HGUHGQHVVKH DWVZHOOLQJDQGSDLQDWWKHFDWK HWHULQVHUWLRQVLWH"
66,page_66,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 66 of 130 Version 5.0 STOP AF First Page 66 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential o Pain-discomfort at the catheter insertion site that can range from mild to severe. o Pseudoane urysm-a collection of blood in the tissue surrounding the catheter insertion site due to ongoing leaking of blood from a blood vessel. o Significant bleeding -blood loss from the catheter insertion site requiring surgery or transfusion of 2 or more units of p acked red blood cells (PRBCs). • Coronary artery spasm, vasospasm -constriction of a blood vessel. • Death-a complication or deterioration of health ultimately leading to a patient’s death. • Dissection of a blood vessel -a tear within the wall of a blood vessel. • Dizziness, lightheadedness- feeling faint, woozy, weak or unsteady. • Embolism- formation and dislodgement of a blood clot (thrombus) or dislodgement of cholesterol/plaque within the blood vessel, which travels downstream into small vessels, blocking blood flow and causing temporary or permanent damage to organs distal to blockage. Emboli are known to cause myocardial infarction, transient ischemic attack, stroke/cardiovascular accident, blurred vision, visual changes, paralysis, paresis, or kidney damage, per ipheral ischemia and may ultimately lead to incapacitation or death. Symptomatic and non -symptomatic. • Endocarditis – inflammation of the inner surface of the heart. • Esophageal injury –damage to your swallowing tube, atrio -esophageal fistula - abnormal passageway between the heart and esophagus, hematemesis (vomiting blood). • Fatigue- extreme tiredness. • Fever- abnormally high body temperature. • Gastroparesis- delayed gastric emptying. • Headache - pain in the head. • Heartblock requiring permanent pacemaker implantation • Heart rhythm disturbances -disruption of normal heart rate or rhythm (e.g. atrial flutter, tachycardia, bradycardia). • Hemothorax –collection of blood around the lungs. • Hiccups- involuntary spasm of the diaphragm and respiratory organs . • Hypertension- high blood pressure. • Hypotension -low blood pressure. • Infection (e.g. sepsis) • Injury to lung - (e.g. bronchial lesion, hemoptysis, constriction, pulmonary hemorrhage, bronchia fistula). • Mild skin discomfort or irritation -redness sensitivity of the skin cause during or after the procedures (e.g. electrodes used with the ECG and Holter recorder might cause mild skin discomfort or irritation or some skin discomfort following electrode remova l or tape removal). • Nausea-a sensation of unease and discomfort in the upper stomach with an urge to vomit."
67,page_67,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 67 of 130 Version 5.0 STOP AF First Page 67 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential • Perforation of a blood vessel or cardiac tissue -unintended puncture through the wall of a blood vessel or cardiac tissue . • Pericardial effusion - fluid collecting in the sac that surrounds the heart. • Pericarditis – inflammation of the sac that surrounds the heart. • Phrenic nerve injury –damage to the nerve that controls breathing. • Pleural effusion – collection of extra fluid around the lungs. • Pneumothorax – collapsed lung. Pulmonary edema - excess fluid in the lungs. • Pulmonary hypertension - high blood pressure that affects the arteries in the lungs and the right side of the heart.Pulmonary vein hematoma - trauma to the pulmonary vein. • Pulmonary vein stenosis – blockage in the blood vessels takes blood from the lungs to the heart. • Renal dysfunction -kidneys fail to adequately filter waste products from the blood. • Right sided heart failure - right side of the heart is not pumping blood to the lung normally. • Shivering - body shaking. • Shortness of breath- difficulty breathing. • Small ischemic cerebral (brain) lesions not accompanied by clinically apparent symptoms have been found on brain imaging performed after an AF ablation pro cedure. So far, the relationship between these lesions and an increased incidence of stroke or transient ischemic attack (a mini stroke) has not been established. However, whether these lesions will result in long term cognitive decline (e.g. loss of memory and trouble thinking) is unclear. • ST elevation - the ST segment of an ECG is abnormally high above the baseline. • Sore throat - pain in the throat. • Urinary infection - an infection in the urinary system. • Vascular complications requiring surgery -damage to an artery (e.g. f emoral) or vein requiring surgical repair. • Vasovagal reaction - reflex of the involuntary nervous system that causes the heart to slow down and blood pressure drops. • Vomiting- forceful expulsion of stomach contents through the mouth and/or nose. The risk s of participating in this clinical study are the same as the cryoablation procedure risks, and also include: • Risks/discomforts associated with sedation/anesthesia: o Hoarseness. o Myalgia (pain in the muscles). o Numbness and tingling of the fingers. o Diarrhea. o Dry mouth. o Sleepiness."
68,page_68,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO x5DGLDWLRQH[SRVXUHGXHWRSRWHQW LDOIRUDGGLWLRQDO&705,VFDQ RU&KHVW;UD\V x3DWFKHVDQGDGKHVLYHXVHGZLWKWKHDPEXODWRU\PRQLWRULQJHTXLSP HQWPD\FDXVHVNLQGLVFRPIRUW RULUULWDWLRQRUVRPHVNLQGLVFRPIRUWIROORZLQJSDWFKUHPRYDO  5LVN0LQLPL]DWLRQ 0HGWURQLFKDVDWWHPSWHGWRPLQLPL ]HWKHSRWHQWLDOULVNVWRVXEM HFWVLQWKLVVWXG\E\WDNLQJWKHIROORZLQJ DFWLRQV  x6HOHFWLQJTXDOLILHGLQ YHVWLJDWRUVDQGWUDLQ LQJVWXG\SHUVRQQHO RQWKH&,3 x5HTXLULQJWKDWLQYHVWLJDWRUVEHD FWLYHO\LQYROYHGLQWKHSURFHG XUHDQGIROORZXSRIWKHVXEMHFWV ZKRXQGHUJRDVWXG\SURFHGXUH x3URYLGLQJJXLGHOLQH VIRUVXEMHFWVHOHFWLRQDQGHYDOXDWLRQ x5HTXLULQJWKDWVXEMHFWVEHIROOR ZHGDWUHJXODULQWHUYDOVIROORZ LQJWKHDEODWLRQSURFHGXUHWR PRQLWRUIRUUHFXUUHQFHRIDWULDO DUUK\WKPLDVDQGWRDVVHVVIRU DGYHUVHHYHQWV 3RWHQWLDO%HQHILWV 7KH$UFWLF)URQW$GYDQFH70&DUGLDF&U\R$EODWLRQ&DWKHWHUPD\UHGXFHRUHOLPLQDWHDWULDOI LEULOODWLRQLQ VXEMHFWVZKRKDYHQRW\HWIDLOHGDQ$$' KRZHYHUVRPHVXEMHFWV PD\QRWUHFHLYHWKLVEHQHILW6XEMHFWV LQWKHFRQWURODUPWUH DWHGZLWKDQ$$'PD\D OVRUHGXFHRUHOLPL QDWHDWULDOILEULOODWLRQ KRZHYHUVRPH VXEMHFWVPD\QRWUHFHLYHWKLVEHQ HILW7KHLQIRUPDWLRQJDLQHGI URPWKHVWXG\FRXOGUHVXOWLQLPSURYHG PDQDJHPHQWRIDWULDOILEULOODW LRQ,WLVSRVVLEOHWKDWVXEMHFW VZLOOH[SHULHQFHQREHQHI LWIURPSDUWLFLSDWLQJ LQWKHVWXG\ 5LVN%HQHILW5DWLRQDOH 7KHFRKRUWRIVXEMHFWVIRULQFOXVLRQLQWKHVWXG\LVV\PSWRPDWL FDVDUHVXOWRIWKHLUDWULDOILEULOODWLRQEXW KDVQRW\HWWULHG$$'WKHUDS\&U\RDEODWLRQWKHUDS\RIIHUVWKH RSSRUWXQLW\WRUHGXFHWKHHSLVRGHVRI DWULDOILEULOODWLRQZLWKRXWWKHVX EMHFWKDYLQJWRWDNH$$'VRU H[SHULHQFHWKHVLGHHI IHFWVRI$$' WKHUDS\ 7KHUHLVQRLQFUHPHQWDOULVNRUEHQHILWIRUVXEMHFWVLQWKHFRQ WURODUPLQWKHVWXG\ ,QWKH86WKHUHDUHQRDEODWLRQ FDWKHWHUVDSSURYHGWRWUHDWVX EMHFWVZLWKSDUR[\VPD ODWULDOILEULOODWLRQ ZKRKDYHQRW\HWDWWHPSWHG$$'WKHUDS\,IVXFFHVVIXOWKLVVW XG\FRXOGGHPRQVWUDWHPHDQLQJIXO WKHUDSHXWLFEHQHILWLQWKLVSDWLH QWSRSXODWLRQDQGSURYLGHSDWL HQWVZLWKDGGLWLRQDO WUHDWPHQWRSWLRQV HDUOLHULQGLVHDVHSURJUHVVLRQ "
69,page_69,
70,page_70,
71,page_71,
72,page_72,
73,page_73,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  5HSRUWLQJRI$GYHUVH(YHQWV )RUWKHSXUSRVHVRIWKLVVWXG\ WKHIROORZLQJ$GYHUVH(YHQWVZL OOEHFROOHFWHGVWDUWLQJDWWKHWLPHWKH VXEMHFWVLJQVWKH,QIRUPHG&RQVH QW)RUPWKURXJKWKHGXUDWLRQRI WKHVXEMHFW¶VSDUWLFL SDWLRQLQWKHVWXG\  x$OOSURFHGXUHUHODWHG$(V x$OOFU\RDEODWLRQV\VWHPUHODWHG$(V x$OO$$'UHODWHG$(V x$OOFDUGLRYDVFXODUUHODWHG$(V x$OO6HULRXV$GYHUVH(YHQWV 6$( V UHJDUGOHVVRIUHODWHGQHVV 5HSRUWLQJRIWKHVHHYHQWVWR0HG WURQLFZLOORFFXURQDQ$GYHUVH (YHQW $( )RUPLQFOXGLQJDGHVFULSWLRQ RI$(GDWHRIRQVHWRI$(GDWH RIDZDUHQHVVRIVLWHWUHDWPHQ WUHVROXWLRQDVVHVVPHQWRIERWKWKH VHULRXVQHVVDQGWKHUHODWHGQHVVW RWKHLQYHVWLJDWLRQDOGHYLFH  (DFK$(PXVWEHUHFRUGHGRQDVHSDUDWH$()RUP([FHSWLRQVLQFO XGH  x'RFXPHQWHGSUHH[LVWLQJFRQGLWLR QVDUHQRWFRQVLGHUHG$(VXQOHV VWKHQDWXUHRUVHYHULW\RIWKH FRQGLWLRQKDVZRUVHQHG$GGLWLRQ DOO\DUUK\WKPLDHSLVRGHVWKDW DUHQRWQHZR UZRUVHQLQJ FRQGLWLRQVDQGIRUZKLFKQRDFWLRQLVWDNHQDUHQRWUHSRUWDEOH DV$(V x8QDYRLGDEOH$GYHUVH(YHQWVOLVWHGLQVHFWLRQQHHGQRWEH UHSRUWHGXQOHVVWKHDGYHUVHHYHQW ZRUVHQVRULVSUHVHQWRXWVLGHWK HVWDWHGWLPHIUDPHSRVWSURFHGX UH x&DUGLRYHUVLRQV '&RU'UXJ IRUUHFXUUHQWV\PSWRPDWLFDWULDOIL EULOODWLRQDQGRWKHUDWULDO DUUK\WKPLDVDUHQRWFRQVLGHUHGVHULRXVDGYHUVHHYHQWV )RUDQ\FKDQJHVLQVWDWXVRIDS UHYLRXVO\UHSRUWHGDGYHUVHHYHQ W LHFKDQJHLQDFWLRQVWDNHQFKDQJHLQ RXWFRPHFKDQJHLQUHODWHGQHVV DQXSGDWHWRWKHRULJLQDO$(P XVWEHSURYLGHG $OODGYHUVHHYHQWV PXVWEHIROORZHGXQWLOWKHDGYHU VHHYHQWKDVEHHQUHVROYHGLV XQUHVROYHGZLWKQR IXUWKHUDFWLRQV SODQQHGWKHVXEMHFWH[LWVWKHVWXG\RUXQWLOVWXG\FORVXUHZK LFKHYHURFFXUVILUVW ,QWKHHYHQWWKDWDVXEMHFWLVH [LWHGIURPWKHVWXG\SULRUWRV WXG\FORVXUHDOOHIIRUWVVKRXOGEHPDGHWR FRQWLQXHIROORZLQJWKHVXEMHFWXQWLODOOXQUHVROYHGSURFHGXUHR UFU\RDEODWLRQV\VWHPUHODWHGDGYHUVH HYHQWVDVFODVVLILHGE\WKHLQYHV WLJDWRUDUHUHVROYHGRUWKH\ DUHXQUHVROYHGZLWKQRIXUWKHUDFWLRQV SODQQHG $WWKHWLPHRIVWXG\H[LWDOOD GYHUVHHYHQWVZLWKDQRXWFRPHR I³8QUHVROYHGIXUWKHUDFWLRQVRUWUHDWPHQW SODQQHG´PXVWEHUHYLHZHGDQGDQ XSGDWHWRWKHRULJLQDO$(PXVW EHUHSRUWHG$WDPLQLPXPLIWKHUH DUHQRFKDQJHVWRWKHGHVFULSWLRQUHODWHGQHVVWHVWDQGSURFHG XUHVRUDFWLRQVWDNHQWKHRXWFRPHPXVW EHXSGDWHGWRUHIOHFW³8QUHVROYHGDWWLPHRIVWXG\FORVXUH´ 6XEMHFWGHDWKVDUHDOVRUHTXLUHG WREHUHSRUWHG5HIHUWRVHFWL RQIRU6XEMHFW'HDWKFROOHFWLRQDQG UHSRUWLQJUHTXLUHPHQWV 'HYLFH'HILFLHQFLHV 'HYLFHGHILFLHQF\ '' LQIRUPDWL RQZLOOEHFROOHFWHGWKURXJKRXW WKHVWXG\DQGUHSRUWHGWR0HGWURQLF 1RWHWKDWGHYLFHGHILF LHQFLHVWKDWUHVXOWLQDQDGYHUVHGHYLFH HIIHFW $'( WRWKHVXEMHFWVKRXOGEH FDSWXUHGDVDQ$GYHUVH(YHQWRQO\"
74,page_74,
75,page_75,
76,page_76,
77,page_77,
78,page_78,
79,page_79,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 79 of 130 Version 5.0 STOP AF First Page 79 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 13.3.1.2. Death Classification and Reporting Sufficient information will be required in order to properly classify the subject’s death. The Investigator shall classify each subject death per the following definitions: • Cardiac Death : A death directly related to the electrical or mechanical dysfunction of the heart. • Sudden Cardiac Death (SCD): Natural death due to cardiac causes, indicated by abrupt loss of consciousness within one hour of the onset of acute symptoms; preexisting heart disease may have been known to b e present, but the time and mode of death are unexpected. If time of onset cannot be determined, SCD will alternativ ely be defined as any unexpected cardiac death occurring out of the hospital or in the emergency room as dead on arrival. • Non-sudden Cardiac Death: All cardiac deaths that are not classified as sudden deaths, including all cardiac deaths of hospitalized subjects on inotropic support. • Non-cardiac Death : A death not classified as a cardiac death. • Unknown Classification : Unknown death classificat ion is intended for use only when there is insufficient or inadequate info rmation to classify the death. The CEC will review deaths and provide a final adjudication of the primary cause of death and cardiac classification. Regulatory reporting of subject deaths will be completed according to local regulatory requirements."
80,page_80,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  3URGXFW&RPSODLQWV )RUGHYLFHVWKDWDUHPDUNHWUHOHDVHGSURGXFWFRPSODLQWUHSRUWL QJLVDSSOLFDEOH7KLVLQFOXGHVZKHQDQ $(LVUHODWHGWRDPDUNHWUHOHDV HGGHYLFHGXULQJWKHVWXG\7K HUHSRUWLQJRISURGXFWFRPSODLQWVLVQRW SDUWRIWKHFOLQLFDOVWXG\DQGV KRXOGEHGRQHLQDGGLWLRQWRWK H$GYHUVH(YHQWUHSRUWLQJUHTXLUHPHQWV 5HIHUWRORFDOUHJXODWLRQVIRUUHSRUWLQJUHTXLUHPHQWV 3URGXFW&RPSODLQW $Q\ZULWWHQHOHFWURQLFRURUDOFRPPXQLFDWLR QWKDWDOOHJHVGHILFLH QFLHVUHODWHGWRWKH LGHQWLW\TXDOLW\GXUDELOLW\U HOLDELOLW\VDIHW\HIIHFWLYHQH VVRUSHUIRUPDQFHRIDPHG LFDOGHYLFHWKDWKDV EHHQSODFHGRQWKHPDUNHW ,WLVWKHUHVSRQVLELOLW\RIWKHLQ YHVWLJDWRUWRUHSRUWDOOSURG XFWFRPSODLQW V DVVRF LDWHGZLWKDPHGLFDO GHYLFHGLVWULEXWHGE\0HGWURQLFUHJDUGOHVVZKHWKHUWKH\DUHUH ODWHGWRLQWHQGHGXVHPLVXVHRUDEXVHRI WKHSURGXFW5HSRUWLQJPXVWEH GRQHLPPHGLDWHO\DQGYLDWKHUH JXODUFKDQQHOVIRUPDUNHWUHOHDVHG SURGXFWV 0HGWURQLFZLOOQRWLI\W KHUHJXODWRU\DXWKRULWLHV HJ)'$ DV DSSOLFDEOHIRUWKHIROORZLQJLQFLGHQWV LPPHGLDWHO\XSRQOHDUQLQJRIWKHP  x$Q\PDOIXQFWLRQRUGHWHULRUDWLRQ LQWKHFKDUDFWHULVWLFVDQGRU SHUIRUPDQFHRIDGHYLFHDVZHOODV DQ\LQDGHTXDF\LQWKHODEHOLQJRULQVWUXFWLRQVIRUXVHZKLFKOH GRUPLJKWKDYHOHGWRWKHGHDWKRU VHULRXVGHWHULRUDWLRQLQWKHVWDWH RIKHDOWKRIDSDWLHQWXVHU RURWKHUSHUVRQ x$Q\WHFKQLFDORUPHGLFDOUHDVRQ UHVXOWLQJLQZLWKGUDZDORIDGH YLFHIURPWKHPDUNHWE\WKH PDQXIDFWXUHU x$VHULRXVGHWHULRUDWLRQLQW KHVWDWHRIKHDWKLQFOXGHV  R/LIHWKUHDWHQLQJLOOQHVVRULQMXU\ R3HUPDQHQWLPSDLUPHQWRIDERG\IXQFWLRQRUSHUPDQHQWGDPDJHWR DERG\VWUXFWXUH R$FRQGLWLRQQHFHVVLWDWLQJPHGLFDORUVXUJLFDOLQWHUYHQWLRQWRS UHYHQWSHUPDQHQW LPSDLUPHQWRIDERG\IXQFWLRQRUSHUPDQHQWGDPDJHWRDERG\VWU XFWXUH 7KHLQYHVWLJDWRUDQG0HGWURQLFPXVWDELGHE\WKHUHSRUWLQJUHTX LUHPHQWVVKRZQLQ7DEOH "
81,page_81,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 81 of 130 Version 5.0 STOP AF First Page 81 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 14. Data Review Committees At regular intervals, an independent Clinical Events Committee (CEC) will review and adjudicate all reported adverse events and deaths for subjects participating in the study. The CEC will consist of a minimum of three (3) non -Medtronic employed physicians that are not participating Investigators for the study, including a CEC chairperson. Medtronic personnel may facilitate and participate in a CEC meeting but will be non -voting members. For adverse events and deaths reviewed by the CEC, Medtronic will provide the CEC with the Investigator’s description and classification. The CEC is responsible for reviewing the Investigator’s assessment and supportive documentation (when available), reviewing applicable definitions, and determining fin al classifications for all adjudication parameters. Additionally, the CEC will provide an adjudication of the death classification for all reported deaths including primary cause of death and cardiac classification. If the CEC disagrees with the Investigator’s classification of the event, the rationale will be provided to the Investigator. If the Investigator agrees with the CEC’s adjudication, the eCRF documenting the event will be updated accordingly. If the Investigator does not agree with the CEC’s adjudication classification, both determinations will be provided within the final report; however, the CEC’s adjudication will be used for data analysis. The disagreement will also be included in reporting to IRB and regulatory authorities, if requ ired."
82,page_82,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 82 of 130 Version 5.0 STOP AF First Page 82 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 15. Statistical Design and Methods Medtronic employees will perform all statistical analyses. Additionally, a separate Statistical Analysis Plan (SAP) will be developed to further describe statistical methods, pre -specified data handling rules (includi ng how missing data will be handled ), and pre - specified analyses, including subgroup analyses, that will be included in study reports (e.g. PMA report, final study report). Any deviation from the pre -specified statistical analyses will be noted in the stu dy report. The SAP will include a comprehensive description of the statistical methods and analyses to be included in reports that include analysis of endpoints. Any change to the data analysis methods described in the CIP will require an amendment to the CIP only if it changes a principal feature of the CIP. Any other change to the data analysis methods described in the CIP, and the justification for making the change, will be described in the clinical study report. Additional exploratory analyses of th e data may be conducted as deemed appropriate. All objectives will be analyzed once all treated subjects complete the 12 month follow -up visit, or have exited the study . A final report will be completed after all subjects complete the final follow -up visit, or have exited the study . No interim analyses are planned. The primary analysis will be conducted using a modified intent -to-treat protocol; all subjects for whom either AAD or cryoballoon ablation therapy is initiated will be analyzed according to their randomization status. Subjects who withdraw consent between randomization and initiation of therapy will be excluded from the primary efficacy analysis."
83,page_83,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  3ULPDU\(IILFDF\2EMHFWLYH 'HPRQVWUDWHWKHVXSHULRULW\RIFU\REDOORRQDEODWLRQDVFRPSDUHG WR$$'WKHUDS\LQWHUPVRIWKHUDWHRI IUHHGRPIURP$)$7$)/LQDQRQG UXJUHIUDFWRU\SDUR[\VPDO$)S RSXODWLRQ +\SRWKHVLV 7KHK\SRWKHVLVWHVWXVHGLQDVVHVVP HQWRIWKHSULPDU\HIILFDF\ REMHFWLYHLVWKDWWKHSURSRUWLRQRIVXEMHFWV ZLWKWUHDWPHQWVXFFHVVDWP RQWKVLVJUHDWHULQVXEMHFWVUDQG RPL]HGWRFU\REDOORRQDEODWLRQFRPSDUHG WRVXEMHFWVUDQGRPL] HGWR$$'WKHUDS\ 7KHIROORZLQJK\SRWKHVLVZLOOEHWHVWHGLQDWZRVLGHGWHVWZLW KĮ   + ȺFU\R Ⱥ$$' +D ȺFU\RȺ$$' :KHUHȺ FU\RDQGȺ$$'DUHWKHSURSRUWLRQRIWUHDWPHQWVXFFHVVHVDWPRQWKVLQWKHP RGLILHGLQWHQWLRQWR WUHDWFRKRUWVRIWKHFU\REDOORRQDEODWLRQDQG$$'JURXSVUHVSH FWLYHO\ (QGSRLQW'HILQLWLRQ $WUHDWPHQWVXFFHVVLVWKHRSSR VLWHRIDWUHDWPHQWIDLOXUH $VXEMHFWLVFRQVLGHUHGDWUHDWPH QWIDLOXUHLIKHVKHH[SHULHQF HVDQ\RIWKHIROORZLQJ   x$FXWHSURFHGXUDOIDLOXUH GHILQH GLQVHFWLRQ WUHDWPHQW DUPRQO\  x'RFXPHQWHG$)$7$)/RQDPEXODWR U\PRQLWRULQJOHDG(&*DIWHU WKH GD\SRVWDEODWLRQ EODQNLQJSHULRG WUHDWPHQWDUP  $$'RSWLPL]DWLRQSHULRG FRQWUR ODUP  R0LQLPXPRIVHFRQGVRQDPEXODWR U\PRQLWRULQJRUVHFRQGVRQ OHDG(&* R1RWH 'RFXPHQWHGRFFXUUHQFHDQGWUHDWPHQWRIW\SLFDOULJKWVLGH GFDYRWULFXVSLGLVWKPXV GHSHQGHQWDWULDOIOXWWHULVQRWFR QVLGHUHGDIDLOXUHLIFRQILUP HGE\HQWUDLQPHQW PDQHXYHUVGXULQJ(3WHVWLQJ x$Q\VXEVHTXHQW$)VXUJHU\RUDE ODWLRQLQWKHOHIWDWULXP x$Q\VXEVHTXHQWFDUGLRYHUVLRQDIWHUWKH GD\SRVWDEODWLRQEOD QNLQJSHULRG WUHDWPHQW DUP $$'RSWLPL]DWLRQSHULRG FRQWURODUP  x&ODVV,RU,,,DQWLDUUK\WKPLFGUXJ  RUVRWDORO XVHDIWHUWKH GD\EODQNLQJSHULRG WUHDWPHQWDUP RQO\  7KH$$'RSWLPL]DWLRQSHULRGLVGHILQHGDVWKHILUVW GD\VDIW HU$$'LQLWLDWLRQ FRQWURODUP 7KH EODQNLQJSHULRGLVGHILQHGDVWKH ILUVW GD\VDIWHUWKHLQGH[ DEODWLRQSURFHGXUH WUHDWPHQWDUP  5HFXUUHQFHVRIDWULDODUUK\WKPLD VGXULQJWKH$$'RSWLPL]DWLRQE ODQNLQJSHULRGVZLOOQRWEHFRXQWHGLQWKH GHWHUPLQDWLRQRIWKHI LUVWFOLQLFDOIDLOXUHIRUWKHSULPDU\HQG SRLQW:LWKLQWKH GD\$$'RSWLPL]DWLRQ SHULRGDQG GD\SRVW DEODWLRQEODQNLQJSHULRGUHFXUUHQWDUUK \WKPLDVFDQEHPDQDJ HGZLWKPHGLFDWLRQV RUFDUGLRYHUVLRQV 3HUIRUPDQFH5HTXLUHPHQWV ,IDWZRVLGHGORJUDQNWHVWVKRZVWKHGLIIHUHQFHLQPRQWKV XFFHVVUDWHVWREHO HVVWKDQWKHSUH VSHFLILHGDOSKDRIWKHQX OOK\SRWKHVLV WKDWFU\REDOORRQ DEODWLRQKDVVLPLODUPRQWKHIILFDF\UDWHV FRPSDUHGWR$$'WKHUDS\ ZLOOEH UHMHFWHGLQIDYR URIWKHDOWHU QDWLYHK\SRWKHVLV WKDWPRQWKVXFFHVV"
84,page_84,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO UDWHVIRUVXEMHFWVWUHDWHGZLWK FU\REDOORRQDEODWLRQLVJUHDWHU WKDQIRUWKRVHWUHDWHGZLWK$$'¶V  GHPRQVWUDWLQJWKHVXSHULRULW\RIWKHFU\REDOORRQDEODWLRQSURFH GXUHIRUWKLVHQGSRLQW 5DWLRQDOHIRUSHUIRUPDQFHFULWHULD 7KHSHUIRUPDQFHUHTXLUHPHQWIRUWKLVREMHFWLYHLQYROYHVVKRZLQJ VXSHULRUWUHDWPHQWHIILFDF\UDWHV WKURXJKPRQWKVLQDUDQGRPL]H GVWXG\DJDLQVWWKHFXUUHQWVWD QGDUGRIFDUHLQDSRSXODWLRQRI SDUR[\VPDO$)SDWLHQWV7KHUDQG RPL]HGQDWXUHRIWKHVWXG\ZLOO SURYLGHWKHKLJKHVW OHYHORIHYLGHQFH WKDWLQWKHHYHQWD VWDWLVWLFDOO\VLJQLILFDQWUHVXOWLVDWWDLQ HGWKDWWKHWUHDWPHQWLVL QGHHGUHVSRQVLEOHIRU WKHGLIIHUHQFHLQPRQWKVXFFHVV $QDO\VLV0HWKRGV 7KHSUREDELOLW\RIDVXEMHFWDFKLHYLQJVXFFHVVDWPRQWKV  GD\V ZLOOEHHVWLPDWHGXVLQJ.DSODQ 0HLHUVXUYLYDODQDO\VLV7KH VWDQGDUGHUURUZLOOEHDSSUR[LPDW HGXVLQJ*UHHQZRRG VI RUPXOD$WZRVLGHG ORJORJFRQILGHQFHLQWHUYDOI RUWKHSUREDELOLW\ZLOOEHFRQ VWUXFWHG$WZRVLGHGOR JUDQNWHVWZLWKĮ  ZLOOEHXVHGWRDVVHVVZKHWKH UWKHIDLOXUHUDWHGLIIHUVEH WZHHQWUHDWPHQWJURXSV 'D\LVGHILQHGDVHLWKHUWKHG D\RIWKHLQGH[FU\RDEODWLRQSU RFHGXUHRUWKHGD\LQZKLFK$$'GUXJ WKHUDS\LVLQLWLDWHG )RUVXEMHFWVZLWKWU HDWPHQWIDLOXUHWKH VXUYLYDOGDWHZLOOEHVHWWRWKHGDWHRIWKH WUHDWPHQWIDLOXUH)RUVXEMHFWVZLWKRXWWUHDWPHQWIDLOXUHWKUR XJKPRQWKVWKRVHVXEMHFWVZLOOEH FHQVRUHGDWWKHODVWVWXG\FRQWDFWGDWHUHFRUGHGRQD&5)ZKLF KPD\LQFOXGHWKHODVWVWXG\YLVLWWKHH[LW GDWHRUGHDWKGDWH,IDVXEMH FWZLWKRXWDWUH DWPHQWIDLOXUH LVORVWWRIROORZXSWKHFHQVRULQJGDWHZLOO EHVHWWRWKHODVWUHFRUGHGVWXG \YLVLWGDWH,IWUHDWPHQWIDL OXUHRFFXUVRQWKHGD\RILQGH[WUHDWPHQW VXUYLYDOWLPHZLOOEHVHWWRGD\V ,IDQRFFXUUHQFHRIGRFXPHQWHG$)$7$)/UHVXOWHGIURPUK\WKPP RQLWRULQJWKDWZDVLQ LWLDWHGDWWKH PRQWKYLVLWWKHQWKHGDWHRIRFFX UUHQFHXVHGLQWKH.DSODQ0HL HUDQDO\VLVZLOOEHWKH PLQLPXPRI GD\VIURPWKHFU\REDOORRQDEODWLR QSURFHGXUHGDWHRI$$'LQLWLD WLRQRUWKHDFWXDOGDWHRIRFFXUUHQFH 7KLVDOORZVFRXQWLQJRIDOO$)$7$)/HYHQWVIRXQGDWWKHP RQWKIROORZXSHYHQLIWKHIROORZXS RFFXUUHGDIWHUGD\VSRVWDEODWLRQ 7KHVXUYLYDOFXUYHVIURPWR PRQWKVZLOOEHSUHVHQWHGIRUE RWKWUHDWPHQWDUPV "
85,page_85,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  6DPSOH6L]H 6DPSOHVL]HDVVXPSWLRQVDUH  x7ZRVLGHGFKLVTXDUHGWHVW x$OSKD  x$$'PRQWKVXFFHVVUDWH  x&U\REDOORRQDEODWLRQJURXSP RQWKVXFFHVVUDWH    x3RZHU!  x$WWULWLRQIURPHQUROOPHQWWR\HDU  7KHDERYHDVVXPSWLRQVUHTXLUH VXEMHFWVSHUDUPZLWKGDWDRU WRWDOVXEMHFWV$GGLQJLQ DWWULWLRQEULQJVWKHRYHUDOOHQU ROOPHQWVDPSOHVL]HWR IRU WKLVREMHFWLYH1RWHWKDWDORJUDQNWHVWZLOO EHXVHGIRUWKHSULPDU\HIILFDF\ DQDO\VLVEXWW KHPRUHFRQVHUY DWLYHFKLVTXDUHGWHVWZDVXVHGIRU VDPSOHVL]HHVWLPDWLRQ 'HWHUPLQDWLRQRI3DWLHQWV'DWDIRU$QDO\VLV $PRGLILHGLQWHQWLRQWRWUHDWS URWRFROZLOOEHXWLOL]HGIRUWKH SULPDU\HIILFDF\DQDO\VLV DOOVXEMHFWVIRU ZKRPHLWKHU$$'RUFU\REDOORRQD EODWLRQWKHUDS\LVLQLWLDWHGZL OOEHDQDO\]HGDFFRUGLQJWRWKHLU UDQGRPL]DWLRQVWDWXV6XEMHFWVZKRZLWKGUDZFRQVHQWEHWZHHQUDQ GRPL]DWLRQDQGLQLWLDWLRQRIWKHUDS\ ZLOOEHH[FOXGHGIURPWKHSULPDU\HIILFDF\DQDO\VLV "
86,page_86,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  3ULPDU\6DIHW\2EMHFWLYH 'HPRQVWUDWHDQDFFHSWDEOHVDIHW\ SURILOHRIWKHFU\REDOORRQDEO DWLRQSURFHGXUHDVDILU VWOLQHWKHUDS\LQD QRQGUXJUHIUDFWRU\SDUR[\VPDO$)SRSXODWLRQ +\SRWKHVLV 7KHIROORZLQJK\SRWKHVLVZLOOEH WHVWHGLQDRQHVLGHGWHVWZLW KĮ   + 3V +D 3V  ZKHUH3 VLVWKHSUREDELOLW\RIDVDIHW\HYH QWLQVXEMHFWV IURPWKHFU\RE DOORRQDUP (QGSRLQW'HILQLWLRQ $SULPDU\VDIHW\HYHQWLVGHILQHG DVDVHULRXVSURFHGXUHUHODWH GRUFU\RDEODWLRQV\VWHPUHODWHGDGYHUVH HYHQWWKDWLQFOXGHVDQ\RIWKHIROORZLQJ  x7,$ZLWKLQGD\V x&HUHEURYDVFXODUDFFLGHQWZLWKLQGD\V x0DMRUEOHHGLQJWKDWUHTXLUHVWUDQVIXVLRQRUUHVXOWVLQDRU JUHDWHUIDOOLQKHPDWRFULW +&7  ZLWKLQGD\V x'HYHORSPHQWRIDVLJQLILFDQWSHULF DUGLDOHIIXVLRQZLWKLQGD\ V$VLJQLILFDQWSHULFDUGLDO HIIXVLRQLVRQHWKDWUHVXOWVLQKHPRG\QDPLFFRPSURPLVHUHTXLUH VHOHFWLYHRUXUJHQW SHULFDUGLRFHQWHVLVRUUHVXOWVLQ DFPRUPRUHSHULFDUGLDOHI IXVLRQDVGRFXPHQWHGE\ HFKRFDUGLRJUDSK\ x6\PSWRPDWLF39VWHQRVLVZLWKLQPRQWKV DFFRPSDQLHGE\RQHRI WKHIROORZLQJ  UHGXFWLRQLQGLDPHWHURIWKHSXO PRQDU\YHLQZLWKV\PSWRPVQRW H[SODLQHGE\RWKHUFRQGLWLRQV  25!UHGXFWLRQLQGLDPHWHURIWKHSXOPRQDU\YHLQ x0,ZLWKLQGD\V x31,XQUHVROYHGDWPRQWKV x$(ILVWXODZLWKLQPRQWKV x0DMRUYDVFXODUFRPSOLFDWLRQWKDWUHTXLUHVLQWHUYHQWLRQSURORQJ VWKHKRVSLWDOVWD\RUUHTXLUHV KRVSLWDODGPLVVLRQ ZLWKLQGD\V  3HUIRUPDQFHUHTXLUHPHQWV ,IWKHXSSHUERXQGRIWKHWZRVL GHG FRQILGHQFHLQWHUYDORI WKHVDIHW\HYHQWUDWHLQFU\REDOORRQDUP VXEMHFWVLV WKLVREMHFWLYHZLOOEHFRQVLGHUHGPHW 5DWLRQDOHIRU3HUIRUPDQFH&ULWHULD 7KHVDIHW\HQGSRLQWGHILQLWLRQDQGSHUIRUPDQFHJRDO 3* RI IRUVDIHW\HYHQWVZHUHEDVHGRQ SUHYLRXVDQGFXUUHQW0HGWURQLF FU\REDOORRQDEODWLRQFDWKHWHUVW XGLHVDVZHOODVEDVHG RQIHHGEDFNIURP )'$VWDII $SULPDU\VDIHW\HYHQW UDWHRIZDVREVHUYHGLQWKH6723$) WULDO7KH$QQXDO5HSRUWIRUWKH 6723$)3$6VWXG\UHSRUWVDPRQWKVDIHW\HYHQWUDWHRI )RUWKLVVWXG\WKHVDIHW\HYHQW GHILQLWLRQKDVEHHQH[SDQGHGDFFR UGLQJWR)'$JXLGDQFHDQGFHU WDLQHYHQWV HJ V\PSWRPDWLF39"
87,page_87,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO VWHQRVLVIURP±FDUGLDFSHUIRUDWLRQWDPSRQDGHIURP± GD\VDIWHUWKHSURFHGXUH QRW LQFOXGHGLQWKHWZRSUHYLRXVVW XGLHVZLOOEHLQFOXGHG%DVHGRQ WKH6723$)WULDODQG6723$)3$6 DGYHUVHHYHQWGDWDDQGWKHH[SDQGHGVDIHW\HYHQWGHILQLWLRQLW LVHVWLPDWHGWKDWW KHFXUUHQWVWXG\ZLOO KDYHDVDIHW\UDWHRI 7KH6723$)SLYRWDOVWXG\DQG6723$)3RVW$SSURYDO6WXG\ 6723 $)3$6 ERWKVHW3*UHTXLUHPHQWVRI :LWKDQHVWLPDWHGVDIHW\UDWHD3*RISURYLGHV VWULFWHUFULWHULDWKDQXVHGLQSULRU FU\REDOORRQVWXGLHVLQRUGHUWR DFFRXQWIRUGLIIHUHQFHVLQWKH VWXG\SRSXODWLRQV $GGLWLRQDOO\WKH6723$)3LYRWDOWULDOUHSRUWHGWKDWRIV XEMHFW¶VH[SHULHQFHGD0DMRU$WULDO )LEULOODWLRQ(YHQWV 0$)(V LQWKH $$'DUP 3DFNHUHWDO $ODUJHV\VWHPDWLFU HYLHZDOVRUHSRUWHG WKDWZLWKGUDZDOVIURP$$'VGXHWR DGYHUVHHYHQWVDYHUDJHG IRU&ODVV,$$'VDQGIRU&ODVV ,,,$$'¶V /DIXHQWH/DIXHQWH9DOHPERLVHWDO 7KHUHIRU HWKHSHUIRUPDQFHFULWHULDHVWDEOLVKHGLQ WKLVVWXG\LVDSSURSULDWHIRUGHPRQV WUDWLQJDQDFFHSWDEOHULVN EHQHILWLQWKLVGUXJQDwYH3$)SRSXODWLRQ $QDO\VLV0HWKRGV 7KHSUREDELOLW\RIDVDIHW\HYHQW ZLWKLQPRQWKVZLOOEHHVWL PDWHGXVLQJ.DSODQ0HLHUVXUYLYDODQDO\VLV *UHHQZRRG¶VIRUPXODZLOOEHXVHGW RDSSUR[LPDWHWKHVWDQGDUGHU URURIWKHVXUYLYDOFXUYHDQGDWZR VLGHGORJORJFRQILGHQFHLQWHUYDODWPRQWKVZLOOEHUHSRUWHG  'D\LVGHILQHGDVWKHGD\RIWKHLQGH[FU\RDEODWLRQSURFHGXUH )RUVXEMHFWVZLWKDVDIHW\HYHQWWKH VXUYLYDOGDWHZLOOEHV HWWRWKHGDWHRIWKHVDIHW\HYHQW)RU VXEMHFWVZLWKRXWDVDIHW\HYHQWFHQVRULQJ ZLOORFFXUDWWKHODVW VWXG\FRQWDFWGDWHZ LWKDFRUUHVSRQGLQJ &5) LHWKHODVWVWXG \YLVLWH[LWGDWHRU GHDWK ,IDVXEMHFWZLWKRXWD VDIHW\HYHQWLVOR VWWRIROORZX SWKH\ZLOOEHFHQVRUHGRQWKHGDWHRIWKH ODVWVWXG\YLVLW $Q\VXEVHTXHQWDEODWLRQVDVXEMHFWPD\KDYHDIWHUGD\ZLOOQR WUHVHWWKHLUVXUYLYDOW LPH WKHGDWHRIWKH LQGH[SURFHGXUHZLOOUHPDLQDVG D\IRUSXUSRVHVRIWKHSULPDU \VDIHW\DQDO\VLV6DIHW\HYHQWVUHODWHGWR UHSHDWDEODWLRQSURFHGXUHVRFFXU ULQJXSWRGD\VDIWHUWKHL QGH[FU\RDEODWLRQGDWHZLOOEHFRQVLGHUHG DVKDYLQJPHWFULWHULDIRUWKHS ULPDU\VDIHW\HQGSRLQWDQGZLO OEHFRXQWHGDVIDLOXUHVIRUWKLVDQDO\VLV 6DPSOH6L]H 6DPSOHVL]HDVVXPSWLRQVDUH  x2QHVDPSOHRQHVLGHGH[DFWELQRPLDOWHVW x$OSKD  x&U\REDOORRQDEODWLRQPRQWKVDIHW\UDWH  x3*  x$WWULWLRQIURPHQUROOPHQWWR\HDU  8QGHUWKHVHFRQGLWLRQVHQUR OOHGVXEMHFWVDUHUHTXLUHGDW UDQGRPL]DWLRQDQGDWWULWLRQLQ RUGHUWRH[SHFW UDQGRPL]HGDQ GDQDO\]DEOHVXEMHFWVDWPRQ WKIROORZXSLQWKHFU\REDOORRQDEODWLRQ DUPZKLFKDIIRUGVSRZHUIRU DRQHVLGHGELQRPLDOWHVWZLWK Į   "
88,page_88,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  'HWHUPLQDWLRQRI3DWLHQWV'DWDIRU$QDO\VLV $OOVXEMHFWVUDQGRPL]HGWRWKHFU\ RDEODWLRQDUPDQGKDYHWKH$U FWLF)URQW$GYDQFH&DUGLDF&U\R$EODWLRQ &DWKHWHULQVHUWHGLQ WRYDVFXODWXUHZLOOEHLQFOXGHG 6XEMHFWVUDQGRPL]HGWRWKH$$'D UPZKRUHFHLYHDFU\RDEODWLRQS URFHGXUHGXULQJIROORZXSZLOOQRWEH LQFOXGHGLQWKHSULPDU\VDIHW\D QDO\VLV KRZHYHUVDIHW\HYHQWV RFFXUULQJLQWKHVHVXEMHFWVZLOOEH UHSRUWHGLQWRWKHVWXG\GD WDEDVHDQGVXPPDUL]HG "
89,page_89,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH  RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  6HFRQGDU\2EMHFWLYHV 7ZRVHFRQGDU\REMHFWLYHV ZLOOEHHYDOXDWHGWRJDLQDGGLWLRQDOLQIRUPDWLRQDERXWWKHSHUI RUPDQFH RIWKH$UFWLF)URQW$GYDQFH&DUGLDF&U\R$EODWLRQFDWKHWHU ZLWKIRXUK\SRWKHV HVWREHWHVWHG  6HFRQGDU\2EMHFWLYH  $VVHVVFKDQJHVLQTXDOLW\RIOLIH EHWZHHQEDVHOLQH DQGPRQWK VLQWKHFU\REDOORRQDEODWLRQDUP7KHUH DUHWZRK\SRWKHVHVWHVWHGLQWKH REMHFWLYHZLWKVHSDUDWHK\SRW KHVLVWHVWVIRU  WKHGLIIHUHQFHLQ FRPSRVLWHVFRUHVIURPWKH$)(47 TXHVWLRQQDLUHWDNHQDWEDVHOLQH DQGPRQWKYLVLWV DQG  IRUWKH GLIIHUHQFHLQFRPSRVLWHVFRUHVIRU WKH(4'TXHVWLRQQDLUHWDNH QDWEDVHOLQHDQGPRQWKYLVLWV  6HFRQGDU\2EMHFWLYH  &RPSDUHKHDOWKFDUHXWLOL]DWLRQEHWZHHQWKHWUHDWPHQWDQGFRQWU RODUPV7KHUHDUH WZRK\SRWKHVHV WHVWHGLQWKHREMHFWLYHZLWKVH SDUDWHK\SRWKHVLVWHVWVIRU   WKHUDWHRIWRWDOKHDOWKFDUHXWLOL]DWLRQ HYHQWV FDUGLRYDVFXODUUHODWHGKRVSLWDOL]DWLRQVHPHUJHQF\URRP YLVLWVRUXQVFKHGXOH GRIILFHYLVLWV RYHU PRQWKVDQG  WKHUDWHRIF DUGLRYHUVLRQV HOHFWULFDORUSK DUPDFRORJLFDO RYHUPRQWKV 7HVWLQJIRUWKHVHREMHFWLYHVZLOOEHSHUIRUPHGLIWKHSULPDU\R EMHFWLYHVDUHPHW$+RFKEHUJPXOWLSOH WHVWLQJSURFHGXUHZLOOEHXWLOL]HG WRPDLQWDLQDQRYHUDOOW\SH ,HUURUUDWHRIIRUWKHIRXUK\SRWKHVHV EHLQJWHVWHGDPRQJWKHWZR VHFRQGDU\REMHFWLYHV 7KH+RFKEHUJSURFHGXUHLVDVWHS ZLVHSURFHGXUHDQGZLOOEHLPSO HPHQWHGDVIROORZV  7KHIRXUK\SRWKHVHVZ LOOEHGHILQHGDV+  +  +  DQG+  )RUHDFKRIWKHK\SRWKHVHVSYDOXHV ZLOOEHFDOFXODWHGDQGVRUWHGS   S   S   S  7KHGH FLVLRQUXOHWRDFFH SWRUUHMHFWHDFK K\SRWKHVLVZLOOIROORZWKHVWHSX SDOJRULWKPZKHUHĮ   6WHS ,IS  ĮDFFHSW+  DQGJRWR6WHSRWKHUZLVHUH MHFWDOOK\SRWKH VHVDQGVWRS 6WHS ,IS  ĮDFFHSW+  DQGJRWR6WHSRWKHUZLVH UHMHFW+  +  DQG+  DQGVWRS 6WHS LIS  DDFFHSW+  DQGJRWR6WHSRWKHUZLVH UHMHFW+  DQG+  DQGVWRS 6WHS ,IS   DUHMHFW +  RWKHUZLVHDFFHSW+   $WULDO)LEULOODWLRQ(IIHFWRQ4XDOLW\RI/LIH $)(47   +\SRWKHVLV 7KHIROORZLQJK\SRWKHVLVZLOOEH WHVWHGLQDWZRVLGHGWHVW   +R $)(47 PRQWK $)(47 EDVHOLQH +D $)(47 PRQWK$)(47 EDVHOLQH :KHUH$)(47 EDVHOLQHLVWKHVFRUHIURPWKH$ )(47DVVHVVHGDWWKHEDVHOLQHYLVLWDQ G$)(47 PRQWKLVWKH FRPSRVLWHVFRUHIURPWKH$)(47D VVHVVPHQWIURPWKH PRQWKIRO ORZXS"
90,page_90,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 90 of 130 Version 5.0 STOP AF First Page 90 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 15.3.1.2. Endpoint Definition The AFEQT questionnaire will be utilized for this objective. The questionnaire is an atrial fibrillation specific health-related quality of life questionnaire to assess the impact of AF on a subject’ s life. The overall score ranges from 0 – 100, with 0 correspond ing to complete disability and 100 corresponding to no disability. The absolute difference between each subject’s baseline and 12 month scores is the endpoint of interest. 15.3.1.3. Analysis Methods The difference in mean AFEQT scores will be assessed utilizing a paired t- test. 15.3.1.4. Performance Criteria If the p-value from the two-sample t -test procedure is less than the alpha level determined by the Hochberg procedure described above , the objective will be considered met. 15.3.1.5. Rationale for Performance Criteria If this analysis shows that scores from the AFEQT , a validated instrument for measuring quality of life in subjects with atrial fibrillation (Spertus, et al. 2011), are significantly higher 12 months after the procedure compared to before the procedure, i t will show a documented association between the cryoballoon ablation procedure and QoL improvement in a non -drug refractory paroxysmal AF population. . While this hypothesis test will not be between randomized groups, in the context of a secondary objective that will only be tested if efficacy has been established, such results would provide evidence of a QoL improvement in cryoballoon ablation -treated patients. 15.3.1.6. Determination of Subjects/Data for Analysis All subjects randomized to the cryoballoon ablation group who have completed both baseline and 12 - month questionnaires will be included and analyzed . Comparison to the AAD arm is not planned as it is expected that a large percentage of AAD arm subjects will have a cryoballoon procedure during the 12 months of follow -up. Having a cryoballoon procedure prior to 12 months will bias the AAD arm’s 12 -month QOL results . 15.3.1.7. Additional analyses The AFEQT questionnaire h as three subscale scores, Daily Activities Subscale, Treatment Concern, and Treatment satisfaction. Each subscale ranges from 0 – 100, where 0 corresponds to low quality -of-life and 100 corresponds to high quality of life. Change in AFEQT subscale score is defined as 12 -month AFEQT subscale score minus baseline AFEQT subscale score. A two -sided 95% confidence interval will be calculated based on the t -distribution."
91,page_91,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO   (4'4XHVWLRQQDLUH  +\SRWKHVLV  7KHIROORZLQJK\SRWKHVLVZLOOEH WHVWHGLQDWZRVLGHGWHVW   +R (4' PRQWK (4' $$' +D (4' PRQWK(4' $$' :KHUH(4' PRQWKLVWKHPHDQFRPSRVLWH(4'VFRUH IURPVXEMHFWVDVVHVVHGDWWKH PRQWKYLVLWDQG (4'EDVHOLQHLVWKHPHDQFRPSRVLWH(4 'VFRUHIRUDWEDVHOLQH   (QGSRLQW'HILQLWLRQ 7KH(XURTRO(4'TXHVWLRQQDLUH ZKLFKFRQVLVWVRIDTXHVWLRQ VXUYH\DQGDYLVXDODQDORJVFDOH LQGLFDWLQJWKHVXEMHFW¶VRYHUD OOKHDOWK ZLOOEHXWLOL]HGIRUW KLVREMHFWLYH&RPSRVLW HVFRUHVZLOOEHLQGH[HG DJDLQVWD86UHIHUHQFHSRSXODWLRQ 6KDZ-RKQVRQDQG&RRQV    $QDO\VLV0HWKRGV  &KDQJHLQ(4'FRPSRVLWHVFRU HLVGHILQHGDVPRQWK(4'VF RUHPLQXVEDVHOLQH(4'VFRUH 'LIIHUHQFHVLQPHDQ(4'VF RUHVEHWZHHQYLVLWVZLOOEHDVVHVVH GXWLOL]LQJDSDLUHGWWHVW$WZRVLGHG FRQILGHQFHLQWHUYDOZLOOEHF DOFXODWHGEDVHGRQWKHWGLVWU LEXWLRQ  3HUIRUPDQFHFULWHULD  ,IWKHSYDOXHIURPWKHSDLUHGW WHVWLVOHVVWKDQWKHDOSKDOH YHOGHWHUPLQHGE\WKH+RFKEHUJSURFHGXUH GHVFULEHGDERYHWKHREMHF WLYHZLOOEHFRQVLGHUHGPHW  5DWLRQDOHIRU3HUIRUPDQFH&ULWHULD  ,IWKLVDQDO\VLVVKRZVWKDW(4' VFRUHVDUHVLJQLILFDQWO\KLJK HUDIWHUPRQWKVIROORZXSFRPSDUHGWR EDVHOLQHLQFU\REDOORRQWUHDWHG VXEMHFWVLWZLOOSURYLGHHYLGH QFHRIDQDVVRFLDWLRQEHWZHHQFU\REDOORRQ DEODWLRQDQGDJHQHUDO4R/LQFUH DVH DVPHDVXUHGE\DYDOLGDWHG LQVWUXPHQW WKDWPD\RUPD\QRWEH FDXVDO:KLOHWKLVK\SRWKHVLVW HVWZLOOQRWEHEHWZHHQUDQGRPL] HGJURXSVLQWKHFRQWH[WRIDVHFRQGDU\ REMHFWLYHWKDWZLOORQO\EHWHVWH GLIHIILFDF\KDVEHHQHVWDEOL VKHGWKHHYLGHQFHSURYLGHGLVVWURQJHUWKDQ LILWZHUHMXVWSHUIRUPHGLQDQ LVRODWHGSUHSRVWFRPSDULVRQ  'HWHUPLQDWLRQRI6XEMHFWV'DWDIRU$QDO\VLV $OOFU\REDOORRQDEODWLRQDUPVXEM HFWVZKRKDYHFRPSOHWHGERWKE DVHOLQHDQGPRQWKTXHVWLRQQDLUHV ZLOOEHLQFOXGHGD QGDQDO\]HG  &RPSDULVRQWRWKH$$'DUPLVQRW SODQQHGDVLWLV H[SHFWHGWKDW DODUJHSHUFHQWDJH RI$$'DUPVXEMHFWV ZLOOKDYHDFU\REDOORRQSURFHGXUHGXULQJWKHPRQWKVRIIROOR ZXS+DYLQJDFU\REDOORRQSURFHGXUH SULRUWRPRQWKVZLOOELDVWKH$$'DUP¶VPRQWK4R/UHVXOWV "
92,page_92,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  &DUGLRYDVFXODUKRVSLWDOL]DWLRQV('DQGXQVFKHGXOHGRIILFHYLVL WV  +\SRWKHVLV 7KHIROORZLQJK\SRWKHVLVZLOOEHWHVWHG +  ǇFU\R Ǉ$$' +D ǇFU\RǇ$$' ZKHUHǇ FU\RDQGǇ$$'DUHWKHPRQWKUDWHVRIFDUGLRYDVFXODU+&8HYHQWVLQWKHFU\R EDOORRQDEODWLRQDQG $$'DUPVUHVSHFWLYHO\  (QGSRLQW'HILQLWLRQ +HDOWKFDUHXWLOL]DWLRQ +&8 HYHQ WVIRUWKLVREMHFWLYHDUHGHIL QHGDVFDUGLRYDVFXODUUHODWHG KRVSLWDOL]DWLRQVFDUGLRYDVFXODU UHODWHGHPHUJHQF\GHSDUWPHQWY LVLWVRUFDUGLRYDVFXODUUHODWHG XQVFKHGXOHGRIILFHYLVLWVRFFXUUL QJZLWKLQPRQW KVDIWHUWKHLQGH[DEODWLRQ FU\RD UP RUWKHLQLWLDWLRQ RIWKHUDS\ $$'DUP (YHQWVRFFXUULQJ!GD\VDIWHULQLWLDW LRQRIWUHDWPHQWEXWEHIRUHWKHPRQWK YLVLWZLOOEHLQFOXGHG  $QDO\VLV0HWKRGV 7KHSUREDELOLW\RIDVXEMHFWDFKL HYLQJIUHHGRPIURP+&8HYHQWV GHILQHGDERYH DW PRQWKVZLOOEH HVWLPDWHGXVLQJ.DSODQ 0HLHUVXUYLYDODQDO\VLV7KHVWDQGDUGH UURUZLOOEHDSSUR[LPDWHGXVLQJ *UHHQZRRG VIRUPXOD$WZRVLGHG ORJORJFRQILGHQFHLQWHUYD OIRUWKHSUREDELOLW\DWPRQWKVZLOO EHFRQVWUXFWHG$WZRVLGHGORJ UDQNWHVWZLOOEHXVHGWRDVVHV VZKHWKHUWKH+&8H YHQWUDWHGLIIHUV EHWZHHQWUHDWPHQWJURXSV 'D\LVGHILQHGDVGD\RIWKHLQGH[FU\RDEODWLRQSURFHGXUHRU WKHGD\LQZKLFKGUXJWKHUDS\LVLQLWLDWHG )RUVXEMHFWVZLWKWUHDWPHQWID LOXUHWKHVXUYLYDOGDWHZLOOEH VHWWRWKHGDWHRIWKH ILUVW+&8HYHQW)RU VXEMHFWVZLWKRXWDQ\+&8HYHQWVWKURXJKPRQWKVWKRVHVXEMH FWVZLOOEHFHQVRUHGDWWKHODVWVWXG\ FRQWDFWGDWHUHFRUGHGRQD&5)Z KLFKPD\LQFOXGHWKHODVWVWXG\ YLVLWWKHH[LWGDWHRUWKHGDWHRIGHDWK ,IDVXEMHFWZLW KRXWDQ\+&8HYHQWVLVOR VWWRIROORZXSWKHF HQVRULQJGDWHZLOOEHVHWWRWKHODVWNQRZQ VWXG\YLVLWGDWH)RU+&8HYHQWV RFFXUULQJRQWKHGD\RILQGH[ WUHDWPHQWVXUYLYDOW LPHZLOOEHVHWWR GD\V 7KHVXUYLYDOFXUYHIURPWRPRQWKVZLOOEHSUHVHQWHGIRUER WKWUHDWPHQWDUPV+&8HYHQWVZLOODOVR EHVXPPDUL]HGE\W\SHDQGWUHDWPHQWJURXS  3HUIRUPDQFH5HTXLUHPHQWV ,IWKHSYDOXHIURPWZRVLGHGORJ UDQNWHVWLVOHVVWKDQWKHDO SKDOHYHOGHWHUPLQHG E\WKH+RFKEHUJ SURFHGXUHGHVFULEHGDERYHWKHR EMHFWLYHZLOOEHFRQVLGHUHGPHW   5DWLRQDOHIRU3HUIRUPDQFH5HTXLUHPHQWV ,IWKHWHVWVSHFLILHGDERYHLQ GLFDWHVDVWDWLVWLFDOO\VLJQLILFD QWLQFUHDVHLQWKHWLPHWR WKHILUVW+&8HYHQW EHWZHHQFU\REDOORRQD EODWLRQDQG$$'WUHD WHGVXEMHFWVWKLVLV VXIILFLHQWHYLGHQF HWRVD\WKDWWKH WUHDWPHQWKDVDORZHUUDWHRIKHDOWKFDUHXWLOL]DWLRQZLWKLQD\ HDURIWUHDWPHQWLQLWLDWLRQGXHWRWKH UDQGRPL]HGDQGLQWHQWLRQWRWUHDWQDWXUHRIWKHFRPSDULVRQ"
93,page_93,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  'HWHUPLQDWLRQRI6XEMHFWV'DWDIRU$QDO\VLV 7KHPRGLILHGLQWHQWWRWUHDWF RKRUWZLOOEHXWLOL]HG$OOVXEM HFWVZKRLQLWLDWHHLWKHU$$'WKHUDS\RU FU\REDOORRQDEODWLRQZLOOEHDQDO\ ]HGDFFRUGLQJWRWKHJURXSWR ZKLFKWKH\ZHUHUDQGRPL]HG &DUGLRYHUVLRQV  +\SRWKHVLV 7KHIROORZLQJK\SRWKHVLVZLOOEH WHVWHGZLWKDWZRVLGHGWHVW  +  ǄFU\R Ǆ$$' +D ǄFU\RǄ$$' ZKHUHǄFU\RDQGǄ$$'DUHWKHPRQWKUDWHVRIFDUGLRYHUVLRQ HLWKHUHOHFWULFDORUS KDUPDFRORJLFDO LQWKH FU\REDOORRQDEODWLRQDQG$$'DUPVUHVSHFWLYHO\  (QGSRLQW'HILQLWLRQ $FDUGLRYHUVLRQHYHQWLVGHILQHG DVDQHOHFWULFDORUSKDUPDFROR JLFDOFDUGLRYHUVLRQSRVWLQGH[DEODWLRQ GLVFKDUJHIRUWKHWUHDWPHQWDUPDQGSRVW$$'LQLWLDWLRQIRUWK H$$'DUP  $QDO\VLV0HWKRGV 7KHSUREDELOLW\RIDVXEMHFWDFKLHYLQJIUHHGRPIURPFDUGLRYHUVL RQ GHILQHGDERYH DWPRQWKV  GD\V ZLOOEHHVWLPDWHGXVLQJ.D SODQ0HLHUVXUYLYDODQDO\VLV 7KHVWDQGDUGHUURUZLOOEHDSSUR[LPDWHG XVLQJ*UHHQZRRG VIRUPXOD$WZRVLGHG ORJORJFRQILGHQFHL QWHUYDOIRUWKHSUREDELOLW\DWPRQWKV ZLOOEHFRQVWUXFWHG$WZRVLGHG ORJUDQNWHVWZLWKVLJQLILFDQ FHOHYHOGHWHUPLQHG E\WKH+RFKEHUJ SURFHGXUHGHVFULEHGDERYHZLOOE HXVHGWRDVVHVVZKHWKHUWKHF DUGLRYHUVLRQUDWHGLIIHUVEHWZHHQ WUHDWPHQWJURXSV 'D\LVGHILQHGDVWKHGD\RIWKHLQGH[FU\RDEODWLRQSURFHGXUH RUWKHGD\LQZKLFKGUXJWKHUDS\LV LQLWLDWHG)RUVXEMHFWVZLWKDW OHDVWRQHFDUGLRYHUVLRQWKHV XUYLYDOGDWHZLOOEHVHWWR WKHGDWHRIWKHILUVW FDUGLRYHUVLRQ)RUVXEMHFWVZLW KRXWDQ\FDUGLRYHUVLRQVWKURXJK PRQWKVWKRVHVXEMHFWVZLOOEH FHQVRUHGDWWKHODVWVWXG\FRQWDFWGDWHUHFRUGHGRQD&5)ZKLFK PD\LQFOXGHWKHODVWVWXG\YLVLWWKHH[LW GDWHRUWKHGDWHRIGHDWK,IDVXEMHFWZLWKRXWDQ\FDUGLRYHU VLRQVLVORVWWRIROORZXSWKHFHQVRULQJGDWH ZLOOEHVHWWRWKHODVW NQRZQVWXG\YLVLWGDWH)RUFDUGLRYHUV LRQVRFFXUULQJRQWKHGD\RILQGH[WUHDWPHQW VXUYLYDOWLPHZLOOEHVHWWRGD\V 7KHVXUYLYDOFXUYHIURPWRPRQWKVZLOOEHSUHVHQWHGIRUER WKWUHDWPHQWDUPV&RXQWVRIDOO FDUGLRYHUVLRQVDGPLQLVWHUHGR YHUPRQWKVZLOODOVREHVXPPDUL ]HG  3HUIRUPDQFH5HTXLUHPHQWV ,IWKHSYDOXHIURPWZRVLGHGORJ UDQNWHVWLVOHVVWKDQWKHDO SKDOHYHOGHWHUPLQHG E\WKH+RFKEHUJ SURFHGXUHGHVFULEHGDERYHWKHR EMHFWLYHZLOOEHFRQVLGHUHGPHW "
94,page_94,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 94 of 130 Version 5.0 STOP AF First Page 94 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 15.3.4.5. Rationale for Performance Criteria If the test specified above indicates a statistically significant increase in the time to the first cardioversion between cryoballoon ablation and AAD -treated subjects, this is sufficient evidence to say that the treatment has a lower rate of cardioversions within a year of treatment initiation, due to the randomized and intention -to-treat nature of the comparison. 15.3.4.6. Determination of Subjects/Data for Analysis The modified intent -to-treat cohort will be utilized. All subjects who initiate either AAD therapy or cryoballoon ablation will be analyzed according to the group to which they were randomized in the assessment of this objective."
95,page_95,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  $QFLOODU\2EMHFWLYHV $QFLOODU\REMHFWLYHVE HHQGHILQHGWRSURYLGHDGGLWLRQDOLQIRUPD WLRQDERXWWKHSHUIRUPDQFHRIWKH$UFWLF )URQW$GYDQFH&DUGLDF&U\R$EODWLRQ&DWKHWHU1RK\SRWKHVHVDUH GHILQHGIRUUHJXODWRU\RUODEHOLQJ SXUSRVHV                                       "
96,page_96,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO                                                    "
97,page_97,
98,page_98,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO                   "
99,page_99,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJH RI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO (WKLFV 6WDWHPHQW V RI&RPSOLDQFH 7KHVWXG\ZLOOEHFRQGXFWHGLQFRP SOLDQFHZLWKLQWHUQDWLRQDOHW KLFDODQGVFLHQWLILFTXDOLW\VWDQGDUGV NQRZQDVJRRGFOLQLFDOSUDFWLFH *&3 *&3LQFOXGHVUHYLHZDQG DSSURYDOE\DQLQGHSHQGHQW,QVWLWXWLRQDO 5HYLHZ%RDUG ,5% (WKLFV&RPPL WWHH (& EHIRUHLQLWLDWLQJDV WXG\FRQWLQXLQJUHYLHZRIDQRQJRLQJ VWXG\E\DQ,5%(&DQGREWDLQLQ JDQGGRFXPHQWLQJWKHIUHHO\JL YHQLQIRUPHGFRQVHQWRIDVXEMHFW EHIRUHLQLWLDWL QJWKHVWXG\  7KHVWXG\ZDVGHVLJQHGWRUHIOH FWWKH*&3SULQFLSOHVRXWOLQHGL Q,62 DQGRWKHULQWHUQDWLRQDO FOLQLFDOUHTXLUHPHQWVRXWOLQHGE HORZ7KHVHLQFOXGHWKHSURWHFW LRQRIWKHULJKWVVDIHW\DQGZHOOEHLQJRI KXPDQVXEMHFWVFRQWUROVWRHQVX UHWKHVFLHQWLILFFRQGXFWDQGF UHGLELOLW\RIWKHFOLQL FDOLQYHVWLJDWLRQDQG WKHGHILQLWLRQRIUHVSRQVLELOLWLH VRIWKHVSRQVRUDQG,QYHVWLJD WRUV,QDFFRUGDQFHZL WK,62VWDQGDUGWKH VSRQVRUVKDOODYRLGLPSURSHULQIO XHQFHRQRULQGXFHPHQWRIWK HVXEMHFWPRQLWRUDQ\,QYHVWLJDWRU V RU RWKHUSDUWLHVSDUWLFLSDWLQJLQRU FRQWULEXWLQJWRWKHFOLQLFDO LQYHVWLJDWLRQ$OO,QYHVWLJDWRUVVKDOODYRLG LPSURSHULQIOXHQFHRQRULQGXFHP HQWRIWKHVXEMHFWVSRQVRUPR QLWRURWKHU,QYHVWLJDWRU V RURWKHU SDUWLHVSDUWLFLSDWLQJLQRUFRQW ULEXWLQJWRWKHFOLQLFDOLQYHVW LJDWLRQ7KH,62VWDQGD UGDOVRLQIRUPHGVWXG\ GHVLJQLQWKHDUHDVRIGHYLFHGHI LFLHQF\UHSRUWLQJDQGULVNHYD OXDWLRQZLWKWKHH[FH SWLRQ WR6HFWLRQ RIWKH,62VWDQGDUG W KDWRQO\WKRVH$GYHU VH(YHQWV $(V ZKLFK DUHFDUGLRYDVFXODUUHODWHGVHULRXV UHJDUGOHVVRIUHODWHGQHVV $$'U HODWHGFU\RDEODWLRQV\VWHPU HODWHGDQGRUSURFHGXUHUHODWHGZLOOEH FROOHFWHG7KLVHQVXUHVDQ\$(VZKLFKFRXOGSRWHQWLDOO\EHUHOH YDQWZLOOEHFROOHFWHG7KHUHLVDVHFRQG H[HPSWLRQ WR6HFWLRQ RIWKH,62VWDQGDUG WKDWGHYLFHDFFR XQWDELOLW\ZLOOQRWEHSHUIRUPHGLQ(XURSH DQGRQO\XSRQSDFNDJHRSHQLQJLQWKH86  7KHVWXG\ZLOOEHFRQGXFWHGDFFRUGLQJWRWKH&,3IHGHUDOQDWL RQDODQGORFDOODZVUHJXODWLRQVVWDQGDUGV DQGUHTXLUHPHQWVRIWKHFRXQWULHVJHRJUDSKLHVZKHUHWKHVWXG\L VEHLQJFRQGXFWHG,Q(XURSHWKHVWXG\ ZLOODOVREHFRQGXFWHGLQDFFRUGDQ FHZLWKWKH'HFODUDWLRQRI+H OVLQNL)RUDOOJHRJUDSKLHVWKH SULQFLSOHVRIWKH'HFODUDWLRQRI+HOVLQNLKDYHEHHQLPSOHPHQWHG WKURXJKWKHSDWLHQW LQIRUPHGFRQVHQW ,& SURFHVV,5%(&DSSURYDOVWXG\WUDLQLQJFOLQLFDOWULDOU HJLVWUDWLRQSUHFOLQLFDOWHVWLQJULVNEHQHILW DVVHVVPHQWDQGSXEOLFDWLRQSROLF\ 8OWLPDWHO\DOOFHQWHUVLQDOO JHRJUDSKLHVZLOOIROORZDQGFRPS O\ZLWK   x3ULQFLSOHVRI'HFODUDWLRQRI+H OVLQNL LQFOXGLQJSULYDF\DQGGD WDSURWHFWLRQODZV RUWKHODZVDQG UHJXODWLRQVRIHDFKSDUWLFLSDWLQJFRXQWU\ZKLFKHYHUDIIRUGVJU HDWHUSURWHFWLRQIRUWKHVWXG\ VXEMHFWV x&)53DUW (OHFWURQLF5HFRUGV(OHFWURQLF6LJQDWXUHV  x&)53DUW )LQDQFLDO'LVFORVXUHE\&OLQLFDO,QYHVWLJDWRUV  x7KHSURFHGXUHVGHVFULEHGZLWKLQWKLV&,3 x/RFDO(WKLFV%RDUGUHTXLUHPHQWV  $OOSDUWLFLSDWLQJJHRJUDSKLHVZLOOPDNHVWXG\GDWDDYDLODEOHWR WKHUHJXODWRU\ERG\VXFKDV)'$RU FRPSHWHQWDXWKRULW\LIWKHUHJXODWRU\ERG\GHHPVDQRQVLWHLQVS HFWLRQQHFHVVDU\7KHUHJXODWRU\ERG\ ZLOOEHDEOHWRLQVSHFWUHFRUGVD WFOLQLFDOFHQWHUVDURXQGWKH ZRUOGWRUHVROYHDQ\XQFHUWDLQWLHVDERXW ZKHWKHUWKHVWXG\ZDVFRQGXFWHGLQDFFRUGDQFHZLWKJRRGFOLQLFD OSUDFWLFH "
100,page_100,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 100 of 130 Version 5.0 STOP AF First Page 100 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential In addition to the regulatory requirements outlined above, the study will be conducted in compliance with relevant local laws. These include but are not limited to: • In the United States, US FDA 21 CFR Parts o 50: Protection of Human subjects, o 56: Institutional Review Boards o 812: Investigational Device Exemptions • In Europe, Declaration of Helsinki 2013, the Competent Authority requirements, the Medical Device Directive (MDD) 93/42/EEC and ISO 14155:2011 with the exceptions stated earlier in this Section The study will be publicly registered prior to first enrollment in accordance with the 2007 Food and Drug Administration Amendments Act (FDAAA) and Declaration of Helsinki on ht tp://clinicaltrials.gov (PL 110 85, Section 810(a)). Approval of the Clinical Investigation Plan (CIP) is required from the following groups prior to any study procedures at a study center: • US Food and Drug Administration (FDA) or regulatory authority • Medtronic • Principal Investigators (where required by local law) • An independent IRB/EC Similarly, approval of subsequent revisions to the CIP is required at each study center from the above mentioned groups prior to implemen tation of the revised CIP at that center. Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable laws and regulations and will comply with applicable local law and custom concerning specific insurance coverage. If required, a clinical insurance statement/certificate will be provided to the IRB/EC. The study is conducted in multiple countries, therefore reimbursement and indemnification will be addressed on a country specific basis in the study documents and center Clinical Trial Agreements."
101,page_101,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 6WXG\$GPLQLVWUDWLRQ 5ROHRIWKH6SRQVRU5HSUHVHQWDWLYHV 6SRQVRUUHSUHVHQWDWLYHVPD\SURYLGHVXSSRUWDVUHTXLUHGIRUWKH VWXG\XQGHUVXSHUYLVLRQRIWKH3ULQFLSDO ,QYHVWLJDWRULQFOXGLQJ  x3URYLGHVWXG\WUDLQLQJUHOHYDQWDQGSHUWLQHQWWRWKHLQYROYHPHQ WRISHUVRQQHOFRQGXFWLQJVWXG\ DFWLYLWLHVDQGLQYHVWLJDWRUUHVSRQVLELOLWLHV x7HFKQLFDOVXSSRUWDWWKHDEODWLRQSURFHGXUHXQGHUWKHVXSHUYLVL RQRIDVWXG\LQYHVWLJDWRUEXWQR GDWDHQWU\VKDOOEHSHUIRUPHGE \0HGWURQLFSHUVRQQHORUWKHLU UHSUHVHQWDWLYHVDWVLWHV x0RQLWRULQJDQGDXGLWLQJDFWLYLWLHV 0RQLWRULQJ ,WLVWKHUHVSRQVLELOLW\RI0HGWURQLFWRHQVXUHSURSHUPRQLWRUL QJRIWKLVFOLQLFDOVWXG\7UDLQHG0HGWURQLF SHUVRQQHORUGHOHJDWHVDSSRLQWHGE\0HGWURQLFPD\SHUIRUPVWXG\ PRQLWRULQJDWWKHVWX G\FHQWHULQRUGHU WRHQVXUHWKDWWKHVWXG\LVFRQGXFWHGLQDFFRUGDQFHZLWKWKH&, 3WKH&OLQLFDO7ULDO$JUHHPHQWDQG DSSOLFDEOHUHJXODWRU\DQGORFDOUHTXLUHPHQWV0HGWURQLFRUGH OHJDWHVPXVWWKHUHIRUHEHDOORZHGGLUHFW DFFHVVWRWKHVXEMHFWV¶FDVHKLVW RULHV FOLQLFDQGKRVSLWDOUHF RUGVDQGRWKHUVRXUFHGDWDGRFXPHQWDWLRQ  XSRQUHTXHVWDVSHUWKH,&)RUP5HVHDUFK$XWKRUL]DWLRQ ZKHUH DSSOLFDEOH DQG&OLQLFDO7ULDO$JUHHPHQW 7KH3ULQFLSDO,QYHVWLJDWRUVKRXOGDOVREHDYDLODEOHGXULQJPRQL WRULQJYLVLWV )UHTXHQF\RIPRQLWRULQJYLVLWVZ LOORFFXUEDVHGRQVXEMHFWHQUR OOPHQWGXUDWLRQRIWKHVWXG\VWXG\ FRPSOLDQFHQXPEHURIDGYHUVHHYH QWVQXPEHURIGHYLDWLRQVILQ GLQJVIURPSUHYLRXVPRQLWRULQJYLVLWVDQG DQ\VXVSHFWHGLQFRQVLVWHQF\LQGDWDW KDWUHTXLUHVLQYHVWLJDWLRQ5 HJXODWRU\GRFXPHQWV  HJ,5%(& DSSURYDOOHWWHUVHWF PD\EHUHYLHZHGDWHDFKVWXG\FHQWHU 0RQLWRULQJIRUWKHVWXG\PD\LQFOXGHEXW DUHQRWOLPLWHGWRVLWHLQLWLDWL RQYLVLWVLQWHULPPRQLWRULQJ YLVLWVDQGFORVHRXWYLVLWVDQGZLOOEHGRQHLQ DFFRUGDQFHZLWKWKHVWXG\VSHFLI LFPRQLWRULQJSODQ7KHH[WHQW RIVRXUFHGDWDYHULILFDWLRQZLOOEH VSHFLILHGLQWKHVWXG\VS HFLILFPRQLWRULQJSODQ 0RQLWRULQJYLVLWVZLOOEHFRQGXFW HGSHULRGLFDOO\WRDVVHVVVLWH VWXG\SURJUHVVWKH LQYHVWLJDWRU¶VDGKHUHQFH WRWKH&OLQLFDO,QYHVWLJDWLRQ3ODQUHJXODWRU\FRPSOLDQFH LQFOXGLQJEXWQRWOLPLWHGWR,5%0(&DSSURYDODQG UHYLHZRIWKHVWXG\PDLQWHQDQFH RIUHFRUGVDQGUHSRUWVDQGUH YLHZRIVRXUFHGRFXPHQWVDJDLQVWVXEMHFW  &5)VDQGIRUXQUHSRUWHGDGYHUVHHYHQWV,Q(XURSHFDOLEUDWLRQ DQGPDLQWHQDQFHRIVWXG\HTXLSPHQWZLOOEH PRQLWRUHG0RQLWRUVIDFLOLWDWHVLWHUHJXODWRU\DQGVWXG\FRPSOL DQFHE\LGHQWLI\LQJ ILQGLQJVRIQRQ FRPSOLDQFHDQGFRPPXQLFDWLQJWKRVHILQGLQJVDORQJZLWKUHFRPPHQ GDWLRQVIRUSUHYHQWDWLYHFRUUHFWLYH DFWLRQVWRVLWHSHUVRQQHO)LQG LQJVDQGQRQFRPSOLDQFHZLOODO VREHFRPPXQLFDWHGWRVWXG\SHUVRQQHOYLD DPRQLWRULQJIROORZXSOHWWHU0RQLWRUV PD\ZRUNZLWKVWXG\SHUVRQQHOWRGHWHUPLQHDSSURSULDWH FRUUHFWLYHDFWLRQ UHFRPPHQGDWLRQVDQGWRLGHQWLI\WUHQGVZLWKLQWKHVWXG\RUDWD SDUWLFXODUFHQWHU 'DWD0DQDJHPHQW 'DWDZLOOEHFROOHFWHGYLDDQHOHFWURQLFGDWDPDQDJHPHQWV\VWHP IRUFOLQLFDOVWXGLHV&5)GDWDZLOOEH VWRUHGLQDVHFXUHSDVVZRUGSURWHFWHGGDWDEDVHZKLFKZLOO EHEDFNHGXSQLJKWO\'DWDZLOOEHUHYLHZHG XVLQJSURJUDPPHGDQGPDQXDOGDWD FKHFNV'DWDTXHULHVZLOOEHPDGHDYDLODEOHWRFHQWHUVIRUUHV ROXWLRQ 7KH,QYHVWLJDWRUPXVWDSSURYHWKHFRPSOHWHG&5)VDQGWKH,QYHVW LJDWRURUDXWKRUL]HGGHVLJQHHPXVW FRPSOHWH&5)VDQGPDNH&5)FRUUHFWLRQV"
102,page_102,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 'DWDFROOHFWHGE\DPEXODWRU\PRQLWRULQJDQGOHDG(&*VZLOOE HPDQDJHGDQGRYHUU HDGE\DFRUHODE )LQDOFODVVLILFDWLRQRIUHFXUUHQ W$)$7$)/ZLOOEHVWRUHGLQW KHVWXG\GDWDEDVH 6WXG\PDQDJHPHQWUHSRUWVPD\EHJHQHUDWHGWRPRQLWRUGDWDTXDOL W\DQGVWXG\SURJUHVV$WWKHHQGRI WKHVWXG\WKHGDWDZLOOEHIUR]H QDQGZLOOEHUHWDLQHGLQGHILQ LWHO\E\0HGWURQLF $OOUHFRUGVDQGRWKHULQIRUPDWLRQDERXWVXEMHFWVSDUWLFLSDWLQJ LQWKLVVWXG\ZLOOEHWUHDWHGDVFRQILGHQWLDO 'DWDZLOOEHWUDQVIHUUHGDQGSURFHVVHGE\0HGWURQLFRUDWKLUG SDUW\GHVLJQDWHGE\0HGWURQLFLQDNH\ FRGHGIRUPXQOHVVLW¶VLPSRVVLEOHWRPDNHLWDQRQ\PRXVIRULQ VWDQFHZKHUHWKHVXEMHFW¶VQDPHFDQQRW EHUHPRYHGIURPWKHGDWDFDUULHU VXFKDVIOXRURVFRS\LPDJHV ,QWKHFDVHWKDWGHLGHQWLI\LQJLV LPSRVVLEOHRULQYROYHVDGLVSURSR UWLRQDWHHIIRUWILOHVFRQWDLQ LQJSHUVRQDOGDWDRIVXEMHFWVVKDOORQO\EH PDGHDFFHVVLEOHWRDXWKRUL]HGSHUVRQV VHFXUHGUROHEDVHGDFFHV V  'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV 7KHVSRQVRURUDUHJXODWRU\DXWK RULW\PD\DXGLWRULQVSHFWWKH VWXG\VLWHWRHYDOXDWHWKHFRQGXFWRIWKH VWXG\7KHFOLQLFDOLQYHVWLJDW RU V LQVWLWXWLRQ V VKDOODOORZ VWXG\UHODWHGPRQLWRULQJDXGLWV,5%UHYLHZ DQGUHJXODWRU\LQVSHFWLRQE\SUR YLGLQJGLUHFWDFFHVVWRVRXUFH GDWDGRFXPHQWV,IGLUHFWDFFHVVLVQRW IHDVLEOHFHUWLILHGFRSLHVVKDOOE HSURYLGHGWRWKHVSRQVRURU UHJXODWRU\DXWKRULW\ &RQILGHQWLDOLW\ $OOUHFRUGVDQGRWKHULQIRUPDWLRQ DERXWVXEMHFWVSDUWLFLSDWLQJ LQWKLVVWXG\ZLOOEHWUHDWHGDVFRQILGHQWLDO 6HHVHFWLRQVDQG IRUIXUWKHULQIRUPDWLRQ  &,3$PHQGPHQWV $SSURYDORIVXEVHTXHQWUHYLVLRQ VWRWKH&,3LVUHTXLUHGDWHDFK VWXG\FHQWHUIURPWKHIROORZLQJJURXSV SULRUWRLPSOHPHQWDWLRQRIWKH UHYLVHG&,3DWWKHFHQWHU x0HGWURQLF x3ULQFLSDO,QYHVWLJDWRUV ZKHUHUHTXLUHGE\ORFDOODZ  x*HRJUDSK\VSHFLILFUHJXODWRU\DX WKRULWLHV LIUHJXODWRU\DSSURY DOLVUHTXLUHG  x$QLQGHSHQGHQW(&RU,5% ,ID&,3DPHQGPHQWRFFXUVFHQWH USHUVRQQHOZLOOQHHGWREHUH WUDLQHGDVQHFHVVDU\ DQGZLOOQHHGWR VXEPLWDQ\FKDQJHVWRWKHLU,5%(&DVUHTXLUHGE\WKHFRPPLWWHH &,3DPHQGPHQWVZLOODOVREHUHSRUWHG WRDQGDSSURYHGE\WKH)'$ 5HFRUG5HWHQWLRQDQG5HSRUWV 0HGWURQLFUHFRUGVDQGUHSRUWVZ LOOEHPDLQWDLQHGLQDSDVVZRUG SURWHFWHGGRFXPH QWPDQDJHPHQW V\VWHPDQGSDSHUGRFXPHQWV ZK HUHDSSOLFDEOH ZLOOEHVWRUHGL QVWRUHGLQVHFXUH GILOHFDELQHWVDW 0HGWURQLFGXULQJWKHFRXUVHRIWKLVVWXG\ $IWHUFORVXUHRIWKHVWXG\0HGW URQLFZLOODUFKLYHUHFRUGVDQGU HSRUWVLQGHILQLWHO\"
103,page_103,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  ,QYHVWLJDWRU5HFRUGV 7KHLQYHVWLJDWRULVUHVSRQVLEOHIRUWKHSUHSDUDWLRQDQGUHWHQWL RQRIWKHUHFRUGV FLWHGEHORZ$OORIWKH EHORZUHFRUGVZLWKWKHH[FHSWLRQRIFDVHKLVWRU\UHFRUGV DQGFDVHUHSRUWIRUPVVKRXOGEHNHSWLQWKH ,QYHVWLJDWRU6LWH)LOH LHWKHVWXG\ ELQGHUSURYLGHGWRWKHLQYHVWLJDWRU RU6XEMHFW6WXG\%LQGHU& 5)V PD\EHPDLQWDLQHGDQGVLJQHGHOHFWURQLF DOO\ZLWKLQWKHHOHFWURQLFGDWD FDSWXUHV\VWHP GXULQJWKHWULDO 7KHIROORZLQJUHFRUGVDUHVXEMHFWWRLQVSHFWLRQDQGPXVWEH UHWDLQHGIRUDSHULRGRIWZR\HDUV RUORQJHU DVORFDOODZRUKRVSLWDO DGPLQLVWUDWLRQUHTXLUHV DIWHUWKHGDWHRQZKLFKWKHLQYHVWLJDW LRQLVWHUPLQDWHG x$OOFRUUHVSRQGHQFHEHWZHHQWKH,5%(&VSRQVRUPRQLWRU)'$DQ GRURWKHUUHJXODWRU\ERGLHV DQGRUWKHLQYHVWLJDWRUWKDWSHUWDLQVWRWKH LQYHVWLJDWLRQLQFO XGLQJUHTXLUHGUHSRUWV x6XEMHFWV¶FDVHKLVWRU\UHFRUGVLQFOXGLQJ  R6LJQHGDQGGDWHG,QIRUPHG&RQVHQW)RUP R2EVHUYDWLRQVRIDGYHUVHHYHQWVDGYHUVHGHYLFHHIIHFWV R0HGLFDOKLVWRU\ R3URFHGXUHDQGIROORZXSGDWD R'RFXPHQWDWLRQRIWKHGDWHVDQGUDWLRQDOHIRUDQ\GHYLDWLRQIURP WKHSURWRFRO x5HSRUWVRI$GYHUVH(YHQWV x6LJQHGDQGGDWHG&5)V x%ODQNFDVHUHSRUWIRUPV (XURSHRQO\  x6XEMHFWVFUHHQLQJORJV LIXVHG DQGVXEMHFWLGHQWLILFDWLRQORJ V (XURSHRQO\  x5DQGRPL]DWLRQOLVW x/LVWRILQYHVWLJDWLRQFHQWHUV x$OODSSURYHGYHUVLRQVRIWKH&,3,&)DQG,QYHVWLJDWRU¶V%URFK XUH5HSRUWRI3ULRU,QYHVWLJDWLRQ 6XPPDU\ x6LJQHGDQGGDWHG&OLQLFDO7ULDO$JUHHPHQWDQG,QYHVWLJDWRU6WDWHPHQW x)LQDQFLDO'LVFORVXUHRI,QYHVWLJDWRUV x&XUUHQWFXUULFXOXPYLWDH VLJQHGDQGGDWHGLQ(XURSH RIDOOSD UWLFLSDWLQJ,QYHVWLJDWRUVDQGNH\ PHPEHUVRILQYHVWLJDWLRQFHQWHUWHDP (XURSHRQO\  x'RFXPHQWDWLRQRIGHOHJDWHGWDVNV x,5%(&DSSURYDOGRFXPHQWDWLRQLQFOXGLQJZULWWHQLQIRUPDWLRQWKD WWKHLQYHVWLJDWRURURWKHU VWXG\VWDIIZKHQPHPEHURIWKH,5%(&GLGQRW SDUWLFLSDWHLQWKHDSSURYDOSURFHVV $SSURYDOGRFXPHQWDWLRQPXVWLQFOXGHWKH,5%(&FRPSRVLWLRQLQ (XURSHDQGZKHUHUHTXLUHG E\ORFDOODZ x5HJXODWRU\DXWKRULW\QRWLILFDWLRQFRUUHVSRQGHQFHDQGDSSURYDO ZKHUHUHTXLUHGE\ORFDOODZ x6WXG\WUDLQLQJUHFRUGVIRUFHQWHUVWDII x,QVXUDQFHFHUWLILFDWHV ZKHUHUHTXLUHGE\WKH,5%(&  x$Q\RWKHUUHFRUGVWKDW)'$RUUHJX ODWRU\DXWKRULWLHVUHTXLUHWR EHPDLQWDLQHG x)LQDO5HSRUWRIWKHFOLQLFDOLQY HVWLJDWLRQSUHSDUHGDQGGLVWULE XWHGE\WKHVSRQVRU x)LQDO,QYHVWLJDWRU5HSRUWSUHSDUHGE\FHQWHUDQGVXEPLWWHGWRW KHLU,5% x)LQDO&OLQLFDO6WXG\5HSRUWLQFOXGLQJWKHVWDWLVWLFDODQDO\VLV  ,QYHVWLJDWRU5HSRUWV 7KH,QYHVWLJDWRULVUHVSRQVLEOHI RUWKHSUHSDUDWLRQ UHYLHZDQG VLJQDWXUH DQGVXEPLVVLRQWRWKHVSRQVRU RIDOOFDVHUHSRUWIRUPVDGYHUVHHYHQWVGHYLFHGHILFLHQFLHV GHDWKVDQGDQ\GHYLDWLRQVIURPWKHFOLQLFDO"
104,page_104,
105,page_105,
106,page_106,
107,page_107,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO x5HJXODWRU\DXWKRULWLHVFRUUHVSRQGHQFHQRWLILFDWLRQDQGDSSURYD ODVUHTXLUHGE\QDWLRQDO OHJLVODWLRQ x,QVXUDQFHFHUWLILFDWHV x5DQGRPL]DWLRQ/LVW x1DPHVFRQWDFWDGGUHVVHVRIPRQLWRUV x0RQLWRULQJYLVLWUHSRUWVDQGIROORZXSOHWWHUV x)RUPVIRUUHSRUWLQJDQ\DGYHUVH HYHQWVDQGDGYHUVHGHYLFHHIIHF WV x6WDWLVWLFDODQDO\VHVDQGXQGHUO\LQJVXSSRUWLQJGDWD x)LQDOUHSRUWRIWKHFOLQLFDOLQYHVWLJDWLRQ x6WXG\WUDLQLQJUHFRUGVIRUFHQWHU SHUVRQQHODQG0HGWURQLFSHUVR QQHOLQYROYHG LQWKHVWXG\ x$Q\RWKHUUHFRUGVWKDWORFDOUHJX ODWRU\DJHQFLHVUHTXLUHWREH PDLQWDLQHG 6SRQVRU5HSRUWV 0HGWURQLFVKDOOSUHSDUHDQGVXEP LWWKHIROORZLQJFRPSOHWHDFFX UDWHDQGWLPHO\UHSRUWVOLVWHGLQWKH WDEOHVEHORZ E\JHRJUDSK\  ,QDGGLWLRQWRWKHUHSRUWVOLVWHG EHORZ0HGWURQLFVKDOOXSRQUHTXHVWRI UHYLHZLQJ,5%(&UHJXODWRU\DJHQF\RU)'$SURYLGHDFFXUDWHF RPSOHWHDQGFXUUHQWLQIRUPDWLRQDERXW DQ\DVSHFWRIWKHLQYHVWLJDWLRQ6DIHW\GDWDUHSRUWLQJUHTXLUHP HQWVDUHOLVWHGLQW KHDGYHUVHHYHQW VHFWLRQ "
108,page_108,
109,page_109,
110,page_110,
111,page_111,
112,page_112,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO 7KHSXEOLFDWLRQFRPPLWWHH¶VUROHLVWR  x0DQDJHHOHPHQWVDGGU HVVHGLQWKHSXEOLFDWLRQSODQ x'HYHORSWKHILQDOSXEOLFDWLRQ SODQXQGHUVHSDUDWHFRYHU x([HFXWHWKHSXEOLFDWLRQSODQ x2YHUVHHWKHSXEOLFDWLRQRISULPD U\VHFRQGDU\ VWXG\UHVXOWV x5HYLHZDQGSULRULWL]HSXEOLFDWLRQSURSRVDOV x3URYLGHLQSXWRQSXEOLFDWLRQFRQWHQW x'HWHUPLQHDXWKRUVKLS x(QVXUHWKH,QWHUQDWLRQDO&RPPL WWHHRI0HGLFDO-RXUQDO(GLWRUV ,&0-( TXDOLW\DQGUXOHVJXLGDQFH LVXVHGDQG x'HWHUPLQHSURFHGXUHIRUGRFXPHQW DWLRQRIGHFLVLRQVUHODWHGWRW KHJHQHUDWLRQRISXEOLFDWLRQV ,QDGGLWLRQWKHFRPPLWWHHZLOODSS O\DQGUHLQIRUFHWKHDXWKRUV KLSJXLGHOLQHVVHWIRUWKLQWKHSXEOLFDWLRQ SODQ0HPEHUVKLSLQWKHSXEOLFDWLRQFRPPLWWHHGRHVQRWJXDUDQW HHDXWKRUVKLS7KHFRPPLWWHHZLOOPHHW DWDVQHHGHG 0DQDJHPHQWRI3ULPDU\6HFRQGDU\DQG$QFLOODU\3XEOLFDWLRQV 7KHSXEOLFDWLRQFRPPLWWHHUHYLHZVSULRULWL]HVDQGPDQDJHVDOO SXEOLFDWLRQVLQFOXGLQJSULPDU\VHFRQGDU\ DQGDQFLOODU\SXEOLFDWLRQV3ULPDU\DQGVHFRQGDU\SXEOLFDWLRQV DUHWKRVHWKDWDGGUH VVDQDO\VHVRIDQ\RU DOOSULPDU\REMHFWLYHVRUVHFRQG DU\REMHFWLYHVUHVSHFWLYHO\D VVSHFLILHGLQWKHFOLQLF DOLQYHVWLJDWLRQSODQ $QDQFLOODU\SXEOLFDWLRQLVDQ\SXEOLFDWLRQWKDWGRHVQRWDGGUH VVWKHVWXG\REMHFWLYH VLGHQWLILHGLQWKH FOLQLFDOLQYHVWLJDWLRQSODQ7KH\LQFOXGHSXEOLFDWLRQVSURSRVH GDQGGHYHORSHGE\RWKHU0HGWURQLF GHSDUWPHQWVRUHQWLWLHVFOLQLFLD QVSDUWLFLSDWLQJLQWKLVFOLQL FDOVWXG\DQGFOLQLFLDQVQRWSDUWLFLSDWLQJLQWKLV FOLQLFDOVWXG\7KHFRPPLWWHHZ LOOZRUNZLWK0HGWURQLFWRHQVX UHWKDWUHTXHVWVGRQRWSUHVHQWFRQIOLFWV ZLWKRWKHUSURSRVDOVDUHQRWGXS OLFDWLYHDQGWRGHWHUPLQHZKL FKDQFLOODU\SXEOLFDWLRQSURSRVDOVLIDQ\ ZLOOEHVXSSRUWHG 7KHFRPPLWWHHPD\GHFLGHWKDWQR SXEOLFDWLRQVLQFOXGLQJDEVWUD FWVZLOOEHSXEOLVKHGSULRUWRWKHHQGRI WKHVWXG\RUZLWKLQGLYLGXDOFHQWHUGDWD5HTXHVWVIRUSXEOLFD WLRQVRQVWXG\REMHFWLY HVXWLOL]LQJVXEVHW GDWD HJUHJLRQDO ZLOOEHHYDO XDWHGIRUVFLHQWLILFYDOLGLW\ DQGWKHDELOLW\RI0 HGWURQLFWRSURYLGH UHVRXUFHV &ULWHULDIRU'HWHUPLQLQJ$XWKRUVKLS 3XEOLFDWLRQVZLOODGKHUHWRDXWKR UVKLSFULWHULDGHILQHGE\WKH ,QWHUQDWLRQDO&RPPLWWHH RI0HGLFDO-RXUQDO (GLWRUV ,&0-(8QLIRUPUHTXLUH PHQWVIRUPDQXVFULSWVVXEPLWWHG WRELRPHGLFDOMRXUQD OVZZZLFPMHRUJ  ,QGLYLGXDODXWKRUVKLSFULWHULDGHILQHGE\WKHWDUJHWMRXUQDORU FRQIHUHQFHZLOOEHIROORZHGZKHQLWGLIIHUV IURP,&0-(FULWHULD 'HFLVLRQVUHJDUGLQJDXWKRUVKLSDQGFRQWULEXWRUVKLSZLOOEHPDG HE\WKHFRPPLWWHH7KHVHOHFWHGDXWKRUV ZLOOEHUHVSRQVLEOHIRUGUDIWLQJ WKHSXEOLFDWLRQ$OOVHOHFWHG DXWKRUVPXVWIXOILOOWKHD XWKRUVKLSFRQGLWLRQV VWDWHGDERYHWREHOLVWHGDVDXWKR UVDQGDOOFRQWULEXWRUVZKR IXOILOOWKHFRQGLWLRQVPXVWEHOLVWHGDV DXWKRUV $OOLQYHVWLJDWRUVQRWOLVWHGDVF RDXWKRUVZLOOEHDFNQRZOHGJHG DVWKH³6723$))LUVW6WXG\,QYHVWLJDWRUV´ DQGZLOOEHLQGLYLGXDOO\OLVWHGD FFRUGLQJWRWKHJXLGHOLQHVRI WKHDSSOLFDEOHVFLHQWLILFMRXUQDOZKHQSRVVLEOH DQGDIILOLDWLRQ$Q\RWKHUFRQWULEXWRUVZLOOEHDFNQRZOHGJHGE \QDPHZLWKWKHLUVSHFLILFFRQWULEXWLRQ LQGLFDWHG"
113,page_113,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO  7UDQVSDUHQF\ 7UDQVSDUHQF\RIVWXG\UHVXOWVZ LOOEHPDLQWDLQHGE\WKHIROORZL QJPHDQV  x$ILQDOUHSRUWGHVFULELQJWKHUH VXOWVRIDOOREMHFWLYHVDQGDQ DO\VLVZLOOEHGLVWULEXWHGWRDOO LQYHVWLJDWRUVDQG,5%V x5HJLVWHULQJDQGSRVWLQJWKHVWXG \UHVXOWVRQ&OLQLFDO7ULDOVJRY EDVHGRQWKHSRVWLQJUXOHV VWLSXODWHG x6XEPLWWLQJIRUSXEOLFDWLRQWKHSU LPDU\VWXG\UHVXOWVDIWHUWKH VWXG\HQGV x'LVFORVLQJFRQIOLFWVRILQWHUHVW HJILQDQFLDO RIWKHFRDX WKRUVRISXEOLFDWLRQVDFFRUGLQJWRWKH SROLFLHVVHWIRUWKE\W KHFRUUHVSRQGLQJMRXUQDOVDQGFRQIHUHQFH V x0DNLQJDQLQGLYLGXDOFHQWHU¶V VWXG\GDWDDFFHVVLEOHWRWKHFRUU HVSRQGLQJLQYHVWLJDWRUDIWHUWKH FRPSOHWLRQRIWKHVWXG\LIUHTXHVWHG 6XVSHQVLRQRU(DUO\7HUPLQDWLRQ 3ODQQHG6WXG\&ORVXUH 6WXG\FORVXUHLVDSURFHVVLQLWLDW HGE\GLVWULEXWLRQRIDVWXG\ FORVXUHOHWWHU6WXG\FORVXUHLVGHILQHGDV FORVXUHRIDFOLQLFDOVWXG\WKDW RFFXUVZKHQ0HGW URQLFDQGRUU HJXODWRU\UHTXLUHPHQWVKDYHEHHQVDWLVILHG SHUWKH&,3DQGRUE\DGHFLVLRQ E\0HGWURQLFRUUHJXODWRU\DXW KRULW\ZKLFKHYHURFFXUVILUVW7KHVWXG\ FORVXUHSURFHVVLVFRPSOHWHXSRQG LVWULEXWLRQRIWKHILQDOUHSR UWRUDIWHUILQDOSD\PH QWVZKLFKHYHURFFXUV ODVW2QJRLQJ,5%(&RYHUVLJ KWLVUHTXLUHGXQWLOWKHRYHUDOOV WXG\FORVXUHSURFHVV LVFRPSOHWH5HIHUWR VHFWLRQVDQGIRUDGGLWLRQDOLQIRUPDWLRQUHJDUGLQJ VWXG\H[LWSURFHGXUHV (DUO\7HUPLQDWLRQRU6XVSHQVLRQ (DUO\WHUPLQDWLRQLVWKHFORVXUH RIDFOLQLFDOVWXG\WKDWRFFXU VSULRUWRPHHWLQJGHIL QHGHQGSRLQWV7KLVLV SRVVLEOHIRUWKHZKROH VWXG\RUDVLQJOHVLWH6WXG\VXVSHQVLR QLVDWHPSRUDU\SRVWSRQHPHQWRIVWXG\ DFWLYLWLHVUHODWHGWRHQUROOP HQW7KLVLVSRVVLEOHIRUWKHZKR OHVWXG\RUDVLQJOHVLWH 6WXG\ZLGHWHUPLQDWLRQRUVXVSHQVLRQ 3RVVLEOHUHDVRQVIRUFRQVLGHULQJVWXG\VXVSHQVLRQRUWHUPLQDWLR QRIWKHVWXG\LQFOXGH EXWDUHQRWOLPLWHG WR  x'HFLVLRQE\0HGWURQLFRUUHJXODWRU\ERG\ ZKHUHWKHVWXG\LVRS HUDWLQJXQGHUUHJXODWRU\ERG\ DXWKRULW\  x$GYHUVHHYHQWVDVVRFLDWHGZLWK WKHV\VWHPRUSURGXFWXQGHULQYH VWLJDWLRQZKLFKPLJKWHQGDQJHU WKHVDIHW\RUZHOIDUHRIWKHVXEMHFW x2EVHUYHGVXVSHFWHGSHUIRUPDQFHGLIIHUHQWIURPWKHSURGXFW¶VGHV LJQLQWHQW x(QUROOPHQWLVVORZHUWKDQDQWLFLSDWHG 6LWHWHUPLQDWLRQRUVXVSHQVLRQ 3RVVLEOHUHDVRQVIRUFOLQLFDOLQYH VWLJDWRURUVLWHWHUPLQDWLRQ RUVXVSHQVLRQLQFOXGHEXWDUHQRWOLPLWHGWR  x)DLOXUHWRREWDLQLQLWLDO,5%DS SURYDORUDQQXDOUHQHZDORIWKH VWXG\ x3HUVLVWHQWQRQFRPSOLDQFHWRW KHFOLQLFDOLQYHVWLJDWLRQ"
114,page_114,")&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH9HUVLRQ  3DJHRI   9HUVLRQ 6723$))LUVW 3DJH RI '(& &OLQLFDO,QYHVWLJDWLRQDO3ODQ  0HGWURQLF&RQILGHQWLDO x/DFNRIHQUROOPHQW x1RQFRPSOLDQFHWRUHJXODWLRQVDQG WKHWHUPVRIWKH&7$ HJIDL OXUHWRVXEPLWGDWDLQDWLPHO\ PDQQHUIDLOXUHWRIROORZXSRQGDWDTXHULHVDQGPRQLWRULQJILQ GLQJVLQDWLPHO\PDQQHU  x,5%(&VXVSHQVLRQRIWKHVLWH x)UDXGRUIUDXGXOHQWPLVFRQGXFW LVGLVFRYHUHG DVGHILQHGE\ORF DOODZDQGUHJXODWLRQV  x,QYHVWLJDWRUUHTXHVW HJQROR QJHUDEOHWRVXSSRUWWKHVWXG\  3URFHGXUHVIRU7HUPLQDWLRQRU6XVSHQVLRQ   0HGWURQLFLQLWLDWHGDQGUHJXODWRU\DXWKRULW\LQLWLDWHG x0HGWURQLFZLOOSURPSWO\LQIRUPW KHFOLQLFDOLQYHVWLJDWRUVRIWK HWHUPLQDWLRQRUVXVSHQVLRQDQGWKH UHDVRQVDQGLQIRUPWKHUHJXODW RU\DXWKRULW\ZKHUHUHTXLUHG x,QWKHFDVHRIVWXG\WHUPLQDWLRQ RUVXVSHQVLRQIRUUHDVRQVRWKH UWKDQDWHPSRUDU\,5%(& DSSURYDOODSVHWKHLQYHVWLJDWRU ZLOOSURPSWO\LQIRUPWKH,5%( &DQGWKHLQVWLWXWLRQ ZKHUH UHTXLUHGSHUUHJXODWRU\UHTXLUHPHQWV  x,QWKHFDVHRIVWXG\WHUPLQDWLRQ WKHLQYHVWLJDWRU PXVWLQIRUP WKHVXEMHFWV RUOHJDOO\DXWKRUL]HG GHVLJQHHVRUJXDUGLDQV8621/< DQGPD\LQIRUPWKHSHUVRQDOS K\VLFLDQRIWKHVXEMHFWVWR HQVXUHDSSURSULDWHFDUHDQGIROORZXSLVSURYLGHG x,QWKHFDVHRIDVWXG\VXVSHQVLR QVXEMHFWHQUR OOPHQWPXVWVWRS XQWLOWKHVXVSHQV LRQLVOLIWHGE\ 0HGWURQLF x,QWKHFDVHRIVWXG\VXVSHQVLRQ HQUROOHGVXEMHFWVVKRXOGFRQWL QXHWREHIROORZHGRXWRI FRQVLGHUDWLRQRIWKHLUVDIH W\ULJKWVDQGZHOIDUH   ,QYHVWLJDWRULQLWLDWHG x7KH,QYHVWLJDWRUZLOOLQIRUP0HGW URQLFDQGSURYLGHDGHWDLOHGZ ULWWHQH[SODQDWLRQRIWKH WHUPLQDWLRQRUVXVSHQVLRQ x7KH,QYHVWLJDWRUZLOOSURPSWO\LQ IRUPWKHLQVWLWXWLRQ ZKHUHUH TXLUHGSHUUHJXODWRU\ UHTXLUHPHQWV  x7KH,QYHVWLJDWRUZLOOSURPSWO\LQ IRUPWKH,5%(&DQGUHJXODWRU\ DXWKRULW\ ZKHUHUHTXLUHGSHU UHJXODWRU\UHTXLUHPHQWV  x7KH,QYHVWLJDWRUZLOOSURPSWO\LQ IRUPWKHVXEMHFW VDQGPD\LQI RUPSHUVRQDOSK\VLFLDQRIWKH VXEMHFWVWRHQVXUHDSSURSULDWH FDUHDQGIROORZXSLVSURYLGHG x,QWKHFDVHRIVWXG\VXVSHQVLRQ HQUROOHGVXEMHFWVVKRXOGFRQWL QXHWREHIROORZHGRXWRI FRQVLGHUDWLRQRIWKHLUVDIH W\ULJKWVDQGZHOIDUH   ,5%(&LQLWLDWHG x7KH,QYHVWLJDWRUZLOOLQIRUP0HGW URQLFDQGSURYLGHDGHWDLOHGZ ULWWHQH[SODQDWLRQRIWKH WHUPLQDWLRQRUVXVSHQVLRQ ZLWKLQEXVLQHVVGD\V x6XEMHFWHQUROOPHQWPXVWVWRS XQWLOWKHVXVSHQVLRQLVOLIWHG x6XEMHFWVDOUHDG\HQUROOHGVKRXOG FRQWLQXHWREHIROORZHGLQDFF RUGDQFHZLWK,5%SROLF\RULWV GHWHUPLQDWLRQWKDWDQRYHUULGL QJVDIHW\FRQFHUQRUHWKLFDOLVVX HLVLQYROYHG x7KH,QYHVWLJDWRUZLOOLQIRUPKLV KHULQVWLWXWLRQ ZKHUHUHTXLUH GSHUORFDOUHTXLUHPHQWV "
115,page_115,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 115 of 130 Version 5.0 STOP AF First Page 115 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential • The Investigator will promptly inform the subjects (or legally authorized designees or guardians, except in Europe), and may inform the personal physician of the subjects, with the rationale for the study termination or suspension • The Investigator will inform local regulatory authority, where required per regulatory requirements"
116,page_116,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 116 of 130 Version 5.0 STOP AF First Page 116 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential 18. References AFFIRM First Antiarrhythmic Drug Substudy Investi. 2003. ""Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug."" J Am Coll Cardiol 42: 20- 9. Arena, G, C Tondo, G Cattafi, and et. al. 2016. ""Cryoballoon ablation as treatment of recent paroxysmal atrial fibrillation. Data from a large cohort of patients followed in a real world multicent er experience."" Heart Rhythm 13: S375 -76. Calkins, et. al. 2017. ""2017 HRS/EHRA/ECAS expert Consensus Statement on catether and surgical ablation of AF."" Heart Rhythm 14 (10): 275 -444. Caulkins, H, and et. al. . 2007. ""HRS/EHRA/ECAS Expert Consensus Statem ent on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow -Up."" Europace 9 (6): 335-379. Cosio, FG, E Aliot, GL Botto, and et. al. . 2008. ""Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhymic treatment at the time of the first detected episode."" Europace 10: 21-7. De Vos, CB, R Pisters, R Nieuwlaat, and et. al. . 2010. ""Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis."" J Am Coll Cardiol 55: 725-31. Go, A, E Hylek, K Phillips, and et. al. 2001. ""Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study."" JAMA 285 (18): 2370 -2375. Hommel, G. 1988. ""A stagewise rejective multiple test procedure based on a modified Bonferroni test."" Biometricka 75: 383- 386. Jais, P, MD O'Neill, Y Takahashi, and et. al. . 2006. ""Stepwise Catheter Ablation of Chronic Atrial Fibrillation: Importance of Discrete Anatomic Sites for Termination."" J Cardiovasc Electrophysiol 17 (Suppl. 3): S28- S36. Jalife, J, and K Kaur. 2015. ""Atrial remodeling, fibrosis, and atrial fibrillation."" Trends Cardiovasc Med 25: 475-84. January, CT, and et. al. . 2014. ""2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."" JACC 64 (21): e1- 76. January, CT, LS Wann, JS Alpert, ME Field, H Calkins, KT Murray, JC Cleveland Jr., et al. 2014. ""2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary."" Journal of the American College of Cardiology. Knight, BP, PG Novak, R Sangrigoli, and et. al. 2016. ""Second generation cryoballoon: results from the multicenter STOP AF Post Approval Study 12 -month clinical outcomes following pulmonary vein isolation using the Arctic Front Adfance."" Cardiostim (abstract). Kuck, KH, J Brugada, A Furnkranz, A Metzner, F Ouyang, KR Julian Chun, A Elvan, et al. 2016. ""Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation."" N Engl J Med 374: 2235-45. Lafuente -Lafuente, C, L Valembois, JF Bergmann, and J Belmin . 2015. ""Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation."" Cochrane Database of Systematic Reviews."
117,page_117,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 117 of 130 Version 5.0 STOP AF First Page 117 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Lafuente -Lafuente, C, S Mouly, MA Longas -Tejero, and et. al. 2006. ""Antiarrhythmic drugs for maintaining sinus rhyt hm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials."" Arch Intern Med 166: 719- 28. Morillo, CA, A Verma, SJ Connolly, and et. al. 2014. ""Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT -2): A randomized trial."" JAMA 311 (7): 692-700. Nattel, S, E Guasch, I Savelieva, and et. al. 2014. ""Early management of atrial fibrillation to prevent cardiovascular complications."" Eur heart J 35: 1448 -56. Nielsen, JC, A Johannessen, P Raatikainen, G Hindricks, H Walfridsson, O Kongstad, S Pehrson, et al. 2012. ""Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation."" New England Journal of Medicine , October 25: 1587- 96. Oral, H, BP Kni ght, H Tada, and et. al. . 2002. ""Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation."" Circulation 105: 1077 -81. Packer, D, R Kowal, K Wheelan , J Irwin, J Champagne, P Guerra, M Dubuc, et al. 2013. ""CryoBalloon ablation: first resu lts of North America STOP AF pivotal trial."" J Am Coll Cardiol 61 (16): 1713 - 1723. Raviele, et. al. . 2012. ""Venice Chart International consensus document on atrial fibrillation: 2011 Update."" J Cardiovasc Electrophysiol 23: 890- 923. Romero, J, C Gianni, L Di Biase, and A Natale. 2015. ""Catheter ablation for long -standing persistent atrial fibrillation: On -treatment analysis of the randomized controlled MANTRA -PAF trial."" Int J Cardiol J 11: 87-93. Shaw, JW, JA Johnson, and SJ Coons. 2004. ""U.S. Valuation of the EQ -5D Heatlh States: Development and Testing of the D1 Valuation Model."" Medical Care. Shulka, A, and AB Curtis. 2014. ""Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression."" Vasc Health Risk Manag 10: 1-12. Spertus, J, P Dorian, R Bubien, S Lewis, D Godejohn, MR Reynolds, DR Lakkireddy, AP Wimmer, A Bhandari, and C Burk. 2011. ""Development and validation of the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) Questionnaire in patients with atrial fibrillat ion."" Circ Arrhythm Electrophysiol , Feb 4: 15 -25. Tanner, H, K Makowski, L Roten , and et. al. 2011. ""Catheter ablation of atrial fibrillation as first -line therapy- a single -center experience."" Europace 13: 646-53. Walters, TE, A Nisbet, GM Morris, and et. al. 2016. ""Progression of atrial remodeling in patients with high - burden atrial fibrillation: Implications for early ablative intervention."" Heart Rhythm 13: 331- 9. Wazni, OM, NF Marrouche, DO Martin, A Verma, M Bhargava, W Saliba, D Bash, et al. 2005. ""Radiofrequency Ablation vs. Antiarrhythmic Drugs as First -Line Treatment of Symptomatic Atrial Fibrillation."" JAMA, June 1: 2634- 40. Wijesurendra, RS, and B Casadei. 2015. ""Atrial fibrillation: effects beyond the atrium?"" Cardiovasc Res 105: 238 -47. Wolf, P, R Abbott, and W Kannel. 1991. ""Atrial fibrillation as an independent risk factor for stroke: the Framingham Study."" Stroke 22 (8): 983 -988."
118,page_118,
119,page_119,
120,page_120,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 120 of 130 Version 5.0 STOP AF First Page 120 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Additional articles Medtronic was aware of or that were published after the searches were conducted were included."
121,page_121,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 121 of 130 Version 5.0 STOP AF First Page 121 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Appendix B: DRAFT DATA COLLECTION ELEMENTS (CASE REPORT FORMS) Draft Case Report Forms for the STOP AF First study will be provided under separate cover. Final CRFs will be provided to study centers via the electronic data management system after the center has fulfilled all requirements for database access."
122,page_122,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 122 of 130 Version 5.0 STOP AF First Page 122 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Appendix C: INFORMED CONSENT FORM TEMPLATE The Informed Consent Form Template will be distributed under separate cover."
123,page_123,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 123 of 130 Version 5.0 STOP AF First Page 123 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Appendix D: PARTICIPATING INVESTIGATOR AND INSTITUTIONS A list of participating Investigators and institutions will be distributed under separate cover."
124,page_124,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 124 of 130 Version 5.0 STOP AF First Page 124 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Appendix E: IRB LIST A final IRB list will be distributed under separate cover ."
125,page_125,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 125 of 130 Version 5.0 STOP AF First Page 125 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Appendix F: FORESEEABLE ADVERSE EVENTS The information provided in this section p ertains to foreseeable adverse events that may be observed in study subjects and may collectively assist in identifying those events for a given device or therapy that are unexpected in nature. The foreseeable adverse events information consists of two pa rts: a listing of potential adverse events associated with cryoablation therapy/procedure and adverse event rates reported in published literature for same therapy/procedure (see Appendix A). An evaluation of potentially anticipated events and reported events in literature may be used in combination with device labeling/IFU, current event reporting information, and other publis hed data to asses s for an unexpected occurrence. The cryoablation procedure involves surgery, therefore, standard adverse events associated with a surgical procedure may be experienced (e.g. anesthesia complications, injury, infections, bleeding, exacerbat ion of pre -existing conditions, healing complications, etc.). The focus of this section is to specifically address in more detail, those events that are foreseeable due to the use, performance, and/or presence of the Arctic Front Advance ™ CryoAblatio n Catheter under investigation. Additional potential risks associated with the Arctic Front Advance ™ CryoAblation Catheter, as well as risk minimization are discussed within section 12. Treatment required for procedure and/or cryoablation system related adverse events that are experienced may include medication or other surgical and medical remedies. The adverse events associated with the use of the Arctic Front Advance ™ CryoAblation Catheter include but are not limited to those in Table 14 and Table 15. Table 14 pertains to the foreseeable/anticipated adverse events that may be observed in the study and may assist in identifying those adverse events that are unexpected in nature. Table 14: Foreseeable Adverse Events Anemia Feeling cold Pseudoaneurysm Anxiety Fever Pulmonary edema Arrhythmia Gastrointestinal discomfort Pulmonary embolism Arteriovenous fistula Gastroparesis Pulmonary hemorrhage Atrial fibrillation Headache Pulmonary hypertension Atrial flutter Heart block Pulmonary infarction Atrio-esophageal fistula Heart failure Pulmonary infiltration Back pain Hematemesis Pulmonary vein"
126,page_126,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 126 of 130 Version 5.0 STOP AF First Page 126 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential stenosis Bleeding Hematoma Renal impairment Blurred vision Hemoptysis Respiratory arrest or pulmonary arrest Bronchial fistula Hemothorax Right bundle branch block Bronchitis Hiccups Shivering Bruising Hypertension Shortness of breath Cardiac arrest or cardiopulmonary arrest Hypotension Sore throat Cardiac perforation or cardiac vein perforation or perforation of surrounding tissue Hypoxia ST segment elevation Cardiac tamponade Injury to pulmonary vein e.g. pulmonary vein dissection, pulmonary vein hematoma Stroke or cerebrovascular accident Cerebral embolism Lightheadedness Syncope Chest discomfort or pain or pressure Lung injury Tachycardia Coronary artery spasm Myocardial infarction Thrombosis or thrombus Cough Nausea Transient ischemic attack Death Nerve injury e.g. phrenic nerve injury Urinary infection Diarrhea Neurological impairment Vascular access site complication"
127,page_127,
128,page_128,
129,page_129,
130,page_130,"056-F275, Clinical Inves tigation Plan Template, Version 2.0 Page 130 of 130 Version 5.0 STOP AF First Page 130 of 130 05DEC2017 Clinical Investigational Plan Medtronic Confidential Appendix G: PRE-CLINICAL TESTING A summary of results from pre -clinical testing with the Arctic Front Advance ™ Cardiac CryoAblation Catheter is provided in the Report of Prior Investigations Summary."
